THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Citation for published version:

Forster, R & Stewart, M 2016, 'Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair', *Cochrane Database of Systematic Reviews*, no. 3, CD004179. <https://doi.org/10.1002/14651858.CD004179.pub2>

Digital Object Identifier (DOI):

[10.1002/14651858.CD004179.pub2](https://doi.org/10.1002/14651858.CD004179.pub2)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Cochrane Database of Systematic Reviews

Publisher Rights Statement:

Authors retain "the right to post a PDF of the final version, as specified by the Publisher, in an institutional repository or any repository mandated by the author's funder, such as PubMed Central, 12 months after publication."

<http://www.cochranelibrary.com/help/open-access-options-for-the-cochrane-library.html>

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Cochrane
Library

Cochrane Database of Systematic Reviews

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair (Review)

Forster R, Stewart M

Forster R, Stewart M.

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.

Cochrane Database of Systematic Reviews 2016, Issue 3. Art. No.: CD004179.

DOI: 10.1002/14651858.CD004179.pub2.

www.cochranelibrary.com

TABLE OF CONTENTS

HEADER	1
ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON	4
BACKGROUND	6
OBJECTIVES	6
METHODS	6
RESULTS	9
Figure 1.	10
Figure 2.	12
Figure 3.	13
ADDITIONAL SUMMARY OF FINDINGS	21
DISCUSSION	32
AUTHORS' CONCLUSIONS	33
ACKNOWLEDGEMENTS	33
REFERENCES	34
CHARACTERISTICS OF STUDIES	38
DATA AND ANALYSES	66
Analysis 1.1. Comparison 1 Heparin versus placebo, Outcome 1 Symptomatic VTE (DVT and PE).	70
Analysis 1.2. Comparison 1 Heparin versus placebo, Outcome 2 Symptomatic DVT (proximal or distal).	71
Analysis 1.3. Comparison 1 Heparin versus placebo, Outcome 3 Symptomatic PE.	72
Analysis 1.4. Comparison 1 Heparin versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic).	73
Analysis 1.5. Comparison 1 Heparin versus placebo, Outcome 5 Asymptomatic DVT.	74
Analysis 1.6. Comparison 1 Heparin versus placebo, Outcome 6 All-cause mortality.	75
Analysis 1.7. Comparison 1 Heparin versus placebo, Outcome 7 Adverse events.	76
Analysis 1.8. Comparison 1 Heparin versus placebo, Outcome 8 Bleeding - major.	77
Analysis 1.9. Comparison 1 Heparin versus placebo, Outcome 9 Bleeding - minor.	78
Analysis 1.10. Comparison 1 Heparin versus placebo, Outcome 10 Reoperation.	79
Analysis 2.1. Comparison 2 Vitamin K antagonists versus placebo, Outcome 1 Symptomatic VTE (DVT and PE).	79
Analysis 2.2. Comparison 2 Vitamin K antagonists versus placebo, Outcome 2 Symptomatic DVT (proximal or distal).	80
Analysis 2.3. Comparison 2 Vitamin K antagonists versus placebo, Outcome 3 Symptomatic PE.	81
Analysis 2.4. Comparison 2 Vitamin K antagonists versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic).	81
Analysis 2.5. Comparison 2 Vitamin K antagonists versus placebo, Outcome 5 All-cause mortality.	82
Analysis 2.6. Comparison 2 Vitamin K antagonists versus placebo, Outcome 6 Adverse events.	83
Analysis 2.7. Comparison 2 Vitamin K antagonists versus placebo, Outcome 7 Bleeding - major.	83
Analysis 3.1. Comparison 3 DOAC versus placebo, Outcome 1 Symptomatic VTE (DVT and PE).	84
Analysis 3.2. Comparison 3 DOAC versus placebo, Outcome 2 Symptomatic DVT (proximal or distal).	84
Analysis 3.3. Comparison 3 DOAC versus placebo, Outcome 3 Symptomatic PE.	85
Analysis 3.4. Comparison 3 DOAC versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic).	86
Analysis 3.5. Comparison 3 DOAC versus placebo, Outcome 5 All-cause mortality.	86
Analysis 3.6. Comparison 3 DOAC versus placebo, Outcome 6 Adverse events.	87
Analysis 3.7. Comparison 3 DOAC versus placebo, Outcome 7 Bleeding - major.	87
Analysis 3.8. Comparison 3 DOAC versus placebo, Outcome 8 Bleeding- clinically relevant non-major.	88
Analysis 3.9. Comparison 3 DOAC versus placebo, Outcome 9 Bleeding - minor.	88
Analysis 3.10. Comparison 3 DOAC versus placebo, Outcome 10 Reoperation.	89
Analysis 3.11. Comparison 3 DOAC versus placebo, Outcome 11 Wound infection.	89
Analysis 4.1. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 1 Symptomatic VTE (DVT and PE).	90
Analysis 4.2. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 2 Symptomatic DVT (proximal or distal).	90

Analysis 4.3. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 3 Symptomatic PE.	91
Analysis 4.4. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic).	92
Analysis 4.5. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 5 Asymptomatic DVT.	92
Analysis 4.6. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 6 Asymptomatic distal DVT.	93
Analysis 4.7. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 7 All-cause mortality.	94
Analysis 4.8. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 8 Bleeding - major.	94
Analysis 5.1. Comparison 5 Vitamin K antagonists versus heparin, Outcome 1 Symptomatic VTE (DVT and PE).	95
Analysis 5.2. Comparison 5 Vitamin K antagonists versus heparin, Outcome 2 Symptomatic DVT (proximal or distal).	96
Analysis 5.3. Comparison 5 Vitamin K antagonists versus heparin, Outcome 3 Symptomatic PE.	96
Analysis 5.4. Comparison 5 Vitamin K antagonists versus heparin, Outcome 4 Total VTE (symptomatic and asymptomatic).	97
Analysis 5.5. Comparison 5 Vitamin K antagonists versus heparin, Outcome 5 All-cause mortality.	98
Analysis 5.6. Comparison 5 Vitamin K antagonists versus heparin, Outcome 6 Bleeding - major.	98
Analysis 5.7. Comparison 5 Vitamin K antagonists versus heparin, Outcome 7 Bleeding - minor.	99
Analysis 5.8. Comparison 5 Vitamin K antagonists versus heparin, Outcome 8 Reoperation.	99
Analysis 6.1. Comparison 6 DOAC versus heparin, Outcome 1 Symptomatic VTE (DVT and PE).	100
Analysis 6.2. Comparison 6 DOAC versus heparin, Outcome 2 Symptomatic DVT (proximal or distal).	101
Analysis 6.3. Comparison 6 DOAC versus heparin, Outcome 3 Symptomatic PE.	102
Analysis 6.4. Comparison 6 DOAC versus heparin, Outcome 4 Total VTE (symptomatic and asymptomatic).	103
Analysis 6.5. Comparison 6 DOAC versus heparin, Outcome 5 Asymptomatic DVT.	104
Analysis 6.6. Comparison 6 DOAC versus heparin, Outcome 6 Asymptomatic proximal DVT.	104
Analysis 6.7. Comparison 6 DOAC versus heparin, Outcome 7 Asymptomatic distal DVT.	105
Analysis 6.8. Comparison 6 DOAC versus heparin, Outcome 8 All-cause mortality.	106
Analysis 6.9. Comparison 6 DOAC versus heparin, Outcome 9 Adverse events.	107
Analysis 6.10. Comparison 6 DOAC versus heparin, Outcome 10 Bleeding - major.	108
Analysis 6.11. Comparison 6 DOAC versus heparin, Outcome 11 Bleeding - clinically relevant, non-major.	109
Analysis 6.12. Comparison 6 DOAC versus heparin, Outcome 12 Bleeding - minor.	110
Analysis 6.13. Comparison 6 DOAC versus heparin, Outcome 13 Reoperation.	111
Analysis 6.14. Comparison 6 DOAC versus heparin, Outcome 14 Wound infection.	112
APPENDICES	112
FEEDBACK	126
HISTORY	126
CONTRIBUTIONS OF AUTHORS	126
DECLARATIONS OF INTEREST	127
SOURCES OF SUPPORT	127
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	127

[Intervention Review]

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Rachel Forster¹, Marlene Stewart¹

¹Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK

Contact address: Rachel Forster, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, EH8 9AG, UK. rbedenis@gmail.com. rachel.forster@ed.ac.uk.

Editorial group: Cochrane Vascular Group.

Publication status and date: New, published in Issue 3, 2016.

Review content assessed as up-to-date: 13 May 2015.

Citation: Forster R, Stewart M. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. *Cochrane Database of Systematic Reviews* 2016, Issue 3. Art. No.: CD004179. DOI: 10.1002/14651858.CD004179.pub2.

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

The optimal duration of thromboprophylaxis after total hip or knee replacement, or hip fracture repair remains controversial. It is common practice to administer prophylaxis using low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) until discharge from hospital, usually seven to 14 days after surgery. International guidelines recommend extending thromboprophylaxis for up to 35 days following major orthopaedic surgery but the recommendation is weak due to moderate quality evidence. In addition, recent oral anticoagulants that exert effect by direct inhibition of thrombin or activated factor X lack the need for monitoring and have few known drug interactions. Interest in this topic remains high.

Objectives

To assess the effects of extended-duration anticoagulant thromboprophylaxis for the prevention of venous thromboembolism (VTE) in people undergoing elective hip or knee replacement surgery, or hip fracture repair.

Search methods

The Cochrane Vascular Information Specialist searched the Specialised Register (last searched May 2015) and CENTRAL (2015, Issue 4). Clinical trials databases were searched for ongoing or unpublished studies.

Selection criteria

Randomised controlled trials assessing extended-duration thromboprophylaxis (five to seven weeks) using accepted prophylactic doses of LMWH, UFH, vitamin K antagonists (VKA) or direct oral anticoagulants (DOAC) compared with short-duration thromboprophylaxis (seven to 14 days) followed by placebo, no treatment or similar extended-duration thromboprophylaxis with LMWH, UFH, VKA or DOACs in participants undergoing hip or knee replacement or hip fracture repair.

Data collection and analysis

We independently selected trials and extracted data. Disagreements were resolved by discussion. We performed fixed-effect model meta-analyses with odds ratios (ORs) and 95% confidence intervals (CIs). We used a random-effects model when there was heterogeneity.

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair (Review)

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Main results

We included 16 studies (24,930 participants); six compared heparin with placebo, one compared VKA with placebo, two compared DOAC with placebo, one compared VKA with heparin, five compared DOAC with heparin and one compared anticoagulants chosen at investigators' discretion with placebo. Three trials included participants undergoing knee replacement. No studies assessed hip fracture repair.

Trials were generally of good methodological quality. The main reason for unclear risk of bias was insufficient reporting. The quality of evidence according to GRADE was generally moderate, as some comparisons included a single study, low number of events or heterogeneity between studies leading to wide CIs.

We showed no difference between extended-duration heparin and placebo in symptomatic VTE (OR 0.59, 95% CI 0.35 to 1.01; 2329 participants; 5 studies; high quality evidence), symptomatic deep vein thrombosis (DVT) (OR 0.73, 95% CI 0.39 to 1.38; 2019 participants; 4 studies; moderate quality evidence), symptomatic pulmonary embolism (PE) (OR 0.61, 95% CI 0.16 to 2.33; 1595 participants; 3 studies; low quality evidence) and major bleeding (OR 0.59, 95% CI 0.14 to 2.46; 2500 participants; 5 studies; moderate quality evidence). Minor bleeding was increased in the heparin group (OR 2.01, 95% CI 1.43 to 2.81; 2500 participants; 5 studies; high quality evidence). Clinically relevant non-major bleeding was not reported.

We showed no difference between extended-duration VKA and placebo (one study, 360 participants) for symptomatic VTE (OR 0.10, 95% CI 0.01 to 1.94; moderate quality evidence), symptomatic DVT (OR 0.13, 95% CI 0.01 to 2.62; moderate quality evidence), symptomatic PE (OR 0.32, 95% CI 0.01 to 7.84; moderate quality evidence) and major bleeding (OR 2.89, 95% CI 0.12 to 71.31; low quality evidence). Clinically relevant non-major bleeding and minor bleeding were not reported.

Extended-duration DOAC showed reduced symptomatic VTE (OR 0.20, 95% CI 0.06 to 0.68; 2419 participants; 1 study; moderate quality evidence) and symptomatic DVT (OR 0.18, 95% CI 0.04 to 0.81; 2459 participants; 2 studies; high quality evidence) compared to placebo. No differences were found for symptomatic PE (OR 0.25, 95% CI 0.03 to 2.25; 1733 participants; 1 study; low quality evidence), major bleeding (OR 1.00, 95% CI 0.06 to 16.02; 2457 participants; 1 study; low quality evidence), clinically relevant non-major bleeding (OR 1.22, 95% CI 0.76 to 1.95; 2457 participants; 1 study; moderate quality evidence) and minor bleeding (OR 1.18, 95% CI 0.74 to 1.88; 2457 participants; 1 study; moderate quality evidence).

We showed no difference between extended-duration anticoagulants chosen at investigators' discretion and placebo (one study, 557 participants, low quality evidence) for symptomatic VTE (OR 0.50, 95% CI 0.09 to 2.74), symptomatic DVT (OR 0.33, 95% CI 0.03 to 3.21), symptomatic PE (OR 1.00, 95% CI 0.06 to 16.13), and major bleeding (OR 5.05, 95% CI 0.24 to 105.76). Clinically relevant non-major bleeding and minor bleeding were not reported.

We showed no difference between extended-duration VKA and heparin (one study, low quality evidence) for symptomatic VTE (OR 1.64, 95% CI 0.85 to 3.16; 1279 participants), symptomatic DVT (OR 1.36, 95% CI 0.69 to 2.68; 1279 participants), symptomatic PE (OR 9.16, 95% CI 0.49 to 170.42; 1279 participants), major bleeding (OR 3.87, 95% CI 1.91 to 7.85; 1272 participants) and minor bleeding (OR 1.33, 95% CI 0.64 to 2.76; 1279 participants). Clinically relevant non-major bleeding was not reported.

We showed no difference between extended-duration DOAC and heparin for symptomatic VTE (OR 0.70, 95% CI 0.28 to 1.70; 15,977 participants; 5 studies; low quality evidence), symptomatic DVT (OR 0.60, 95% CI 0.11 to 3.27; 15,977 participants; 5 studies; low quality evidence), symptomatic PE (OR 0.91, 95% CI 0.43 to 1.94; 14,731 participants; 5 studies; moderate quality evidence), major bleeding (OR 1.11, 95% CI 0.79 to 1.54; 16,199 participants; 5 studies; high quality evidence), clinically relevant non-major bleeding (OR 1.08, 95% CI 0.90 to 1.28; 15,241 participants; 4 studies; high quality evidence) and minor bleeding (OR 0.95, 95% CI 0.82 to 1.10; 11,766 participants; 4 studies; high quality evidence).

Authors' conclusions

Moderate quality evidence suggests extended-duration anticoagulants to prevent VTE should be considered for people undergoing hip replacement surgery, although the benefit should be weighed against the increased risk of minor bleeding. Further studies are needed to better understand the association between VTE and extended-duration oral anticoagulants in relation to knee replacement and hip fracture repair, as well as outcomes such as distal and proximal DVT, reoperation, wound infection and healing.

PLAIN LANGUAGE SUMMARY

Anticoagulants taken for longer periods to prevent deep vein thrombosis or pulmonary embolism after hip or knee replacement

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair (Review) 2

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

Patients undergoing surgery have an increased risk of developing blood clots in their veins. These clots may be in the deep veins of the leg (deep vein thrombosis (DVT)) or travel to the lungs (pulmonary embolism (PE)). Venous thromboembolism (VTE) is the combined term for DVT and PE. Prevention of these blood clots (prophylaxis) after surgery may reduce the risk of postoperative vein clots. These potential benefits, however, have to be balanced against the associated risks of bleeding. The optimal duration of prophylaxis after total hip or knee replacement, or hip fracture repair remains controversial. It is common practice to administer prophylaxis using drugs such as low-molecular-weight heparin and unfractionated heparin (anticoagulants) until discharge from hospital and for a minimum of seven to 14 days after surgery. Current international guidelines recommend extending prophylaxis for up to 35 days following major orthopaedic surgery but recognise that the recommendation is weak due to moderate quality evidence. In addition, new oral anticoagulants (direct oral anticoagulants (DOAC)) show potential benefits such as taking tablets by mouth instead of injection, lack of frequent monitoring and few known drug interactions. Interest in this topic therefore remains high.

Study characteristics and key results

A total of 16 studies were included, with 24,930 randomised participants (current until May 2015). The main outcomes of interest were symptomatic (showing symptoms) VTE, including DVT and PE, and bleeding (major, clinically relevant non-major and minor bleeding). Six studies compared heparin with placebo, one compared the vitamin K antagonist (VKA) warfarin with placebo, two compared DOAC with placebo, one compared VKA with heparin, five compared DOAC with heparin and one study compared using a variety of anticoagulant treatments with placebo. Only three trials included participants undergoing knee replacement and no studies included participants undergoing hip fracture repair.

For the comparison heparin versus placebo (six studies) no differences were found between the study arms for symptomatic VTE, symptomatic DVT, symptomatic PE and major bleeding. Minor bleeding was increased in the heparin group. Clinically relevant non-major bleeding was not reported.

The comparison VKA versus placebo (one study) and the comparison placebo with anticoagulants chosen at the discretion of the investigators (one study) showed no differences between the study arms for symptomatic VTE, symptomatic DVT, symptomatic PE and major bleeding. Clinically relevant non-major bleeding and minor bleeding were not reported.

For the comparison DOACs versus placebo (two studies), reduced symptomatic VTE and symptomatic DVT were found in favour of the DOAC but no differences were found for symptomatic PE, major bleeding, clinically relevant non-major bleeding and minor bleeding.

Comparing extended-duration VKA with extended-duration LMWH (one study) there was no difference between the study arms for symptomatic VTE, symptomatic DVT, symptomatic PE, major bleeding and minor bleeding. Clinically relevant non-major bleeding was not reported.

Comparing extended-duration DOAC with extended-duration LMWH (five studies) there was no difference between the study arms for symptomatic VTE, symptomatic DVT, symptomatic PE, major bleeding, clinically relevant non-major bleeding and minor bleeding.

Quality of the evidence

Overall, the included studies were of good methodological quality, with the majority of studies having little risk of bias due to study design and reporting. The majority of concerns came from lack of reporting of specific details. The quality of the evidence was generally moderate, either because only one study was included in a comparison, because of few events or because there were a lot of differences between the findings of the studies meaning that the data were difficult to interpret. Further studies are needed to better understand the relationship between VTE and extended-duration oral anticoagulants for knee replacement and hip fracture repair as well as outcomes such as DVT below the knee and above the knee, reoperation, wound infection and healing.

SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *[Explanation]*

Heparin compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair						
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Setting: hospital and outpatient setting Intervention: heparin Comparison: placebo						
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo	Risk with heparin				
Symptomatic VTE (DVT and PE) Treatment duration 28 - 42 days	Study population		OR 0.59 (0.35 to 1.01)	2329 (5 RCTs)	⊕⊕⊕⊕ HIGH	-
	33 per 1000	20 per 1000 (12 to 33)				
Symptomatic DVT (proximal or distal) Treatment duration 28 - 42 days	Study population		OR 0.73 (0.39 to 1.38)	2019 (4 RCTs)	⊕⊕⊕○ MODERATE ¹	-
	24 per 1000	18 per 1000 (9 to 33)				
Symptomatic PE Treatment duration 28 - 42 days	Study population		OR 0.61 (0.16 to 2.33)	1595 (3 RCTs)	⊕⊕○○ LOW ¹²	-
	6 per 1000	4 per 1000 (1 to 15)				
Bleeding - major Treatment duration 28 - 42 days	Study population		OR 0.59 (0.14 to 2.46)	2500 (5 RCTs)	⊕⊕⊕○ MODERATE ¹	-
	4 per 1000	2 per 1000 (0 to 9)				

Clinically relevant non-major bleeding Treatment duration 28 - 42 days	see comment	-	-	-	not reported
Bleeding - minor Treatment duration 28 - 42 days	Study population	OR 2.01 (1.43 to 2.81)	2500 (5 RCTs)	⊕⊕⊕⊕ HIGH	-
	46 per 1000 88 per 1000 (65 to 119)				

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **DVT:** deep vein thrombosis; **OR:** odds ratio; **PE:** pulmonary embolism; **RCT:** randomised controlled trial; **VTE:** venous thromboembolism

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Downgraded by one level, low number of events leading to imprecision of results

² Downgraded by one level, some heterogeneity present ($I^2 = 49\%$) leading to wide CIs

BACKGROUND

Description of the condition

Venous thromboembolism describes the formation of a clot in the deep veins (deep vein thrombosis or DVT - usually of the lower extremities) and the subsequent embolisation of the clot to the pulmonary circulation (pulmonary embolisation or PE) or both. DVT of the lower limbs is associated with localised pain, swelling and erythema as well as the development of pulmonary emboli (PE), and the more localised and chronic post thrombotic syndrome. PE presents with shortness of breath, pain on inspiration, tachycardia and right heart overload, and if untreated, can lead to circulatory collapse and death.

The incidence of VTE, in mostly white populations, is between 100 and 200 per 100,000 person years (Heit 2015; White 2003). Of these, it is estimated that 45 to 117 per 100,000 person years are due to DVT (without PE) and 29 to 78 per 100,000 person years are due to PE (with or without DVT) (Heit 2015). Recurrent VTE occurs in approximately 7.4% of patients by one year, rising to 30.4% of patients by 10 years (Cushman 2007; Heit 2015; White 2003).

Although DVT and PE can occur spontaneously, there are many risk factors for VTE, including periods of inactivity, dehydration, hospitalisation, trauma, clotting disorders and previous thrombosis, varicose veins with phlebitis, pregnancy, oral combined hormonal contraceptives, malignancy, obesity, smoking and age (NICE 2010).

Prophylactic strategies in those deemed to be at risk (for example those undergoing surgical procedures or prolonged hospital in-patient stays) are recommended by international guidelines published by the National Institute for Health and Care Excellence (NICE) (NICE 2010; NICE 2012), The American College of Chest Physicians (ACCP) (Guyatt 2012) and the Scottish Intercollegiate Guidelines Network (SIGN) (SIGN 2010) and include the use of anticoagulation such as LMWH, UFH, oral direct factor Xa inhibitor (rivaroxaban), oral direct thrombin inhibitor (dabigatran), pentasaccharides (fondaparinux), and mechanical compression such as compression stockings and intermittent pneumatic compression devices.

Description of the intervention

It is common practice to administer prophylaxis until discharge from hospital, and for a minimum of seven to 14 days after surgery. However, in patients receiving in-hospital prophylaxis, the prevalence of venographic DVT (a blood clot in the leg detected by venography) is still 15% to 30% at the time of hospital discharge (Eriksson 1997; Mohr 1993; Nurmohamed 1992) while an additional 10% to 25% of patients develop new asymptomatic DVT during the next three to four weeks (Dahl 1997; Fragmin Trial;

French Study; Hirsh 1998). It is estimated, based on the available literature, that fewer than 10% of patients with venographically documented DVT will develop symptomatic VTE.

Extended-duration prophylaxis is prophylaxis which starts at admission and continues well beyond discharge, typically for an additional 21 to 28 days after discharge, leading to a period of prophylaxis of approximately 35 days (NICE 2010). Randomised trials have demonstrated that extending prophylaxis beyond the time of hospital discharge substantially reduces the risk of developing new asymptomatic thrombi at 30 to 45 days (Dahl 1997; Fragmin Trial; French Study) and this has led these investigators to recommend that prophylaxis of longer duration should be used in all patients undergoing total hip replacement (THR).

However, two prospective studies, conducted in patients without known proximal DVT at the time of discharge from hospital, demonstrated that the incidence of new out-of-hospital symptomatic DVT or pulmonary embolism (PE) without extended-duration prophylaxis was only approximately 2% after three months of follow-up (Leclerc 1998; Robinson 1997). This data suggest that the majority of asymptomatic thrombi remain clinically silent irrespective of whether extended-duration prophylaxis is given. Meanwhile, the impact of extended-duration prophylaxis on symptomatic VTE remains to be clarified. Heit 2000 showed that a significant reduction in symptomatic VTE could not be demonstrated and therefore concluded that prophylaxis confined to the in-hospital phase is adequate in most patients.

Why it is important to do this review

Current ACCP and NICE guidelines (Guyatt 2012; NICE 2010) for the prevention of VTE recommend extending thromboprophylaxis for up to 35 days following major orthopaedic surgery but recognise that the recommendation is weak due to moderate quality evidence (Guyatt 2012). In addition, recent oral anticoagulants that exert effect by direct inhibition of thrombin or activated factor X lack the need for monitoring and have few known drug interactions. Differences between anticoagulants for the extended duration also warrant further investigation. Interest in this topic therefore remains high.

OBJECTIVES

To assess the effects of extended-duration anticoagulant thromboprophylaxis for the prevention of venous thromboembolism (VTE) in people undergoing elective hip or knee replacement surgery, or hip fracture repair.

METHODS

Criteria for considering studies for this review

Types of studies

Randomised controlled studies which assessed extended duration of anticoagulant thromboprophylaxis for the prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.

We defined extended-duration thromboprophylaxis as thromboprophylaxis of duration of five to seven weeks.

We included studies which used objective methods (e.g. ultrasound, venogram, V-Q scan) to confirm the diagnosis of symptomatic and asymptomatic VTE (DVT or PE). We included data on asymptomatic DVT from these studies only if screening was performed using ascending lower-limb contrast venography. We included open-label, as well as double-blind studies.

Types of participants

Patients undergoing elective total hip or knee replacement surgery or hip fracture repair. Patients undergoing revisions of a previous hip or knee replacement were included.

Types of interventions

We included studies which assessed extended-duration thromboprophylaxis (five to seven weeks) using accepted prophylactic doses of anticoagulants LMWH, UFH, vitamin K antagonists or direct oral anticoagulants (DOACs) compared with short duration thromboprophylaxis therapy (seven to 14 days) followed by placebo or no treatment or similar extended duration of thromboprophylaxis therapy with anticoagulants LMWH, UFH, vitamin K antagonists or DOACs. Other antithrombotic therapy used in the prevention of VTE in major orthopaedic surgery was excluded.

Types of outcome measures

Primary outcomes

Symptomatic VTE (including DVT and PE)

Secondary outcomes

Total VTE (symptomatic or asymptomatic)

Asymptomatic DVT

Asymptomatic proximal and distal DVT

All-cause mortality

Adverse events

Bleeding events (major, clinically relevant non-major bleeding and minor bleeding)

Reoperation

Wound infection

Wound healing

Search methods for identification of studies

Electronic searches

The Cochrane Vascular Information Specialist (CIS) searched the Specialised Register (last searched May 2015) and the Cochrane Central Register of Controlled Trials (CENTRAL) 2015, Issue 4, part of *The Cochrane Library*, www.cochranelibrary.com. See [Appendix 1](#) for details of the search strategy used to search CENTRAL. The Specialised Register is maintained by the CIS and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL, AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used are described in the [Specialised Register](#) section of the Cochrane Vascular module in *The Cochrane Library* (www.cochranelibrary.com).

The CIS searched the following trial databases for details of ongoing and unpublished studies;

World Health Organization International Clinical Trials Registry <http://apps.who.int/trialsearch/>

ClinicalTrials.gov <http://clinicaltrials.gov/>

ISRCTN Register <http://www.isrctn.com/>

Searching other resources

We searched references sections of relevant reports for further studies.

Data collection and analysis

Selection of studies

Studies identified in the search were individually evaluated by two review authors (RF and MS) based on title, abstract or full report for possible inclusion and any disagreements resolved by discussion.

Data extraction and management

Two review authors (RF and MS) independently extracted data on study characteristics, efficacy and safety outcomes. Extracted information included study design, country, setting, intention-to-treat methods, number of participants randomised, number of participants excluded post-randomisation, losses to follow up, age, sex, inclusion criteria, exclusion criteria, treatment and control details and duration of treatment, primary and secondary outcomes, funding, and how VTE outcomes were confirmed using objective methods. Data extracted for study outcomes included symptomatic VTE (DVT and PE), total VTE (symptomatic and asymptomatic), asymptomatic DVT documented by ascending lower limb contrast venography (stratified by proximal (popliteal

vein and above) and distal (calf vein) DVT, where possible), all-cause mortality, adverse events and bleeding events (major, clinically relevant non-major and minor bleeding). We also extracted data for reoperation, wound infection and wound healing. We accepted the primary study authors' definitions for DVT, PE and bleeding events. Any disagreements were resolved through discussion.

Assessment of risk of bias in included studies

RF and MS independently assessed the methodological quality of included studies using the 'Risk of bias' tool according to [Higgins 2011](#). The following domains were assessed: selection bias (random sequence generation, allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective reporting) and other bias. We classified the domains as low risk, high risk, or unclear risk according to [Higgins 2011](#). Disagreements were resolved by discussion.

Measures of treatment effect

We divided studies into six groups based on the treatment profile.

1. Heparin (LMWH or UFH) versus placebo
2. Vitamin K antagonists versus placebo
3. DOACs versus placebo
4. Anticoagulant chosen at investigators' discretion versus placebo
5. Vitamin K antagonists versus heparin (LMWH or UFH)
6. DOACs versus heparin (LMWH or UFH)

We pooled data for each of the comparisons for the outcomes of symptomatic VTE, total VTE, asymptomatic DVT documented by ascending lower limb contrast venography, all-cause mortality, adverse events, bleeding events, reoperation, wound infection and wound healing. The pooled data for each outcome were used to create a meta-analysis by calculating odds ratios (ORs) with 95% confidence intervals (CIs), as all outcomes were dichotomous. We used fixed-effect models, unless there was evidence of a large amount of heterogeneity (see [Assessment of heterogeneity](#)), in which case a random-effects model was implemented.

Unit of analysis issues

The unit of analysis was the individual patient.

Dealing with missing data

Where appropriate we used all randomised participants for the analysis. However, many of the included studies had many participants excluded after randomisation, creating a large disparity between the number of participants randomised and the number available for assessment of VTE at the end of the study. After discussion between the review authors, we decided it was generally inappropriate to include all randomised participants in our analysis,

and would use the 'intention-to-treat' populations as reported by the studies. This population generally consisted of all participants that received treatment and had evaluable testing of VTE at the end of the study. If these values were not available, we utilised the reported per-protocol data. Where necessary, we contacted study authors to provide missing data.

Assessment of heterogeneity

A test for heterogeneity examines the null hypothesis that all studies are evaluating the same effect. For each included meta-analysis we obtained a value comparing the test statistic with a χ^2 distribution. To help readers assess the consistency of results of studies in a meta-analysis, Review Manager software (RevMan) ([RevMan 2014](#)) includes a method (I^2 statistic) that describes the percentage of total variation across studies due to heterogeneity rather than by chance. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity ([Higgins 2003](#)). For the purposes of this review, if a meta-analysis was found to have an I^2 value of > 50%, we calculated the ORs using a random-effects model instead of a fixed-effect model.

Assessment of reporting biases

To detect reporting bias we planned to construct funnel plots for meta-analyses that included at least 10 studies, as funnel plots with fewer than 10 studies lack the power to distinguish chance from real asymmetry ([Egger 1997](#)).

Data synthesis

We planned to use fixed-effect models for each meta-analysis to pool data, unless there was evidence of heterogeneity (see [Assessment of heterogeneity](#)), in which case we planned to use a random-effects model to derive the ORs and 95% CIs.

Subgroup analysis and investigation of heterogeneity

We pre-specified the following subgroup analyses for the primary outcome symptomatic VTE:

1. hip replacement versus knee replacement versus hip fracture repair;
2. according to duration of in-hospital prophylaxis (up to 10 days, 10 to 14 days, 15 days or more) in trials comparing extended anticoagulant thromboprophylaxis versus placebo or no treatment;
3. performing mandatory discharge venography versus not performing mandatory discharge venography in trials comparing extended anticoagulant thromboprophylaxis versus placebo or no treatment;
4. patients undergoing revisions of a previous hip or knee replacement.

Sensitivity analysis

We conducted sensitivity analyses to further explore the robustness of our results. To identify any study that may have exerted a disproportionate influence on the summary treatment effect, we removed studies from the analysis that accounted for over 50% of the weighted summary statistic, where three or more studies were included, to see if these heavily-weighted studies altered the findings. We also planned to examine the effect of excluding studies that were at high risk of bias from the analysis, based on the 'Risk of bias' tool. We planned to carry out sensitivity analysis only when two or more studies remained in the analysis after the removal of the studies in question.

Summary of findings

We constructed a 'Summary of findings' table for each comparison using the GRADEpro GDT software ([GRADEpro GDT 2015](#)) to present the main findings of the review. We included the outcomes symptomatic VTE, symptomatic DVT, symptomatic PE, major bleeding, clinically relevant non-major bleeding and minor bleeding in the 'Summary of findings' table. We calculated assumed

control intervention risks from the mean number of events in the control groups of the selected studies for each outcome. The system developed by the Grading of Recommendation, Assessment, Development and Evaluation Working Group (GRADE working group) was used for grading the quality of evidence as high, moderate, low and very low, based on within-study risk of bias, directness of evidence, heterogeneity, precision of effects estimates, and risk of publication bias ([Atkins 2004](#)). For completeness, additional 'Summary of findings' tables were created for the remaining outcomes of this review and presented in the appendices.

RESULTS

Description of studies

Results of the search

See [Figure 1](#)

Figure 1. Study flow diagram.

Included studies

We included a total of 16 studies with 24,930 randomised participants (ADVANCE 3; Barrellier 2010; Dahl 1997; DaPP Study; EXTEND Study; Fragmin Trial; French Study; Heit 2000; Kolb 2003; Prandoni 2002; RECORD 1 Trial; RECORD 2 Trial; RE-NOVATE II Trial; RE-NOVATE Trial; SACRE Study; Zhang 2014). Nearly all the included randomised studies were multicentre, with just three recruiting from only a single centre (French Study; Prandoni 2002; Zhang 2014). Three studies were conducted in France (Barrellier 2010; French Study; SACRE Study), one study in Norway (Dahl 1997), one in Denmark (DaPP Study), one in the US (Heit 2000) and another in the US and Canada (Fragmin Trial), one in Germany and Czech Republic (Kolb 2003), one in Italy (Prandoni 2002), one in China (Zhang 2014) and six that involved centres in multiple countries, ranging from 16 up to 27 countries (ADVANCE 3; EXTEND Study; RECORD 1 Trial; RECORD 2 Trial; RE-NOVATE II Trial; RE-NOVATE Trial). The duration of treatment ranged between the studies, with the majority having treatment periods for an average of 35 days (ADVANCE 3; Barrellier 2010; Dahl 1997; DaPP Study; EXTEND Study; Fragmin Trial; French Study; RECORD 1 Trial; RECORD 2 Trial; Zhang 2014). Both RE-NOVATE II Trial and RE-NOVATE Trial had treatment periods of 28 to 35 days. One study had a four-week post-discharge period on top of a median nine-day hospital phase (Prandoni 2002). Two studies had six-week treatment periods (Heit 2000; SACRE Study), with the final study having a treatment period “up to 42 days” (Kolb 2003).

Heparin versus placebo

A total of six trials with 3221 participants compared heparin with placebo (Dahl 1997; DaPP Study; Fragmin Trial; French Study; Heit 2000; Kolb 2003). Four of the studies evaluated participants undergoing total hip replacement (Dahl 1997; DaPP Study; Fragmin Trial; French Study), two evaluated a combined group of hip and knee replacements (Heit 2000; Kolb 2003). Heit 2000 presented results for the hip and knee replacement groups separately, while Kolb 2003 presented results for the combined group only.

Five included studies evaluated LMWH versus placebo: three evaluated dalteparin (Dahl 1997; DaPP Study; Fragmin Trial), one evaluated enoxaparin (French Study) and one evaluated the cer-toparin (Kolb 2003). Heit 2000 compared the anticoagulant ardeparin sodium versus placebo. It should be noted that ardeparin has been removed from the market in the US since 2000, but not for reasons of efficacy or safety (Dotzel 2002).

Duration of the in-hospital/initial phase ranged from four days to 14 days. Heit 2000 reported four to 10 days, while Dahl 1997

and DaPP Study reported seven days for the initial phase. The French Study and Kolb 2003 had 14 days for their initial phase. The Fragmin Trial did not report this timeframe. At the time of discharge from the hospital or at the end of the initial phase Dahl 1997, Fragmin Trial and the French Study had mandatory venography to test for DVT. The DaPP Study did state that they identified those with DVT at the end of the initial phase, but did not state their methods. While Heit 2000 and Kolb 2003 did not use objective methods to test for DVT at the end of the initial phase of the trial.

Vitamin K antagonists versus placebo

One trial with 360 participants compared the VKA antagonist warfarin with placebo (Prandoni 2002). Prandoni 2002 evaluated participants undergoing total hip replacement. Duration of the in-hospital/initial phase had a median of nine days (Prandoni 2002). At the time of discharge from the hospital Prandoni 2002 performed ultrasonography on all participants to determine incidence of DVT before the second phase of the trial.

DOACs versus placebo

Two trials with 2549 participants compared DOACs with placebo (RECORD 2 Trial; Zhang 2014). Both studies evaluated participants undergoing total hip replacement (RECORD 2 Trial; Zhang 2014).

The RECORD 2 Trial compared the oral anticoagulant rivaroxaban with enoxaparin in the initial phase, then the enoxaparin group began taking placebo. Zhang 2014 evaluated rivaroxaban compared with no treatment. Duration of the in-hospital/initial phase was reported by Zhang 2014 as seven days for the initial phase while RECORD 2 Trial reported 10 to 14 days. At the end of the initial phase Zhang 2014 performed ultrasonography on all participants to determine incidence of DVT before the second phase of the trial. The RECORD 2 Trial did not use objective methods to test for DVT at the end of the initial phase of the trial.

Anticoagulant treatments chosen at the investigators' discretion versus placebo

One trial with 857 participants compared thromboprophylaxis using anticoagulant treatments chosen at the investigators' discretion with placebo in participants undergoing total knee replacement (Barrellier 2010). The anticoagulation treatment was either heparin, enoxaparin, dalteparin, tinzaparin, nadroparin or fondaparinux (Barrellier 2010). Duration of the in-hospital/initial phase was reported as 10 days. At the end of the initial phase Barrellier 2010 performed ultrasonography on all participants to determine incidence of DVT before the second phase of the trial.

Vitamin K antagonists versus heparin

One study with a total of 1289 randomised participants evaluated acenocoumarol versus rivarparin sodium ([SACRE Study](#)). All participants began on the LMWH rivarparin sodium until 3 ± 1 days after surgery when participants were randomised to either continue on rivarparin sodium or cross over to acenocoumarol for six weeks. Participants showing clinical signs or symptoms of DVT, PE or major bleeding were not randomised. It is not clear whether those experiencing clinical signs or symptoms of DVT and PE at the randomisation stage underwent objective testing using venography or duplex scanning. The [SACRE Study](#) randomised participants undergoing a total hip replacement.

DOACs versus heparin

Five studies with a total of 16,654 randomised participants evaluated DOAC versus heparin therapy ([ADVANCE 3](#); [EXTEND Study](#); [RECORD 1 Trial](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)). All five studies evaluated participants undergoing a total hip replacement. One study compared apixaban versus enoxaparin ([ADVANCE 3](#)). One study evaluated ximelagatran versus enoxaparin ([EXTEND Study](#)), although this study was terminated early due to safety concerns with ximelagatran. Two studies compared dabigatran etexilate with enoxaparin, one with two doses of dabigatran of 220 mg and 150 mg ([RE-NOVATE Trial](#)) and the other

only evaluated the 220 mg dosage ([RE-NOVATE II Trial](#)). Rivaroxaban was compared to enoxaparin in one study ([RECORD 1 Trial](#)). As these five studies compared two different anticoagulant treatments and randomised participants prior to surgery, there was no initial phase and objective assessment of VTE after initial phase as seen in the studies described above comparing anticoagulants versus placebo.

Excluded studies

A total of seven studies were assessed as excluded ([Comp 2001](#); [EPCAT II](#); [Kristensen 1990](#); [Manganelli 1998](#); [NPHDO Study Group](#); [PENTHIFRA PLUS Study](#); [Swedish Study](#)). Six studies had extended duration, but did not meet the five week minimum requirement ([Comp 2001](#); [EPCAT II](#); [Manganelli 1998](#); [NPHDO Study Group](#); [PENTHIFRA PLUS Study](#); [Swedish Study](#)). [Kristensen 1990](#) did not evaluate a treatment comparison within the scope of this review: heparin plus indomethacin versus heparin plus placebo.

A total of 175 records were deemed not relevant mainly due to the duration of the thromboprophylaxis being 10 to 14 days and not extended duration.

Risk of bias in included studies

See [Figure 2](#) and [Figure 3](#) for further information on risk of bias.

Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
ADVANCE 3	+	+	+	+	+	+	?
Barrellier 2010	+	+	?	+	+	-	+
Dahl 1997	?	?	+	+	+	-	+
DaPP Study	+	?	+	+	+	+	+
EXTEND Study	+	+	+	+	?	?	-
Fragmin Trial	+	+	+	+	+	+	+
French Study	+	+	+	+	+	+	+
Heit 2000	+	+	+	+	+	+	+
Kolb 2003	?	?	+	?	+	+	+
Prandoni 2002	+	+	?	+	+	+	-
RECORD 1 Trial	+	+	+	+	?	+	?
RECORD 2 Trial	+	+	+	+	?	+	?
RE-NOVATE II Trial	+	+	+	+	?	+	?
RE-NOVATE Trial	+	+	+	+	+	+	+
SACRE Study	+	+	?	+	+	+	+
Zhang 2014	+	?	?	?	+	+	+

Overall risk of bias was moderate to low with the largest concerns being some studies either not reporting on listed outcomes or reporting outcomes they did not pre-define, leading to selective reporting bias, and other bias, mainly stemming from early termination or potential conflicts of interest due to the involvement of pharmaceutical companies.

Allocation

Adequate random sequence generation was described in the majority of studies, but two studies did not provide enough detail to make an assessment, and were rated as unclear (Dahl 1997; Kolb 2003).

Likewise, nearly all studies provided enough information to determine if allocation concealment was adequate, yet four studies did not give enough detail (Dahl 1997; DaPP Study; Kolb 2003; Zhang 2014).

Blinding

Performance bias was generally low as most studies were double-blind and utilised a placebo. However, four studies were given an unclear rating as one study was open-label (Barrellier 2010) and three studies did not state either way if they were open-label or double-blind, but as no placebo was acknowledged, they were most likely open-label (Prandoni 2002; SACRE Study; Zhang 2014). It is unclear if knowing the treatment would have an effect on the outcomes.

All studies, except for two (Kolb 2003; Zhang 2014) used a blinded assessor or committee to evaluate at least some, if not all, outcomes. Kolb 2003 and Zhang 2014 may have used blinded assessors, but no details were given.

Incomplete outcome data

Twelve of the 16 included studies had low risk of attrition bias as all participants were accounted for in the analysis, and thorough explanations were given for exclusions. Four studies, while all participants were accounted for, did not give adequate explanations for why some participants stopped taking their medication or never started (EXTEND Study; RECORD 1 Trial; RECORD 2 Trial; RE-NOVATE II Trial).

Selective reporting

The majority of studies had no evidence of reporting bias, but two were rated as high risk of bias because one study had bleeding events listed as an outcome but did not fully report the number of events (Barrellier 2010) and the other reported on several outcomes that were not listed as a pre-planned outcome (Dahl 1997). The EXTEND Study was given an unclear rating as defined outcomes were not reported on after early termination of the trial.

Other potential sources of bias

Two studies were given a high risk of other bias as one study was terminated early due to safety issues and also the funding pharmaceutical company was highly involved in the study design, data collection and analysis (EXTEND Study), and the other study was also terminated early because they had a very high statistical significance with the first 360 enrolled participants (Prandoni 2002). A further four studies also had pharmaceutical companies as funding bodies that were very involved in the design, data collection and analysis of the studies, which could be a conflict of interest (ADVANCE 3; RECORD 1 Trial; RECORD 2 Trial; RE-NOVATE II Trial).

Effects of interventions

See: [Summary of findings for the main comparison](#) Heparin compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair; [Summary of findings 2](#) Vitamin K antagonists compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair; [Summary of findings 3](#) DOAC compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair; [Summary of findings 4](#) Anticoagulants (chosen at investigators' discretion) compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair; [Summary of findings 5](#) Vitamin K antagonists compared to heparin for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair; [Summary of findings 6](#) DOAC compared to heparin for people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Heparin versus placebo

See [Summary of findings for the main comparison](#) and [Appendix 2](#)

Symptomatic VTE (DVT and PE)

Five studies assessed symptomatic VTE (Dahl 1997; Fragmin Trial; French Study; Heit 2000; Kolb 2003) and the fixed-effect model found no difference between the study arms: OR 0.59, 95% CI 0.35 to 1.01; participants = 2329; studies = 5; $I^2 = 0\%$; high quality evidence; [Analysis 1.1](#).

Subgroup analysis by hip or knee replacement showed no differences between the subgroups and no differences between heparin and placebo were observed for the individual surgery groups ([Analysis 1.1](#)).

The findings did not change in studies with an in-hospital or initial phase of 10 to 14 days, or with less than 10 days of in-hospital/initial phase or when the studies that did not have mandatory, objective detection of DVT at hospital discharge were excluded (data analyses not shown).

Symptomatic DVT

Four studies assessed symptomatic DVT (distal or proximal) (Dahl 1997; Fragmin Trial; French Study; Heit 2000) and the fixed-effect model found no difference between the study arms: OR 0.73, 95% CI 0.39 to 1.38; participants = 2019; studies = 4; I^2 = 0%; moderate quality evidence; Analysis 1.2.

Subgroup analysis by hip or knee replacement showed no differences between the subgroups and no differences between heparin and placebo were observed for the individual surgery groups (Analysis 1.2).

The findings did not change in studies with an in-hospital or initial phase of 10 to 14 days, or with less than 10 days of in-hospital/initial phase or when the studies that did not have mandatory, objective detection of DVT at hospital discharge were excluded (data analyses not shown).

Symptomatic PE

The fixed-effect model evaluating three studies for symptomatic PE (Dahl 1997; French Study; Heit 2000), showed no difference between heparin or placebo (OR 0.61, 95% CI 0.16 to 2.33; participants = 1595; studies = 3; I^2 = 49%; low quality evidence) Analysis 1.3.

Subgroup analysis by hip or knee replacement showed no differences between the subgroups and no differences between heparin and placebo were observed for the individual surgery groups (Analysis 1.3).

The findings did not change in studies with an in-hospital or initial phase of 10 to 14 days, or with less than 10 days of in-hospital/initial phase or when the studies that did not have mandatory, objective detection of DVT at hospital discharge were excluded (data analyses not shown).

Regarding sensitivity analysis, Dahl 1997 was found to account for 64.1% of the participants within this outcome, but after its removal no difference was seen in the findings.

Total VTE (symptomatic or asymptomatic)

For the six reporting studies (Dahl 1997; DaPP Study; Fragmin Trial; French Study; Heit 2000; Kolb 2003), the fixed-effect model found decreased odds of any VTE event in favour of heparin (OR 0.39, 95% CI 0.28 to 0.56; participants = 2544; studies = 6; I^2 = 0%; high quality evidence) Analysis 1.4.

For the five studies reporting on hip replacement, the fixed-effect model found decreased odds in favour of heparin (OR 0.37, 95% CI 0.25 to 0.56; participants = 1511; studies = 5; I^2 = 0%) Analysis

1.4. The single study reporting on knee replacement found no difference between the study arms (OR 0.78, 95% CI 0.21 to 2.92; participants = 723) Analysis 1.4. The single study reporting on a combined group of hip or knee replacement participants found decreased odds in favour of heparin (OR 0.38, 95% CI 0.16 to 0.90; participants = 310) Analysis 1.4.

When comparing the subgroup of studies evaluating 10 to 14 day in-hospital/initial phase treatment duration and those that included objective DVT screening at discharge, the findings were still in favour of heparin treatment (data analyses not shown).

Asymptomatic DVT

In the five studies that reported on asymptomatic DVT (Dahl 1997; DaPP Study; Fragmin Trial; French Study; Kolb 2003), the fixed-effect model showed a decreased odds favouring the heparin treatment group (OR 0.38, 95% CI 0.24 to 0.60; participants = 1304; studies = 5; I^2 = 0%; high quality evidence) Analysis 1.5.

When evaluating hip replacement only, the four included studies retained a decreased odds of asymptomatic DVT (OR 0.35, 95% CI 0.21 to 0.58; participants = 994; studies = 4; I^2 = 0%) Analysis 1.5. The single study reporting on a combined group of hip or knee replacement participants found no difference between the study arms (OR 0.54, 95% CI 0.19 to 1.52; participants = 310) Analysis 1.5.

When comparing the subgroup of studies evaluating 10 to 14 day in-hospital/initial phase treatment duration and those that included objective DVT screening at discharge, the findings were still in favour of heparin treatment (data analyses not shown).

Asymptomatic proximal DVT

None of the included studies reported on asymptomatic proximal DVT. Many did report asymptomatic or proximal DVT separately, but given the provided data, it was not possible to determine which events fell into both categories.

Asymptomatic distal DVT

No studies reported asymptomatic distal DVT. See above description. Many did report asymptomatic or distal DVT separately, but given the provided data, it was not possible to determine which events fell into both categories.

All-cause mortality

For the five included studies that evaluated all-cause mortality for heparin versus placebo (Dahl 1997; Fragmin Trial; French Study; Heit 2000; Kolb 2003), there was no difference between the study arms (OR 1.01, 95% CI 0.31 to 3.26; participants = 2518; studies = 5; I^2 = 0%; moderate quality evidence) Analysis 1.6.

There was also no difference in the four studies evaluating participants undergoing hip replacement (OR 0.56, 95% CI 0.11 to

2.75; participants = 1485; studies = 4; $I^2 = 0\%$) [Analysis 1.6](#), or in the one study undergoing knee replacement (OR 0.98, 95% CI 0.06 to 15.65; participants = 723) [Analysis 1.6](#). The single study reporting on a combined group of hip or knee replacement participants also found no difference between the study arms (OR 4.69, 95% CI 0.22 to 98.42; participants = 310) [Analysis 1.6](#). When only evaluating studies that had an in-hospital/initial phase of 10 to 14 days or studies that included objective DVT verification at discharge, there was still no difference between study arms (data analysis not shown).

Adverse events

Only two studies evaluating participants undergoing hip replacement reported on adverse events ([DaPP Study](#); [French Study](#)) and found no difference between study arms (OR 1.06, 95% CI 0.68 to 1.64; participants = 460; $I^2 = 4\%$; moderate quality evidence [Analysis 1.7](#)), although it should be noted that there was minimal or no description of the criteria for adverse event reporting, and it varied greatly between the two reporting studies. Too few studies remained for subgroup analysis by initial phase duration or objective DVT verification at discharge (data analyses not shown).

Bleeding events (major, clinically relevant non-major, minor)

Major bleeding was reported in five studies ([DaPP Study](#); [Fragmin Trial](#); [French Study](#); [Heit 2000](#); [Kolb 2003](#)) and minor bleeding was reported in five studies ([DaPP Study](#); [Fragmin Trial](#); [French Study](#); [Heit 2000](#); [Kolb 2003](#)). Clinically relevant non-major bleeding was not reported by the included studies comparing heparin and placebo.

There was no difference in major bleeding between the study arms (OR 0.59, 95% CI 0.14 to 2.46; participants = 2500; studies = 5; $I^2 = 0\%$; moderate quality evidence [Analysis 1.8](#)).

For participants undergoing hip replacement, there was no difference in major bleeding (OR 0.32, 95% CI 0.03 to 3.10; participants = 1494; studies = 4; $I^2 = 0\%$) [Analysis 1.8](#). There was no difference in major bleeding in participants undergoing knee replacement (OR 0.99, 95% CI 0.14 to 7.06; participants = 696; studies = 1; $I^2 = 0\%$) [Analysis 1.8](#). The single study reporting on a combined group of hip or knee replacement participants reported no major bleeding in either study arm (0/161 heparin versus 0/149 placebo).

There was an increased odds of minor bleeding in the heparin treatment group compared with placebo (OR 2.01, 95% CI 1.43 to 2.81; participants = 2500; studies = 5; $I^2 = 0\%$; high quality evidence) [Analysis 1.9](#).

For participants undergoing hip replacement, there was an increased odds of minor bleeding in the heparin treatment group compared with placebo (OR 2.25, 95% CI 1.53 to 3.30; participants = 1494; studies = 4; $I^2 = 0\%$) [Analysis 1.9](#). There was no

difference in minor bleeding in participants undergoing knee replacement (OR 1.23, 95% CI 0.58 to 2.59; participants = 696; studies = 1) [Analysis 1.9](#). The single study reporting on a combined group of hip and knee replacement participants also reported no difference in minor bleeding in both study arms (OR 2.79, 95% CI 0.11 to 69.13; participants = 310; studies = 1; $I^2 = 0\%$) [Analysis 1.9](#).

There were no changes to the findings when only comparing studies with a in-hospital/initial phase of 10 to 14 days or studies that had objective DVT testing at discharge (data analyses not shown).

Reoperation

The [DaPP Study](#) reported that two participants required reoperation but did not report from which study arm. [Dahl 1997](#) reported reoperation due to bleeding to be a safety outcome but did not present data. The [Fragmin Trial](#), [Heit 2000](#) and [Kolb 2003](#) did not report on reoperation. The [French Study](#) reported that no reoperations were required following bleeding [Analysis 1.10](#).

Wound infection

[DaPP Study](#), [French Study](#), [Heit 2000](#) and [Kolb 2003](#) did not report on wound infection. [Dahl 1997](#) reported that the majority of adverse events were luxation of prosthesis and infection but did not report specific numbers for the study arms. The [Fragmin Trial](#) reported wound infection as part of complications associated with wound haematoma but no specific details for infection were provided.

Wound healing

None of the six studies comparing heparin with placebo reported wound healing ([Dahl 1997](#); [DaPP Study](#); [Fragmin Trial](#); [French Study](#); [Heit 2000](#); [Kolb 2003](#)).

Vitamin K antagonists versus placebo

One study evaluated vitamin K antagonist versus placebo ([Prandoni 2002](#)), in participants undergoing hip replacement, and therefore no subgroup analysis between hip and knee replacement was undertaken. We found no difference between the treatment groups for any of the evaluated outcomes except for total VTE. See [Summary of findings 2](#) and [Appendix 3](#).

Symptomatic VTE (DVT and PE)

No difference between VKA and placebo was observed for symptomatic VTE (OR 0.10, 95% CI 0.01 to 1.94; participants = 360; moderate quality evidence) [Analysis 2.1](#).

Symptomatic DVT

No difference between VKA and placebo was observed for symptomatic DVT (OR 0.13, 95% CI 0.01 to 2.62; participants = 360; moderate quality evidence) [Analysis 2.2](#).

Symptomatic PE

No difference between VKA and placebo was observed for symptomatic PE (OR 0.32, 95% CI 0.01 to 7.84; participants = 360; moderate quality evidence) [Analysis 2.3](#).

Total VTE (symptomatic or asymptomatic)

[Prandoni 2002](#) showed decreased odds of any VTE event in favour of VKA versus placebo (OR 0.10, 95% CI 0.01 to 0.81; participants = 360; moderate quality evidence) [Analysis 2.4](#).

Asymptomatic DVT

[Prandoni 2002](#) did not report on asymptomatic DVT.

Asymptomatic proximal DVT

[Prandoni 2002](#) did not report on asymptomatic proximal DVT.

Asymptomatic distal DVT

[Prandoni 2002](#) did not report on asymptomatic distal DVT.

All-cause mortality

[Prandoni 2002](#) reported no deaths in either study arm (0/184 VKA versus 0/176 placebo) [Analysis 2.5](#).

Adverse events

[Prandoni 2002](#) reported no adverse events in either study arm (0/184 VKA versus 0/176 placebo) [Analysis 2.6](#).

Bleeding events (major, clinically relevant non-major, minor)

There were no differences between the study arms in major bleeding (OR 2.89, 95% CI 0.12 to 71.31; participants = 360; low quality evidence) [Analysis 2.7](#). [Prandoni 2002](#) did not report clinically relevant non-major bleeding or minor bleeding.

Reoperation

[Prandoni 2002](#) did not report on reoperation.

Wound infection

[Prandoni 2002](#) did not report on wound infection.

Wound healing

[Prandoni 2002](#) did not report on wound healing.

DOACs versus placebo

Two studies evaluated DOACs versus placebo ([RECORD 2 Trial](#); [Zhang 2014](#)) in participants undergoing hip replacement, and therefore no subgroup analysis between hip and knee replacement was undertaken. [Zhang 2014](#) reported assessment of symptomatic DVT only and is therefore only included in the analysis for symptomatic DVT. See [Summary of findings 3](#) and [Appendix 4](#).

Symptomatic VTE (DVT and PE)

The [RECORD 2 Trial](#) reported on symptomatic VTE showing a reduced odds of VTE in favour of the DOAC treatment (OR 0.20, 95% CI 0.06 to 0.68; participants = 2419; moderate quality evidence) [Analysis 3.1](#).

Symptomatic DVT

A reduced odds of symptomatic DVT in favour of DOAC treatment was observed (OR 0.18, 95% CI 0.04 to 0.81; participants = 2459; studies = 2; I^2 = not applicable; high quality evidence) [Analysis 3.2](#).

Symptomatic PE

No difference between DOACs and placebo was observed for symptomatic PE (OR 0.25, 95% CI 0.03 to 2.25; participants = 1733; studies = 1; low quality evidence) [Analysis 3.3](#).

Total VTE (symptomatic or asymptomatic)

The [RECORD 2 Trial](#) showed decreased odds of any VTE event in favour of DOAC treatment versus placebo (OR 0.19, 95% CI 0.11 to 0.33; moderate quality evidence) [Analysis 3.4](#).

Asymptomatic DVT

The [RECORD 2 Trial](#) and [Zhang 2014](#) do not report on asymptomatic DVT.

Asymptomatic proximal DVT

The [RECORD 2 Trial](#) and [Zhang 2014](#) do not report on asymptomatic proximal DVT.

Asymptomatic distal DVT

The [RECORD 2 Trial](#) and [Zhang 2014](#) do not report on asymptomatic distal DVT.

All-cause mortality

There were no differences between the study arms in all-cause mortality (OR 0.33, 95% CI 0.07 to 1.66; participants = 1733; studies = 1; low quality evidence [Analysis 3.5](#)).

Adverse events

The [RECORD 2 Trial](#) reported no differences in adverse events (OR 0.87, 95% CI 0.74 to 1.03; participants = 2457; moderate quality evidence) [Analysis 3.6](#).

Bleeding events (major, clinically relevant non-major, minor)

There were no differences in any of the bleeding event categories reported by [RECORD 2 Trial](#); major bleeding (OR 1.00, 95% CI 0.06 to 16.02; participants = 2457; low quality evidence [Analysis 3.7](#)); clinically relevant bleeding (OR 1.22, 95% CI 0.76 to 1.95; participants = 2457; moderate quality evidence [Analysis 3.8](#)); minor bleeding (OR 1.18, 95% CI 0.74 to 1.88; participants = 2457; moderate quality evidence [Analysis 3.9](#)).

Reoperation

The [RECORD 2 Trial](#) reported reoperation following bleeding; no cases of reoperation (0/1228 DOAC versus 0/1229 placebo) were reported [Analysis 3.10](#).

Wound infection

The [RECORD 2 Trial](#) reported no differences in post-operative wound infections (OR 1.34, 95% CI 0.46 to 3.86; participants = 2457; low quality evidence) [Analysis 3.11](#).

Wound healing

The [RECORD 2 Trial](#) and [Zhang 2014](#) did not report wound healing.

Anticoagulant treatments chosen at the investigators' discretion versus placebo

One study evaluated anticoagulant treatment chosen at the investigators' discretion versus placebo ([Barrellier 2010](#)) in participants undergoing knee replacement, and therefore no subgroup analysis between hip and knee replacement was undertaken. The anticoagulation treatment was either heparin, enoxaparin, dalteparin, tinzaparin, nadroparin or fondaparinux, at the discretion of the

investigator at the study location. See [Summary of findings 4](#) and [Appendix 5](#).

Symptomatic VTE (DVT and PE)

No difference between anticoagulant treatment and placebo was observed for symptomatic VTE (OR 0.50, 95% CI 0.09 to 2.74; participants = 557; low quality evidence) [Analysis 4.1](#).

Symptomatic DVT

No difference between anticoagulant treatment and placebo was observed for symptomatic DVT (OR 0.33, 95% CI 0.03 to 3.21; participants = 557; low quality evidence) [Analysis 4.2](#).

Symptomatic PE

No difference between anticoagulant treatment and placebo was observed for symptomatic PE (OR 1.00, 95% CI 0.06 to 16.13; participants = 557; low quality evidence) [Analysis 4.3](#).

Total VTE (symptomatic or asymptomatic)

The [Barrellier 2010](#) study showed decreased odds of any VTE event in favour of anticoagulant treatment versus placebo (OR 0.26, 95% CI 0.14 to 0.50; participants = 557; moderate quality evidence) [Analysis 4.4](#).

Asymptomatic DVT

[Barrellier 2010](#) showed a significant difference in new cases of asymptomatic DVT favouring anticoagulant treatment compared to placebo (OR 0.26, 95% CI 0.13 to 0.54; participants = 557; moderate quality evidence) [Analysis 4.5](#). [Barrellier 2010](#) reported on asymptomatic distal DVT cases only.

Asymptomatic proximal DVT

[Barrellier 2010](#) did not report asymptomatic proximal DVT.

Asymptomatic distal DVT

[Barrellier 2010](#) reported asymptomatic distal DVT as described above ([Analysis 4.6](#)).

All-cause mortality

[Barrellier 2010](#) reported no deaths in either study arm (0/422 anticoagulant treatment versus 0/420 placebo) [Analysis 4.7](#).

Adverse events

[Barrellier 2010](#) did not report adverse events.

Bleeding events (major, clinically relevant non-major, minor)

There were no differences between the treatment groups in major bleeding (OR 5.05, 95% CI 0.24 to 105.76; participants = 557; low quality evidence). [Analysis 4.8](#). [Barrellier 2010](#) did not report clinically relevant non-major bleeding or minor bleeding.

Reoperation

[Barrellier 2010](#) reported on reoperation as part of their definition of major bleeding outcome (bleeding leading to reoperation) but did not report this data separately.

Wound infection

[Barrellier 2010](#) did not report on wound infection.

Wound healing

[Barrellier 2010](#) did not report on wound healing.

Vitamin K antagonists versus heparin

One study evaluated vitamin K antagonists versus heparin ([SACRE Study](#)) in participants undergoing hip replacement, and therefore no subgroup analysis between hip and knee replacement was undertaken. We found no difference between the treatment groups for any of the evaluated outcomes. See [Summary of findings 5](#) and [Appendix 6](#).

Symptomatic VTE (DVT and PE)

No difference was observed in symptomatic VTE between the treatment groups (OR 1.64, 95% CI 0.85 to 3.16; participants = 1279; low quality evidence) [Analysis 5.1](#).

Symptomatic DVT

There was also no difference between the treatment groups for symptomatic DVT (OR 1.36, 95% CI 0.69 to 2.68; participants = 1279; low quality evidence) [Analysis 5.2](#).

Symptomatic PE

No cases of PE were reported in the heparin group (0/643) compared with 4 cases in the VKA group (4/636). No difference was found between the treatment groups for the outcome of symptomatic PE (OR 9.16, 95% CI 0.49 to 170.42; participants = 1279; low quality evidence) [Analysis 5.3](#).

Total VTE (symptomatic or asymptomatic)

There was no difference in total VTE between the treatment groups (OR 1.64, 95% CI 0.85 to 3.16; participants = 1279; low quality evidence) [Analysis 5.4](#).

Asymptomatic DVT

The [SACRE Study](#) did not report asymptomatic DVT.

Asymptomatic proximal DVT

The [SACRE Study](#) did not report asymptomatic proximal DVT.

Asymptomatic distal DVT

The [SACRE Study](#) did not report asymptomatic distal DVT.

All-cause mortality

No cases of death were reported in the heparin group (0/643) compared with 2 cases in the VKA group (2/636). There was no difference in all-cause mortality between the treatment groups (OR 5.07, 95% CI 0.24 to 105.83; participants = 1279; low quality evidence) [Analysis 5.5](#).

Adverse events

The [SACRE Study](#) did not report adverse events.

Bleeding events (major, clinically relevant non-major, minor)

There were no differences between the treatment groups in major or minor bleeding (OR 3.87, 95% CI 1.91 to 7.85; participants = 1272; low quality evidence, [Analysis 5.6](#), and OR 1.33, 95% CI 0.64 to 2.76; participants = 1279; low quality evidence [Analysis 5.7](#), respectively). The [SACRE Study](#) did not report clinically relevant non-major bleeding.

Reoperation

The [SACRE Study](#) reported on reoperation as part of their definition of major bleeding outcome (bleeding leading to reoperation; reoperation was required in 11 participants (two in the rivaroxaban group and nine in the acenocoumarol group (OR 4.60, 95% CI 0.99 to 21.38; participants = 1279; low quality evidence).

Wound infection

The [SACRE Study](#) did not report wound infection.

Wound healing

The [SACRE Study](#) did not report wound healing.

DOACs versus heparin

Five studies evaluated DOACs versus heparin therapy ([ADVANCE 3](#); [EXTEND Study](#); [RECORD 1 Trial](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)). The studies evaluating DOACs versus heparin were only performed in participants undergoing hip replacement, and therefore no subgroup analysis between hip and knee replacement was undertaken. As these studies compared two different anticoagulant treatments and randomised participants prior to surgery, there was no initial phase and objective assessment of VTE after the initial phase. Therefore these subgroup analyses were not possible. We found no difference between the treatment groups for most of the evaluated outcomes. Due to heterogeneity in the data, some of the meta-analyses in this treatment profile used random-effects models. See [Summary of findings 6](#) and [Appendix 7](#).

Symptomatic VTE (DVT and PE)

The random-effects model evaluating five studies ([ADVANCE 3](#); [EXTEND Study](#); [RECORD 1 Trial](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)) found no difference in symptomatic VTE between the treatment groups (OR 0.70, 95% CI 0.28 to 1.70; participants = 15,977; $I^2 = 55\%$; low quality evidence) [Analysis 6.1](#).

Symptomatic DVT

There was no difference between the treatment groups for symptomatic DVT, as evaluated by the random-effects model in five studies ([ADVANCE 3](#); [EXTEND Study](#); [RECORD 1 Trial](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)) (OR 0.60, 95% CI 0.11 to 3.27; participants = 15,977; $I^2 = 65\%$; low quality evidence) [Analysis 6.2](#).

Symptomatic PE

No difference was found between the DOAC and LMWH treatment groups for the outcome of symptomatic PE (OR 0.91, 95% CI 0.43 to 1.94; participants = 14,731; studies = 5; $I^2 = 0\%$; moderate quality evidence) [Analysis 6.3](#).

Total VTE (symptomatic or asymptomatic)

There was significant difference in total VTE in the random-effects model evaluating four studies favouring DOACs ([ADVANCE 3](#); [RECORD 1 Trial](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)) (OR 0.53, 95% CI 0.29 to 0.97; participants = 12,447; $I^2 = 87\%$; moderate quality evidence) [Analysis 6.4](#).

Asymptomatic DVT

In the random-effects model, there was no difference in asymptomatic DVT between treatment groups in the two reporting studies ([ADVANCE 3](#); [RE-NOVATE Trial](#)) (OR 0.56, 95% CI 0.19 to 1.59; participants = 6559; $I^2 = 92\%$; low quality evidence) [Analysis 6.5](#).

Asymptomatic proximal DVT

Only a single study ([RE-NOVATE Trial](#)) reported on asymptomatic proximal DVT (OR 0.73, 95% CI 0.46 to 1.15; participants = 2704; moderate quality evidence) [Analysis 6.6](#).

Asymptomatic distal DVT

As for asymptomatic proximal DVT, a single study ([RE-NOVATE Trial](#)) reported on asymptomatic distal DVT (OR 1.22, 95% CI 0.75 to 1.99; participants = 2639; moderate quality evidence) [Analysis 6.7](#).

All-cause mortality

For the five reporting studies ([ADVANCE 3](#); [EXTEND Study](#); [RECORD 1 Trial](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)), there was no difference in all-cause mortality between the treatment groups based on the fixed-effect model ((OR 1.63, 95% CI 0.64 to 4.16; participants = 14,966; studies = 5; $I^2 = 0\%$; moderate quality evidence) [Analysis 6.8](#). Regarding sensitivity analysis, the [RECORD 1 Trial](#) was found to account for 56% of the participants within this outcome, but after its removal no difference was seen in the findings.

Adverse events

There was also no difference in adverse events between treatment groups in the three studies reporting adverse events ([RECORD 1 Trial](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)) (OR 0.96, 95% CI 0.88 to 1.05; participants = 9908; studies = 3; $I^2 = 0\%$; high quality evidence) [Analysis 6.9](#). Regarding sensitivity analysis, the [RECORD 1 Trial](#) was found to account for 50.8% of the participants within this outcome, but after its removal no difference was seen in the findings.

Bleeding events (major, clinically relevant non-major, minor)

Major bleeding was reported in five studies ([ADVANCE 3](#); [EXTEND Study](#); [RECORD 1 Trial](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)), clinically relevant non-major bleeding was reported in four studies ([ADVANCE 3](#); [RECORD 1 Trial](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)), and minor bleeding was reported in four studies ([ADVANCE 3](#); [EXTEND Study](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)).

There were no differences in any of the bleeding event categories within the studies reporting on bleeding events; major bleeding, OR 1.11, 95% CI 0.79 to 1.54; participants = 16,199; studies = 5; $I^2 = 21\%$, high quality evidence [Analysis 6.10](#); clinically relevant bleeding OR 1.08, 95% CI 0.90 to 1.28; participants = 15,241; studies = 4; $I^2 = 7\%$, high quality evidence [Analysis 6.11](#); minor bleeding OR 0.95, 95% CI 0.82 to 1.10; participants = 11,766; studies = 4; $I^2 = 0\%$, high quality evidence [Analysis 6.12](#).

For minor bleeding, [ADVANCE 3](#) accounted for 53.3% of the participants, and when removed in a sensitivity analysis there were no differences in the association.

Reoperation

Four studies reported on reoperation relating to bleeding ([ADVANCE 3](#); [RECORD 1 Trial](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)) showing no differences between the study arms (OR 1.06, 95% CI 0.34 to 3.24; participants = 15241; studies = 4; $I^2 = 0\%$; moderate quality evidence) [Analysis 6.13](#).

The [RE-NOVATE Trial](#) accounted for > 50 % of the weight and when removed in a sensitivity analysis there were no differences in the association.

Wound infection

Three studies reported on wound infection ([RECORD 1 Trial](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)). The [RE-NOVATE](#)

[Trial](#) reported one participant who died of septicaemia and GI bleeding following ischaemic bowel resection but reported no other cases of wound infection. Pooling [RECORD 1 Trial](#) and [RE-NOVATE II Trial](#) showed no differences in wound infections between the treatment arms (OR 0.89, 95% CI 0.46 to 1.72; participants = 6446; studies = 2; $I^2 = 0\%$; moderate quality evidence) [Analysis 6.14](#).

Wound healing

None of the five studies included in this comparison reported on wound healing ([ADVANCE 3](#); [EXTEND Study](#); [RECORD 1 Trial](#); [RE-NOVATE II Trial](#); [RE-NOVATE Trial](#)).

Reporting bias, subgroup and sensitivity analysis

We did not construct funnel plots for meta analyses because the meta analyses did not include at least 10 studies.

We planned to apply subgroup analysis to examine participants undergoing revisions of a previous hip or knee replacement or hip fracture repair, but we unfortunately found this to be impossible because these data were not reported separately. As the duration of the in-hospital/initial phase ranged from four days to 14 days, subgroup analysis for 15 days or more was not required. Results of the other planned subgroup analyses are reported above. We did not consider any studies to be of low quality based on the 'Risk of bias' tool and therefore did not perform the planned sensitivity analysis for this reason.

ADDITIONAL SUMMARY OF FINDINGS *[Explanation]*

Vitamin K antagonists compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair						
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Setting: hospital and outpatient setting Intervention: vitamin K antagonists Comparison: placebo						
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo	Risk with vitamin K antagonists				
Symptomatic VTE (DVT and PE) Treatment duration 28 - 42 days	Study population		OR 0.10 (0.01 to 1.94)	360 (1 RCT)	⊕⊕⊕○ MODERATE ¹	-
	23 per 1000	2 per 1000 (0 to 43)				
Symptomatic DVT (proximal or distal) Treatment duration 28 - 42 days	Study population		OR 0.13 (0.01 to 2.62)	360 (1 RCT)	⊕⊕⊕○ MODERATE ¹	-
	17 per 1000	2 per 1000 (0 to 43)				
Symptomatic PE Treatment duration 28 - 42 days	Study population		OR 0.32 (0.01 to 7.84)	360 (1 RCT)	⊕⊕⊕○ MODERATE ¹	-
	6 per 1000	2 per 1000 (0 to 43)				
Bleeding - major Treatment duration 28 - 42 days	see comment		OR 2.89 (0.12 to 71.31)	360 (1 RCT)	⊕⊕○○ LOW ¹²	no events recorded in placebo group
Clinically relevant non-major bleeding Treatment duration 28 - 42 days	see comment		-	-	-	not reported

Minor bleeding Treatment duration 28 - 42 days	see comment	-	-	-	not reported
--	-------------	---	---	---	--------------

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **DVT:** deep vein thrombosis; **OR:** odds ratio; **PE:** pulmonary embolism; **RCT:** randomised controlled trial; **VTE:** venous thromboembolism

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Downgraded by one level, results from a single study only so heterogeneity could not be assessed

² Downgraded by one level, number of events small leading to wide CI and imprecision of results

DOAC compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair						
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair						
Setting: hospital and outpatient setting						
Intervention: DOAC						
Comparison: placebo						
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo	Risk with DOAC				
Symptomatic VTE (DVT and PE) Treatment duration 28 - 42 days	Study population		OR 0.20 (0.06 to 0.68)	2419 (1 RCT)	⊕⊕⊕○ MODERATE ¹	-
	12 per 1000	3 per 1000 (1 to 8)				
Symptomatic DVT (proximal or distal) Treatment duration 28 - 42 days	Study population		OR 0.18 (0.04 to 0.81)	2459 (2 RCTs)	⊕⊕⊕⊕ HIGH	-
	9 per 1000	2 per 1000 (0 to 7)				
Symptomatic PE Treatment duration 28 - 42 days	Study population		OR 0.25 (0.03 to 2.25)	1733 (1 RCT)	⊕⊕○○ LOW ¹²	-
	5 per 1000	1 per 1000 (0 to 10)				
Bleeding - major Treatment duration 28 - 42 days	Study population		OR 1.00 (0.06 to 16.02)	2457 (1 RCT)	⊕⊕○○ LOW ¹²	-
	1 per 1000	1 per 1000 (0 to 13)				
Bleeding-clinically relevant non-major Treatment duration 28 - 42 days	Study population		OR 1.22 (0.76 to 1.95)	2457 (1 RCT)	⊕⊕⊕○ MODERATE ¹	-

	27 per 1000	33 per 1000 (21 to 51)			
Bleeding - minor Treatment duration 28 - 42 days	Study population		OR 1.18 (0.74 to 1.88)	2457 (1 RCT)	⊕⊕⊕○ MODERATE ¹
	28 per 1000	32 per 1000 (21 to 51)			-

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **DOAC:** direct oral anticoagulant; **DVT:** deep vein thrombosis; **OR:** odds ratio; **PE:** pulmonary embolism; **RCT:** randomised controlled trial; **VTE:** venous thromboembolism

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Downgraded by one level, results from a single study so heterogeneity cannot be assessed

² Downgraded by one level, low number of events leading to wide CI and imprecision of results

Anticoagulants (chosen at investigators' discretion) compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair						
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Setting: hospital and outpatient setting Intervention: anticoagulant (chosen at investigators' discretion) Comparison: placebo						
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo	Risk with anticoagulant (chosen at investigators' discretion)				
Symptomatic VTE (DVT and PE) Treatment duration 28 - 42 days	Study population 14 per 1000	7 per 1000 (1 to 38)	OR 0.50 (0.09 to 2.74)	557 (1 RCT)	⊕⊕○○ LOW ¹²	-
Symptomatic DVT (proximal or distal) Treatment duration 28 - 42 days	Study population 11 per 1000	4 per 1000 (0 to 34)	OR 0.33 (0.03 to 3.21)	557 (1 RCT)	⊕⊕○○ LOW ¹²	-
Symptomatic PE Treatment duration 28 - 42 days	Study population 4 per 1000	4 per 1000 (0 to 55)	OR 1.00 (0.06 to 16.13)	557 (1 RCT)	⊕⊕○○ LOW ¹²	-
Bleeding - major Treatment duration 28 - 42 days	see comment		OR 5.05 (0.24 to 105.76)	557 (1 RCT)	⊕⊕○○ LOW ¹²	no major bleeding recorded in the placebo groups

Clinically relevant non-major bleeding Treatment duration 28 - 42 days	see comment	-	-	-	not reported
Minor bleeding Treatment duration 28 - 42 days	see comment	-	-	-	not reported

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **DVT:** deep vein thrombosis; **OR:** odds ratio; **PE:** pulmonary embolism; **RCT:** randomised controlled trial; **VTE:** venous thromboembolism

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Downgraded by one level, results from a single study so heterogeneity could not be assessed

² Downgraded by one level, low number of events leading to wide CIs and imprecision of results

Vitamin K antagonists compared to heparin for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair						
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Setting: hospital and outpatient setting Intervention: vitamin K antagonists Comparison: heparin						
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with heparin	Risk with vitamin K antagonists				
Symptomatic VTE (DVT and PE) Treatment duration 28 - 42 days	Study population		OR 1.64 (0.85 to 3.16)	1279 (1 RCT)	⊕⊕○○ LOW ¹²	-
	23 per 1000	38 per 1000 (20 to 70)				
Symptomatic DVT (proximal or distal) Treatment duration 28 - 42 days	Study population		OR 1.36 (0.69 to 2.68)	1279 (1 RCT)	⊕⊕○○ LOW ¹²	-
	23 per 1000	31 per 1000 (16 to 60)				
Symptomatic PE Treatment duration 28 - 42 days	see comment		OR 9.16 (0.49 to 170.42)	1279 (1 RCT)	⊕⊕○○ LOW ¹³	no cases of symptomatic PE reported in the heparin study arm
Bleeding - major Treatment duration 28 - 42 days	Study population		OR 3.87 (1.91 to 7.85)	1272 (1 RCT)	⊕⊕○○ LOW ¹²	-
	16 per 1000	58 per 1000 (30 to 111)				
Bleeding - clinically indicated non-major Treatment duration 28 - 42 days	see comment		-	-	-	clinically indicated non-major bleeding events not reported in single included study in this

		comparison			
Bleeding - minor Treatment duration 28 - 42 days	Study population	OR 1.33 (0.64 to 2.76)	1279 (1 RCT)	⊕⊕○○ LOW ¹²	-
	20 per 1000 27 per 1000 (13 to 54)				

* **The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **DVT:** deep vein thrombosis; **OR:** odds ratio; **PE:** pulmonary embolism; **RCT:** randomised controlled trial; **VKA:** vitamin K antagonist; **VTE:** venous thromboembolism

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Downgraded by one level, single study so heterogeneity could not be assessed

² Downgraded by one level, wide CI

³ Downgraded by one level, low number of events leading to imprecision of results

DOAC compared to heparin for people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair						
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Setting: hospital and outpatient setting Intervention: DOAC Comparison: heparin						
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with heparin	Risk with DOAC				
Symptomatic VTE (DVT and PE) Treatment duration 28 - 42 days	Study population		OR 0.70 (0.28 to 1.70)	15977 (5 RCTs)	⊕⊕○○ LOW ¹²	-
	4 per 1000	3 per 1000 (1 to 8)				
Symptomatic DVT (proximal or distal) Treatment duration 28 - 42 days	Study population		OR 0.60 (0.11 to 3.27)	15977 (5 RCTs)	⊕⊕○○ LOW ²³	-
	3 per 1000	2 per 1000 (0 to 9)				
Symptomatic PE Treatment duration 28 - 42 days	Study population		OR 0.91 (0.43 to 1.94)	14731 (5 RCTs)	⊕⊕⊕○ MODERATE ²	-
	2 per 1000	2 per 1000 (1 to 4)				
Bleeding - major Treatment duration 28 - 42 days	Study population		OR 1.11 (0.79 to 1.54)	16199 (5 RCTs)	⊕⊕⊕⊕ HIGH	-
	8 per 1000	9 per 1000 (7 to 13)				
Bleeding - clinically relevant, non-major Treatment duration 28 - 42 days	Study population		OR 1.08 (0.90 to 1.28)	15241 (4 RCTs)	⊕⊕⊕⊕ HIGH	-

	33 per 1000	36 per 1000 (30 to 42)			
Bleeding - minor Treatment duration 28 - 42 days	Study population		OR 0.95 (0.82 to 1.10)	11766 (4 RCTs)	⊕⊕⊕⊕ HIGH
	66 per 1000	63 per 1000 (55 to 72)			-

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **DOAC:** direct oral anticoagulant; **DVT:** deep vein thrombosis; **OR:** odds ratio; **PE:** pulmonary embolism; **RCT:** randomised controlled trial; **VTE:** venous thromboembolism

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Downgraded by one level for inconsistency (heterogeneity, $I^2 = 55\%$)

² Downgraded by one level for imprecision due to low number of events leading to wide CI

³ Downgraded by one level for inconsistency (heterogeneity, $I^2 = 65\%$)

DISCUSSION

Summary of main results

We have shown that extended-duration prophylaxis with DOACs in patients undergoing major hip or knee replacement surgery significantly reduces the risk of symptomatic VTE. This benefit is achieved with no excess adverse events or major bleeding but with increased minor bleeding. A significant reduction in PE or mortality could not be shown but the direction of the treatment effect for these outcomes was consistent with that seen for the primary outcome, suggesting that a similar reduction for these outcomes might be expected.

Our findings of a significant treatment benefit of extended-duration prophylaxis for prevention of symptomatic VTE are based on a pooled analysis of both hip and knee replacement trials. However, our meta-analysis cannot draw a fully informed conclusion for participants undergoing knee replacement as far fewer studies evaluated these types of participants separately, as compared with hip replacement.

When comparing extended-duration anticoagulants (DOACs and VKA) versus extended-duration LMWHs there were no differences between the treatments in symptomatic and asymptomatic VTE and showed decreased odds in total VTE for DOACs versus LMWH. There was also no difference in mortality, adverse events or bleeding events. These findings support the use of less invasive oral anticoagulants versus the more invasive LMWHs which often have to be administered by injection into subcutaneous tissue. However, it needs to be kept in mind that several of the meta-analyses were underpowered and showed heterogeneity. We hope with the inclusion of new studies in future updates of this review we will be better able to draw stronger conclusions regarding these treatment comparisons.

One widely recognised impediment to the more widespread use of effective prophylaxis in patients undergoing hip or knee replacement is concern about the risk of bleeding. In this regard, the data from our review are reassuring in that, even with sustained use for up to six weeks, prophylactic-dose anticoagulants is not associated with an excess in major bleeding in all comparisons except for the comparison of VKA versus heparin.

Overall completeness and applicability of evidence

This review included a total of 16 studies with nearly 25,000 randomised participants. Despite this large number of included studies some comparisons included a single study only, or few events were recorded, which led to wide confidence intervals, and difficulties interpreting the data.

There are other antithrombotic therapies besides the ones evaluated in this review that might be used for prevention of VTE

in major orthopaedic surgery or out-of-hospital prophylaxis, for example aspirin, which were not addressed in this review. We plan to include these in future updates of this review.

Although compliance with extended-duration prophylaxis seemed to be 90% or higher in most trials included in our meta-analyses, the definition of compliance varied among the studies and not all studies reported the level of compliance with randomised treatment allocation that was achieved. However, the probable impact of lack of compliance is to reduce the power of a randomised trial to detect a significant treatment benefit. Therefore an even greater benefit of extended-duration prophylaxis might be realised in populations in which higher levels of compliance are achieved.

Wang 2014 reported that surgical site infections and reoperations in the three months following joint replacements may be associated with anticoagulant use and this may be a barrier to extended thromboprophylaxis but our meta-analyses are underpowered to draw conclusions on this issue due to a lack of reporting of wound infections, wound healing and reoperations in the studies included in this review.

Quality of the evidence

Despite examining the totality of the evidence by pooling results from all the available properly randomised trials, the total number of participants randomly assigned and the number of outcome events was modest. Therefore, our meta-analyses potentially lacked statistical power to provide precise estimates of frequency and treatment effect for clinically important outcomes such as PE. However, DVT and PE represent clinical manifestations of the same underlying disease process. Therefore, strategies that are effective for the prevention of DVT, especially those proximally located, are likely also to be effective for the prevention of non-fatal and fatal PE.

There was a lot of variation in the design of studies included in our meta-analyses. However, differences among trials are inevitable since individual trials look at different populations with different treatment protocols, and there is always some heterogeneity, even within individual trials (Lau 1998; Thompson 1994). Differences in trial design do not necessarily preclude pooling of their results since, in a meta-analysis, individual participants are directly compared only with other participants within the same trial, and not across the trials. The validity of our approach is further supported by the external consistency of our findings with the results of individual trials.

The quality of the evidence varied by comparison and was on average moderate. Heterogeneity was found between studies comparing DOAC and heparin, and for some outcomes, such as PE and mortality, few events were recorded during the study periods leading to imprecision. For three comparisons, only one study was identified. See [Summary of findings for the main comparison](#); [Summary of findings 2](#); [Summary of findings 3](#); [Summary of](#)

findings 4; Summary of findings 5; Summary of findings 6 for further details.

Potential biases in the review process

Every effort was made to limit potential biases in the review through duplication of study selection, data extraction and assessment of risk of bias by two review authors. Also, we utilised pre-designed data extraction forms and discussed any disagreements and undertook a meticulous and exhaustive search for both published and unpublished studies.

Despite these techniques to reduce bias, there are still areas of concern. One issue was with the total numbers of participants used in the meta-analyses. Most of the included studies had large numbers of participants that were excluded after randomisation. This was due mainly to detecting DVT at discharge from the hospital, non-compliance, adverse events and non-evaluable objective testing of DVT. Due to these large numbers of exclusions it was inappropriate to use all randomised participants, and we therefore attempted to use the most reliable intention-to-treat population as reported by the study authors. This method required us to adapt the numbers used by the study authors, which did vary between studies. We did not stratify according to the use of mechanical prophylaxis since, in most studies, the use of mechanical prophylaxis was left to the discretion of the local investigator and is usually not reported separately in the final study report. However, this should not lead to any bias because the use of mechanical methods is likely to be balanced between the two groups as a result of proper use of randomisation.

Agreements and disagreements with other studies or reviews

A recently published meta-analysis evaluated extended duration using new oral anticoagulants versus extended duration using LMWHs (Liew 2014). The four included studies are also included in our review. For symptomatic VTE they found a risk ratio in favour of oral anticoagulants of 0.42 (95% CI 0.21 to 0.86). Although Liew 2014 included RE-NOVATE Trial in their review, they did not include this study in the evaluation of symptomatic VTE, which led to the major differences in our findings, as the two dabigatran treatment groups had a large number of VTEs, compared with the LMWH group. Liew 2014 also did not include

the SACRE Study. Liew 2014 found no difference in mortality or bleeding events, which is similar to our own review.

A meta-analysis published in 2001 compared extended-duration prophylaxis to short duration followed by placebo or no treatment (Eikelboom 2001). Eikelboom 2001 included nine studies, five of which were also included in our review and the other four we excluded because we deemed they did not meet the five-week treatment-duration requirement for this review. Eikelboom 2001's findings were similar to ours, with a decreased odds of symptomatic DVT in the extended duration treatment group (OR 0.38, 95% CI 0.24 to 0.61), no difference in major bleeding but an increase in minor bleeding.

AUTHORS' CONCLUSIONS

Implications for practice

Extended-duration thromboprophylaxis should be considered for people undergoing hip or knee replacement, but the risk of increased minor bleeding should be carefully considered.

Implications for research

Continued research in this area is needed, specifically as newer, and possibly safer medications become available. Oral anticoagulants could be a promising alternative to LMWHs that require daily injections, but the evidence is currently insufficient. Specifically, further research is required to better understand the association between VTE and extended-duration oral anticoagulants in relation to knee replacement and hip fracture repair as well as outcomes such as distal and proximal DVT, reoperation, wound infection and healing, regarding the optimal duration of extended therapy, possibility of combining therapies and effects of extended therapies on length of hospital stay. An assessment of cost-effectiveness as part of the further research is also warranted.

ACKNOWLEDGEMENTS

The review authors thank Dr DJ Quinlan, Dr JW Eikelboom, and Dr JD Douketis for their work on the protocol of this review and Prof G Stansby and Dr R Hughes for their clinical input.

REFERENCES

References to studies included in this review

ADVANCE 3 *{published data only}*

- * Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. *New England Journal of Medicine* 2010;**363**(26):2487–98.
- NCT00423319. Study of an investigational drug for the prevention of thrombosis-related events following hip replacement surgery (ADVANCE-3). <https://clinicaltrials.gov/ct2/show/NCT00423319?term=NCT00423319&rank=1> (accessed 30 August 2015).
- Pineo GF, Gallus AS, Raskob GE, Chen D, Ramirez L-M, Ramacciotti E, et al. Apixaban after hip or knee arthroplasty versus enoxaparin: Efficacy and safety in key clinical subgroups. *Journal of Thrombosis and Haemostasis* 2013;**11**(3):444–51.
- Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Lassen MR. Apixaban versus enoxaparin for thromboprophylaxis after joint replacement surgery: pooled analysis of major venous thromboembolism and bleeding in 8,464 patients from the advance 2 and 3 trials [Abstract No. 192]. *Blood*. 2010; Vol. 116.
- Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. *Journal of Bone and Joint Surgery. British Volume* 2012;**94**(2):257–64.

Barrellier 2010 *{published data only}*

- Barrellier MT, Lebel B, Parienti JJ, Mismetti P, Duthiel JJ, Vielpeau C, et al. Short versus extended thromboprophylaxis after total knee arthroplasty: a randomized comparison. *Thrombosis Research* 2010;**126**(4):e298–304.

Dahl 1997 *{published data only}*

- Anon. Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?. *Prescrire International* 2000;**9**(45):197–98.
- Arnesen H, Dahl OE, Aspelin T, Seljeftot I, Kierulf P, Lyberg T. Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. *Journal of Thrombosis and Haemostasis* 2003;**1**(5):971–5.
- * Dahl OE, Andreassen G, Aspelin T, Muller C, Mathiesen P, Nyhus S, et al. Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). *Thrombosis and Haemostasis* 1997;**77**(1):26–31.
- Dahl OE, Andreassen G, Muller C, Mathisen P, Nyhus S, Aspelin T, et al. The effect of prolonged thromboprophylaxis with dalteparin on the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) 35 days after hip

replacement surgery (HRS). *Thrombosis and Haemostasis* 1995;**73**(6):1094-Abstract No 743.

DaPP Study *{published data only}*

- Lassen MR, Borris LC. Prolonged thromboprophylaxis with low molecular weight heparin (Fragmin) after elective total hip arthroplasty - a placebo controlled study. *Thrombosis and Haemostasis*. 1995; Vol. 73, issue 6:1104.
- * Lassen MR, Borris LC, Anderson BS, Jensen HP, Skejo Bro HP, Andersen G, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty--the Danish Prolonged Prophylaxis (DaPP) Study. *Thrombosis Research* 1998;**89**(6):281–7.

EXTEND Study *{published data only}*

- Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, et al. Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran. *Thrombosis Research* 2009;**123**(3):488–94.

Fragmin Trial *{published data only}*

- Hull RD. New insights into extended prophylaxis after orthopaedic surgery - the North American Fragmin Trial experience. *Haemostasis*. 2000; Vol. 30, issue Suppl 2: 95–100.
- * Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. *Archives of Internal Medicine* 2000;**160**(14):2208–15.

French Study *{published data only}*

- Planes A, Vochelle N. The post-hospital discharge venous thrombosis risk of the orthopedic patient. *Orthopedics* 1997;**20**(2 Suppl):18–21.
- Planes A, Vochelle N, Compan D, Weisslinger N, Huet Y. Efficacy and safety of prolonged administration of enoxaparin in the prevention of deep venous thrombosis after elective total hip replacement. *Orthopaedic Transactions*. 1996; Vol. 20, issue 1:274.
- Planes A, Vochelle N, Darmon J-Y, Fagola M, Bellaud M, Compan D, et al. Efficacy and safety of postdischarge administration of enoxaparin in the prevention of deep venous thrombosis after total hip replacement. A prospective randomised double-blind placebo-controlled trial. *Drugs* 1996;**52**(Suppl 7):47–54.
- * Planes A, Vochelle N, Darmon J-Y, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. *Lancet* 1996;**348**(9022):224–8.
- Planes A, Vochelle N, Darmon JY. Out-of-hospital prophylaxis with low-molecular-weight heparin in hip surgery: the French study--venographic outcome at 35 days. *Chest* 1998;**114**(2 Suppl Evidence):125S–9S.

Heit 2000 {published data only}

Heit JA, Elliott CG, Trowbridge AA, Hirsh J, Gent M. Extended out-of-hospital LMWH venous thromboembolism prophylaxis after total hip or knee replacement surgery. *Blood* 1998;**92**:500a.

* Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. *Annals of Internal Medicine* 2000;**132**(11): 853–61.

Kolb 2003 {published data only}

Kolb G, Bodamer I, Galster H, Grambach K, Koudela K, Eisele RR, et al. Prolonged prophylaxis with the low molecular weight heparin certoparin reduces the rate of venous thromboembolism after orthopedic surgery. *Journal of Thrombosis and Haemostasis*. 2003; Vol. Suppl: Abstract: P1868.

* Kolb G, Bodamer I, Galster H, Seidlmayer C, Grambach K, Koudela K, et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. *Thrombosis and Haemostasis* 2003;**90**(6):1100–5.

Prandoni 2002 {published data only}

Prandoni P, Bruchi O, Sabbion P, Tanduo C, Scudeller A, Sardella C, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. *Archives of Internal Medicine* 2002;**162**(17):1966–71.

RECORD 1 Trial {published data only}

Anon. Prevention of thromboembolism after knee replacement surgery: rivaroxaban one tablet/once daily superior to twice daily injectable enoxaparin in preventing venous blood clots after total knee replacement surgery in pivotal phase III trial. <http://www.bayer.ca/> 2008.

Cohn DM, Hermanides J, Devries JH, Kamphuisen PW, Kuhls S, Homering M, et al. Stress-induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty. Analysis from the RECORD trials. *Thrombosis and Haemostasis* 2012;**107**(2):225–231.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Oral rivaroxaban compared with subcutaneous enoxaparin for extended thromboprophylaxis after total hip arthroplasty: The RECORD1 trial. *Blood (ASH Annual Meeting Abstracts)* 2007;**110**(11):6.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Oral rivaroxaban versus subcutaneous enoxaparin for extended thromboprophylaxis after total hip replacement: RECORD1 (abstract 222). *British Journal of Haematology* 2008;**141**(Suppl 1):82.

* Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *New England Journal of Medicine* 2008;**358**(26):2765–75.

Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, et al. Oral rivaroxaban for the prevention of

symptomatic venous thromboembolism after elective hip and knee replacement. *Journal of Bone and Joint Surgery. British Volume* 2009;**91**(5):636–44.

Eriksson BI, Rosencher N, Friedman RJ, Homering M, Dahl OE. Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. *Thrombosis Research* 2012;**130**:147–51.

Haas S, Borris LC, Friedman RJ, Huisman MV, Kakkar AK, Geerts W, et al. Rivaroxaban, an oral, direct factor Xa inhibitor in extended prophylaxis of thromboembolism after total hip replacement: RECORD1 (abstract O58). *Pathophysiology of Haemostasis and Thrombosis* 2008;**36** (Suppl 1):A15.

Lassen MR, Gent M, Kakkar AK, Eriksson BI, Homering M, Berkowitz SD, et al. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: Results from the RECORD programme. *Journal of Bone and Joint Surgery. British Volume* 2012;**94**(11):1573–8.

NCT00329628. Rivaroxaban (10mg) given once daily in patients undergoing total hip replacement compared to enoxaparin. <https://clinicaltrials.gov/ct2/show/NCT00329628?term=NCT00329628&rank=1> (accessed 30 August 2015).

Rosencher N, Llau JV, Mueck W, Loewe A, Berkowitz SD, Homering M. Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). *Acta Anaesthesiologica Scandinavica* 2013; **57**(5):565–72.

RECORD 2 Trial {published data only}

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Bandel TJ, et al. A phase III study of extended thromboprophylaxis with oral rivaroxaban versus short-term subcutaneous enoxaparin after total hip replacement: RECORD2 (abstract O59). *Pathophysiology of Haemostasis and Thrombosis* 2008;**36**(Suppl 1):A15.

* Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. *Lancet* 2008;**372**(9632): 31–9.

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. Extended thromboprophylaxis with rivaroxaban compared with short-term thromboprophylaxis with enoxaparin after total hip arthroplasty: The RECORD2 trial. *Blood (ASH Annual Meeting Abstracts)* 2007;**110**(11):307.

Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, et al. RECORD2: extended thromboprophylaxis with rivaroxaban versus short-term thromboprophylaxis with enoxaparin after total hip replacement (abstract 176). *British Journal of Haematology* 2008;**141**(Suppl 1):65.

Mouret P, Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Muntz J, et al. Extended thrombosis prophylaxis with rivaroxaban in comparison to short-term thrombosis prophylaxis with enoxaparin after total hip replacement:

The RECORD2 study. *Medizinische Klinik* 2008;**103**(3): 15.

NCT00332020. Regulation of coagulation in orthopedic surgery to prevent DVT and PE, a controlled, double-blind, randomized study of BAY 59-7939 in the extended prevention of VTE in patients undergoing elective total hip replacement (RECORD 2). <https://clinicaltrials.gov/ct2/show/NCT00332020?term=NCT00332020&rank=1> (accessed 30 August 2015).

RE-NOVATE II Trial *{published data only}*

* Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II): A randomised, double-blind, non-inferiority trial. *Thrombosis and Haemostasis* 2011;**105**(4): 721–9.

Huo M, Eriksson B, Dahl O, Kurth A, Hantel S, Hermansson K, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: the RE-NOVATE II randomised trial [Abstract No. 0564]. *Haematologica* 2010; Vol. 92:233.

NCT00657150. Dabigatran etexilate compared with enoxaparin in prevention of venous thromboembolism (VTE) following total hip arthroplasty. <https://clinicaltrials.gov/ct2/show/NCT00657150?term=RE-NOVATE&rank=1> (accessed 30 August 2015).

RE-NOVATE Trial *{published data only}*

* Eriksson BI, Dahl OE, Rosensch N, Kurth AA, Van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. *Lancet* 2007;**370**(9591):949–56.

Eriksson BI, Dahl OE, Rosensch N, Kurth AA, Van Dijk N, Frostick SP, et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement (abstract OW-049). *Journal of Thrombosis and Haemostasis* 2007;**5**(Suppl 2):OW-049.

NCT00168818. Dabigatran etexilate in extended VTE prevention after hip replacement surgery. <https://clinicaltrials.gov/ct2/show/NCT00168818?term=RE-NOVATE&rank=2> (accessed 30 August 2015).

SACRE Study *{published data only}*

* Samama CM, Vray M, Barre J, Fiessinger JN, Rosensch N, Lecompte T, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. *Archives of Internal Medicine* 2002;**162**(19):2191–6.

Zhang 2014 *{published data only}*

Zhang H, Lin J, Li H, Guan Z, Zhou D, Kon B, et al. Effects of thromboprophylaxis duration on coagulation indicators after total hip replacement. *National Medical Journal of China* 2014;**94**(7):525–8.

References to studies excluded from this review

Comp 2001 *{published data only}*

* Comp PC, Spiro TE, Friedman RJ, Whitsett TL, Johnson GJ, Gardiner GA, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. *Journal of Bone & Joint Surgery - American Volume* 2001;**83-A**(3): 336–45.

Spiro TE. A double-blind multicenter clinical trial comparing long term enoxaparin and placebo treatments in the prevention of venous thromboembolic disease after hip and knee replacement surgery. *Blood*. 1997; Vol. 90, issue Suppl 1:295a.

EPCAT II *{published data only}*

NCT01720108. Extended venous thromboembolism prophylaxis comparing rivaroxaban to aspirin following total hip and knee arthroplasty (EPCAT II). <https://clinicaltrials.gov/ct2/show/NCT01720108> (accessed 30 August 2015).

Kristensen 1990 *{published data only}*

Kristensen SS, Pedersen P, Pedersen NW, Schmidt SA, Kjaersgaard-Andersen P. Combined treatment with indomethacin and low-dose heparin after total hip replacement. *Journal of Bone and Joint Surgery. American Volume* 1990;**72**:447–9.

Manganelli 1998 *{published data only}*

* Manganelli D, Pazzagli M, Mazzantini D, Punzi G, Manca M, Vignali C, et al. Prolonged prophylaxis with unfractionated heparin is effective to reduce delayed deep vein thrombosis in total hip replacement. *Respiration* 1998;**65**(5):369–74.

Palla A, Manganelli D, Rossi G. Prolonged prophylaxis with unfractionated heparin (UH) is effective to reduce delayed deep vein thrombosis (DVT) in total hip replacement (THR). *European Respiratory Journal*. 1997; Vol. 10, issue Suppl 25:5S.

NPHDO Study Group *{published data only}*

* Haentjens P, Delince P, The Belgian Nadroparin Post-Hospital Discharge In Orthopedics (NPHDO) Study Group. Prevention of venous thromboembolism after hospital discharge. Continued pharmacologic prophylaxis versus no prophylaxis in patients undergoing total hip replacement. *Hip International* 2001;**11**(1):25–36.

Haentjens P, The Belgian Nadroparin Post-Hospital Discharge in Orthopedics (NPHDO) Study Group. Post-hospital discharge prevention of deep vein thrombosis with nadroparin calcium after elective total hip replacement. *British Journal of Anaesthesia* 1999;**82**(Suppl 1):78.

The Belgian Nadroparin Post Hospital Discharge in Orthopedics (NPHDO) Study Group. Post hospital discharge prevention of deep vein thrombosis with nadroparin calcium after total hip arthroplasty. *Haemostasis*. 1998; Vol. 28, issue Suppl 2:292.

PENTHIFRA PLUS Study *{published data only}*

Anon. A multicenter, multinational, randomized, double-blind study of fondaparinux sodium (Org31540/SR90107A) versus placebo for the prolonged prevention of

VTE in hip fracture surgery. (PENTHIFRA PLUS). Study No: EFC4582. GlaxoSmithKline Clinical Trial Register 2005.

Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. No episode of thrombocytopenia after four-week administration of fondaparinux, a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study. *Journal of Thrombosis and Haemostasis* 2003;**1**(Suppl 1):P2050.

Dobesh PP. Novel concepts: emerging data and the role of extended prophylaxis following hip fracture surgery. *American Journal of Health-System Pharmacy* 2003;**60**(22 Suppl 7):S15–9.

Eriksson BI. A multicenter, randomized, placebo-controlled, double-blind study of fondaparinux for the prolonged prevention of venous thromboembolism in hip fracture surgery. Abstracts of the Sicot/Sirot XXII World Congress 2002:318.

Eriksson BI, Lassen MR. Consistency of efficacy of extended thromboprophylaxis with fondaparinux (arixtra) in prevention of venous thromboembolism (VTE) after hip fracture surgery according to different composite efficacy endpoints: the PENTHIFRA-PLUS study. *Journal of Thrombosis and Haemostasis* 2003;**1**(Suppl 1):Abstract P2064.

* Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: A multicenter, randomized, placebo-controlled, double-blind study. *Archives of Internal Medicine* 2003 Jun 9;**163**(11):1337–42.

Eriksson BI, Lassen MR, Colwell CW, Jr. Efficacy of fondaparinux for thromboprophylaxis in hip fracture patients. *Journal of Arthroplasty* 2004;**19**(7 Suppl 2):78–81.

Lassen M, Bauer KA, Eriksson BI, Turpie AGG. Absence of transaminase increase after 4-week administration of fondaparinux (Arixtra®) a new synthetic and selective inhibitor of factor Xa in the PENTHIFRA-PLUS study. *Journal of Thrombosis and Haemostasis* 2003;**1**(Suppl 1): Abstract number: P2052.

Swedish Study {published data only}

* Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlund U, Nicolas S, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. *New England Journal of Medicine* 1996;**335**(10):696–700.

Bergqvist D, Jönsson B. Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement. *Haemostasis* 2000;**30 Suppl 2**:130–5.

Nilsson PE, Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlund U, et al. The post-discharge prophylactic management of the orthopedic patient with low-molecular-weight heparin: enoxaparin. *Orthopedics* 1997;**20 Suppl**: 22–5.

Additional references

Atkins 2004

Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y,

Flottorp S, et al. Grading quality of evidence and strength of recommendations. *BMJ* 2004;**328**(7454):1490–4.

Cushman 2007

Cushman M. Epidemiology and risk factors for venous thrombosis. *Seminars in Hematology* 2007;**44**(2):62–9.

Dotzel 2002

Dotzel, MM. Determination that ardeparin sodium injection was not withdrawn from sale for reasons of safety or effectiveness. US Food and Drug Administration 2002: <http://www.fda.gov/ohrms/dockets/98fr/052302b.htm> (date accessed September 2015).

Egger 1997

Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ (Clinical Research Ed.)* 1997;**315**(7109):629–34.

Eikelboom 2001

Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. *Lancet* 2001;**358**(9275):9–15.

Eriksson 1997

Eriksson BI, Wille-Jørgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement [see comments]. *New England Journal of Medicine* 1997;**337**(19):1329–35.

GRADEpro GDT 2015 [Computer program]

McMaster University (developed by Evidence Prime, Inc). Available from www.gradepr.org. GRADEpro Guideline Development Tool (GRADEpro GDT). McMaster University (developed by Evidence Prime, Inc). Available from www.gradepr.org, 2015.

Guyatt 2012

Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;**141**(2 Suppl):7S–47S. [DOI: 10.1378/chest.1412S3]

Heit 2015

Heit JA. Epidemiology of venous thromboembolism. *Nature Reviews Cardiology* 2015;**12**:464–74. [DOI: 10.1038/nrcardio.2015.83]

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327** (7414):557–60.

Higgins 2011

Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March

- 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
- Hirsh 1998**
Hirsh J. Evidence for the needs of out-of-hospital thrombosis prophylaxis: introduction. *Chest* 1998;**114**(2 Suppl Evidence):113S–4S.
- Lau 1998**
Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. *Lancet* 1998;**351**(9096):123–7.
- Leclerc 1998**
Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1,984 patients. *Chest* 1998;**114**(2 Suppl II):115S–8S.
- Liew 2014**
Liew A. Extended-duration new oral anticoagulants for venous thromboprophylaxis in patients undergoing total hip arthroplasty: A meta-analysis of the randomized controlled trials. *Journal of Thrombosis and Haemostasis* 2014;**12**(1):107–9.
- Mohr 1993**
Mohr DN, Silverstein MD, Murtaugh PA, Harrison JM. Prophylactic agents for venous thrombosis in elective hip surgery: Meta-analysis of studies using venographic assessment. *Archives of Internal Medicine* 1993;**153**(19):2221–8.
- NICE 2010**
National Clinical Guideline Centre. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Methods evidence and guidance. <http://www.nice.org.uk/guidance/cg92/evidence/cg92-venous-thromboembolism-reducing-the-risk-full-guideline3> (accessed September 2015).
- NICE 2012**
National Clinical Guideline Centre. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical Guideline. Methods, evidence and recommendations. <http://www.nice.org.uk/guidance/cg144/evidence/cg144-venous-thromboembolic-diseases-full-guideline3> (accessed September 2015).
- Nurmohamed 1992**
Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. *Lancet* 1992;**340**(8812):152–6.
- RevMan 2014 [Computer program]**
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
- Robinson 1997**
Robinson KS, Anderson DR, Gross M, Petrie D, Leighton R, Stanish W, et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. *Annals of Internal Medicine* 1997;**127**(6):439–45.
- SIGN 2010**
Scottish Intercollegiate Guidelines Network. Thrombosis Guidelines Prevention and management of venous thromboembolism. A national clinical guideline. <http://www.sign.ac.uk/pdf/sign122.pdf> (accessed September 2015).
- Thompson 1994**
Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. *BMJ (Clinical research ed.)* 1994;**309**(6965):1351–5.
- Wang 2014**
Wang Z, Anderson FA Jr, Ward M, Bhattacharyya T. Surgical site infections and other postoperative complications following prophylactic anticoagulation in total joint arthroplasty. *PLoS ONE* 2014;**9**(4):e91755. [10.1371/journal.pone.0091755. eCollection 2014]
- White 2003**
White RH. The epidemiology of venous thromboembolism. *Circulation* 2003;**107**:I–4–I–8.
- References to other published versions of this review**
- Quinlan 2002**
Quinlan DJ, Eikelboom JW, Douketis JD. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. *Cochrane Database of Systematic Reviews* 2002, Issue 2. [DOI: 10.1002/14651858.CD004179]
* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

ADVANCE 3

Methods	<p>Study design: Randomised, double-blind, double-dummy, clinical trial</p> <p>Country: Multi-Country (21)</p> <p>Setting: Multicentre (160 sites); home and hospital; March 2007 to May 2009</p> <p>Intention-to-treat: Yes, primary analysis on all except those that had no or venograms or uninterpretable venography, also per-protocol efficacy analysis excluding protocol violations - protocol violations not described - safety data ITT minus those that did not receive at least one dose</p> <p>For the purposes of our meta-analyses we used a mixture of all randomised and ITT population, as reported appropriate by the study authors</p>
Participants	<p>Number randomised: Total n = 5407 (apixaban n = 2708; enoxaparin n = 2699)</p> <p>Exclusions post randomisation: Total n = 1616 (Apixaban: 363 had no venography, 396 had uninterpretable venograms (efficacy), 35 did not have at least one dose (safety) . Enoxaparin: 40 did not receive at least one dose (safety); 364 no venography, 418 uninterpretable venogram (efficacy))</p> <p>Losses to follow up: No reports of loss to follow up</p> <p>Age mean (range): Apixaban 60.9 (19 - 92); enoxaparin 60.6 (19 - 93)</p> <p>Sex (%F): Apixaban 52.8%; enoxaparin 53.8%</p> <p>Inclusion criteria: Patients scheduled to undergo elective total hip replacement or revision of previously inserted hip replacement</p> <p>Exclusion criteria: Main reasons for exclusion: active bleeding; contraindication to anticoagulant prophylaxis; need for ongoing anticoagulant or antiplatelet treatment</p>
Interventions	<p>Treatment: 2.5 mg apixaban, orally, twice daily, initiated 12 - 24 hours after surgery</p> <p>Control: 40 mg enoxaparin, subcutaneously, once daily, initiated 12 hours before surgery</p> <p>Duration: Prophylaxis continued for 35 days (32 to 38 day range) after surgery; follow-up evaluations also occurred at 65 and 95 days after surgery</p>
Outcomes	<p>Primary: Composite of asymptomatic or symptomatic DVT, nonfatal PE, or death from any cause; bleeding during treatment period (classed as major, clinically relevant non-major and minor bleeding, and composite of major and clinically relevant)</p> <p>Secondary: Major VTE: composite of symptomatic or asymptomatic proximal DVT, nonfatal PE or death related to VTE</p> <p>Bleeding definitions: Major bleeding - acute, clinically overt bleeding accompanied by one or more of the following: a decrease in haemoglobin level of 2 g/dL or more over 24 hours; transfusion of 2 or more units of packed red cells; bleeding into the operated joint necessitating reoperation or intervention; intramuscular bleeding; fatal bleeding; Minor bleeding - clinically overt but did not meet the criteria for major or clinically relevant non-major bleeding; Clinically relevant non-major bleeding - acute, clinically overt episodes such as wound haematoma, bruising or ecchymosis, gastrointestinal bleeding, haemoptysis, haematuria or epistaxis that did not meet the criteria for major bleeding</p>

ADVANCE 3 (Continued)

Notes	Funding: Bristol-Myers Squibb and Pfizer Method of VTE evaluation/confirmation: bilateral venography was performed after 35 days	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomised using interactive telephone system, randomisation schedule generated at the randomisation centre of Bristol-Myers Squibb with the use of SAS software and was stratified according to study site, with a block size of four
Allocation concealment (selection bias)	Low risk	Interactive telephone system
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Described as double-blind, double-dummy, participants received either placebo tablets or injections based on treatment allocation
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All VTE, bleeding and adverse events were reviewed by an independent, blinded, adjudication committee
Incomplete outcome data (attrition bias) All outcomes	Low risk	All losses-to-follow-up were recorded per treatment group with adequate reasoning
Selective reporting (reporting bias)	Low risk	All outcomes reported on
Other bias	Unclear risk	Reasons for protocol violations not described; Funded by Bristol-Myers Squibb and Pfizer; data were collected and monitored by the sponsors, and data and safety monitoring board were given a fee by the sponsors

Barrellier 2010

Methods	Study design: Randomised, open-label, prospective, non-inferiority, parallel group trial Country: France Setting: Multicentre (17 centres); hospital and home; June 2004 to June 2007 Intention-to-treat: No For the purposes of our meta-analyses we used the per-protocol population, as reported by the study authors	
Participants	Number randomised: Total n = 857 (extended n = 430; short n = 427)* Exclusions post randomisation: Extended: exclusion criteria: 7, not treated: 13; short: exclusion criteria 2, consent withdrawal 4 not treated: 33 Losses to follow up: Extended n = 1; short n = 1 Age mean years (SD): Extended 70.9 (8.1); short 70.1 (8.6) Sex % M: Extended 37.9%; short 35.4% Inclusion criteria: 45 years or older; scheduled for a first total unilateral knee arthroplasty Exclusion criteria: History of confirmed symptomatic venous thromboembolism at any time, stroke or myocardial infarction within the previous month, current active bleed, gastrointestinal bleeding or hemorrhagic stroke within the previous six months, brain, spinal, ophthalmological or other major surgery within the previous month, active cancer, renal impairment, hepatic impairment, a contraindication to anticoagulant therapy, hypersensitivity to heparin and patients who required therapeutic anticoagulation	
Interventions	Treatment: Anticoagulant treatment was chosen by the investigator and could be: heparin (5000 U, two to three times per day), enoxaparin (4000 IU), dalteparin (5000 IU) , tinzaparin (4500 IU), body-weight adjusted nadroparin, fondaparinux (2.5 mg) Control: No specific control, only short duration prophylaxis Duration: 10 ± 2 days 'short thromboprophylaxis'; 35 ± 5 days 'extended thromboprophylaxis'	
Outcomes	Primary: Composite of proximal DVT, symptomatic DVT, non-fatal symptomatic PE, major bleeding, heparin-induced thrombocytopenia, all-cause mortality Secondary: Ultrasonographic distal DVT Bleeding definitions: Major bleeding fatal bleeding, bleeding that was intracranial, intraocular, retroperitoneal, gastrointestinal or intra-articular, bleeding leading to reoperation, or bleeding requiring cessation of treatment	
Notes	Funding: Caen University Hospital with unrestricted grant from the French Health Ministry Method of VTE evaluation/confirmation: All participants were examined for DVT by bilateral whole-leg ultrasonography on Day 35 ± 5, or earlier if thrombosis was clinically suspected *For the analysis, we only included participants that had negative ultrasonographic scans at discharge, as most comparative studies excluded these participants with positive ultrasonographic scans at discharge	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement

Barrellier 2010 (Continued)

Random sequence generation (selection bias)	Low risk	Concealed randomisation was performed using a centralised telephone system, according to a permuted block design with block size of four, with stratification by centre and by the presence or absence of distal deep-vein thrombosis on whole leg ultrasonography
Allocation concealment (selection bias)	Low risk	"Concealed randomization was performed using a centralized telephone system"
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Open-label
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Sonographer was not blinded; Primary outcomes were reviewed by a central, independent, blinded adjudication committee
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants accounted for
Selective reporting (reporting bias)	High risk	Safety outcomes reported as "the bleeding risk was very low (0.7%)", no further details provided
Other bias	Low risk	Sponsored by the Caen University Hospital with an unrestricted grant from the French Health Ministry - which had no other role in the study

Dahl 1997

Methods	<p>Study design: Randomised, prospective, double-blind, placebo-controlled trial</p> <p>Country: Norway</p> <p>Setting: Multicentre, hospital and home, January 1993 - June 1994</p> <p>Intention-to-treat: Yes, after withdrawals removed.</p> <p>For the purposes of our meta-analyses we used the reported ITT population</p>
Participants	<p>Number randomised: Total n = 265 (extended LMWH n = 134; placebo n = 131)</p> <p>Exclusions post randomisation: Total n = 38 (extended LMWH n = 17; placebo n = 21) withdrawn for reasons other than DVT or PE (21/38 due to adverse events: 10 extended LMWH and 11 placebo)</p> <p>Losses to follow up: No losses to follow-up all participants received treatment until the day of final visit</p> <p>Age mean years: Extended LMWH 70.98, placebo 71.4</p> <p>Sex %F: Extended LMWH 68.5%; placebo 73.6%</p> <p>Inclusion criteria: 18 years or older; admitted to hospital for elective primary or sec-</p>

	ondary hip replacement; obtained written consent form Exclusion criteria: Known renal or liver insufficiency; cerebral bleeding less than three months before surgery or known haemorrhagic diathesis; eye or ear surgery within one month before surgery; severe hypertension; septic endocarditis; threatened arterial circulation in the leg; body weight less than 40 kg; anticoagulant therapy less than one week before surgery; known hypersensitivity to heparin, low-molecular-weight heparin, dextran or contrast media; pregnancy or breastfeeding; inability to comply with study protocol; previous surgery within study	
Interventions	Treatment: Dalteparin 5000 IU, injections once daily for four weeks Control: Initial treatment with dalteparin 5000 IU followed by placebo (sodium chloride) injections, once daily Duration: 35 days (7 days initial treatment + 28 days continued treatment)	
Outcomes	Primary: Verified VTE on days 7 and 35 Secondary: Haematological assessment; safety: reoperation due to bleeding, wound haematoma and local haematoma at injection site	
Notes	Funding: Not reported Method of VTE evaluation/confirmation: DVT verified by bilateral venography and PE verified by perfusion ventilation or chest X-ray	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information given to determine adequate randomisation
Allocation concealment (selection bias)	Unclear risk	Insufficient information given to determine adequate allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Described as double-blinded and gave placebo subcutaneous injections
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Venograms, X-rays and V-Q scans evaluated after the study by a blinded specialist
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants accounted for, ITT and PP analysis
Selective reporting (reporting bias)	High risk	VAS patient acceptability reported but not reported as pre-planned, as was pain at injection site and serious adverse events, bleeding not reported as outcomes

Other bias	Low risk	No evidence of other bias
------------	----------	---------------------------

DaPP Study

Methods	<p>Study design: Randomised, double-blind, placebo-controlled, parallel group, prospective trial</p> <p>Country: Denmark</p> <p>Setting: Multicentre; hospital and home; January to November 1994</p> <p>Intention-to-treat: Yes</p> <p>For the purposes of our meta-analyses we used the reported ITT population</p>
Participants	<p>Number randomised: Total n = 281 (extended LMWH n = 140; placebo n = 141)</p> <p>Exclusions post randomisation: Total n = 66 (extended LMWH n = 27; placebo n = 39);</p> <p>39 due to inadequate or missing phlebographies, 14 withdrew consent, 8 adverse events, 2 placebo patients with symptoms of PE had inconclusive lung scans, 2 withdrawn due to reoperation and 1 used other anticoagulant drug</p> <p>Losses to follow up: Not reported</p> <p>Age median years (range): Extended LMWH 68 (30 - 94); placebo 70 (28 - 91)</p> <p>Sex M/F: Extended LMWH 66/74; placebo 62/79</p> <p>Inclusion criteria: All participants admitted for total hip replacement; age 18 years or older</p> <p>Exclusion criteria: Previous surgery in the study; simultaneous participation in another pharmacological study; informed consent not obtained; high probability for drop-out; renal insufficiency; hepatic insufficiency; prothrombin < 0.7; platelet count < 100 x 10⁹/L; treatment with oral anticoagulants or heparin within seven days before inclusion; hypersensitivity to heparin, LMWH or contrast media; documented bleeding within three months prior to surgery; intracranial bleeding within three months prior to surgery; eye, ear or CNS surgery within one month prior to surgery; hypertension with diastolic pressure > 120 mmHg; septic endocarditis; body weight < 40 kg; known pregnancy or lactation</p>
Interventions	<p>Treatment: Dalteparin subcutaneous injections (5000 anti-Xa), once daily</p> <p>Control: Initial treatment with dalteparin (5000 anti-Xa) followed by placebo (sodium chloride) injections, once daily placebo subcutaneous injections, once daily, started after discharge</p> <p>Duration: 35 days after surgery</p>
Outcomes	<p>Primary: DVT and PE</p> <p>Secondary: Bleeding complications and adverse events; haemological analysis</p> <p>Bleeding definitions: No definition for major bleeding was provided</p>
Notes	<p>Funding: Not reported</p> <p>Method of VTE evaluation/confirmation: Bilateral ascending phlebography at the end of treatment to detect DVT; PE detected by perfusion/ventilation lung scan or pulmonary angiography</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation was performed with a separate randomisation list for each centre
Allocation concealment (selection bias)	Unclear risk	Insufficient information given to determine adequate allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo injections, saline, given to control participants
Blinding of outcome assessment (detection bias) All outcomes	Low risk	All venograms were evaluated by a panel of three radiologists who were unaware of the result of the randomisation
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants accounted for, similar numbers in groups, no missing outcome data
Selective reporting (reporting bias)	Low risk	All outcomes reported on
Other bias	Low risk	No indication of other bias

EXTEND Study

Methods	<p>Study design: Randomised, double-blind, parallel-group study</p> <p>Country: Multi-country (16 countries)</p> <p>Setting: Multicentre; hospital and home; September 2005 to February 2006</p> <p>Intention-to-treat: No analysis performed as study stopped prematurely</p> <p>For the purposes of our meta-analyses we used the per-protocol population as reported by the authors</p>
Participants	<p>Number randomised: Total n = 1158; 641 completed at time of termination (ximelagatran n = 580; enoxaparin n = 578)</p> <p>Exclusions post randomisation: Total n = 150 (ximelagatran n = 70; enoxaparin n = 80)</p> <p>Not treated: 23 melagatran, 16 enoxaparin;</p> <p>Premature stop: 47 melagatran, 64 enoxaparin</p> <p>Losses to follow up: Study terminated early</p> <p>Age median years (range): Hip replacement: ximelagatran 64.7 (24 - 89); enoxaparin 63.9 (21 - 89); Fracture surgery: ximelagatran 73.1 (44 - 91); enoxaparin 70.7 (26 - 94)</p> <p>Sex M/F: Hip replacement: ximelagatran 229/250; enoxaparin 211/268; Fracture surgery: Ximelagatran 17/60; enoxaparin 23/50</p> <p>Inclusion criteria: 18 years or older; undergoing primary elective unilateral total hip replacement or surgery for hip fracture</p> <p>Exclusion criteria: "same as in the previously reported phase III studies in orthopaedic surgery on ximelagatran"</p>

EXTEND Study (Continued)

Interventions	Treatment 1: 3 mg ximelagatran subcutaneously 4 - 8 hours after surgery and twice daily for up to 2 days post-op, followed by 24 mg oral ximelagatran twice daily Treatment 2: 40 mg enoxaparin subcutaneous once daily starting the night before surgery or post-operatively Duration: 32 - 38 days after surgery; Randomised within 5 days before surgery	
Outcomes	Primary: Efficacy outcomes: composite of proximal DVT, any clinically suspected and objectively confirmed DVT and/or PE, VTE-related death or death where VTE could not be ruled out. Safety outcomes: major bleeding events, transfusions of whole blood and packed red blood cells, injection site haematomas > 2 cm, clinically verified and adjudicated myocardial infarction, evidence of hepatic injury Secondary: No distinction between primary and secondary Bleeding definitions: Major bleeding - transfusions of whole blood and packed red blood cells, injection site haematomas > 2 cm, clinically verified and adjudicated myocardial infarction, evidence of hepatic injury	
Notes	Funding: AstraZeneca, Sweden; employees of AstraZeneca contributed to study design, interpretation of results and decision to submit paper Method of VTE evaluation/confirmation: bilateral compression ultrasound (CUS) of the legs at the end of treatment period	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Interactive web-based randomisation system; stratified by type of surgery
Allocation concealment (selection bias)	Low risk	Used web-based randomisation system
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes adjudicated by a blinded, independent committee
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	ITT numbers do not add up; insufficient information given
Selective reporting (reporting bias)	Unclear risk	No details of the VTE events were provided
Other bias	High risk	Terminated early due to safety issues, AstraZeneca supported trial - had influence on study design, interpretation of results and decision to submit paper

Fragmin Trial

Methods	<p>Study design: Randomised, double-blind, clinical trial</p> <p>Country: USA and Canada</p> <p>Setting: Multicentre (18 centres); hospital and home</p> <p>Intention-to-treat: Yes, ITT: VTE analysis performed on participants who had successful venography; safety analysis with those who had successful venogram at day six</p> <p>For the purposes of our meta-analyses we used the reported ITT population</p>
Participants	<p>Number randomised: Total n = 991 but only n = 569 received treatment (pre-op dalteparin n = 199; post-op dalteparin n = 190; warfarin/placebo n = 180)</p> <p>Exclusions post randomisation: Total n = 293: 94 refused participation, 40 adverse event in-hospital, 12 unable to self inject, 42 other reasons, plus 105 no or inadequate venography</p> <p>Losses to follow up: No reports of losses to follow up but could be part of 42 other reasons for no venography</p> <p>Age mean years (SD): Pre-op dalteparin 62 (12); post-op dalteparin 63 (12); warfarin/placebo 63 (12)</p> <p>Sex M/F: Pre-op dalteparin 106/93; post-op dalteparin 87/103; warfarin/placebo 94/86</p> <p>Inclusion criteria: Aged 18 years or older; scheduled for elective unilateral total hip replacement; gave informed consent</p> <p>Exclusion criteria: Documented bleeding within three months before surgery; known hypersensitivity to heparin, LMWH, warfarin or contrast media; defective haemostasis; ongoing anticoagulant therapy; pregnancy or breastfeeding; clinically significant hepatic dysfunction; renal insufficiency; severe hypertension; septic endocarditis; weight less than 40 kg; eye, ear or central nervous system surgery within one month before hip surgery; diseases with unfavourable prognosis or concurrent disease making study participation medically complicated; simultaneous participant in another study or receiving any investigation drug 30 days or less before surgery; previous randomisation into this study; use of pneumatic compression stockings during study period</p>
Interventions	<p>Treatment 1: Dalteparin sodium, subcutaneous, 5000 IU once daily, commenced two hours before surgery plus placebo capsules while in hospital</p> <p>Treatment 2: Dalteparin sodium, subcutaneous, 5000 IU once daily, commenced four hours after surgery plus placebo capsules while in hospital</p> <p>Control: Placebo</p> <p>Duration: 35 ± 2 days</p>
Outcomes	<p>Primary: Venogram-confirmed DVT and proximal DVT</p> <p>Secondary: PE, bleeding complications, death</p> <p>Bleeding definitions: Major bleeding - clinically overt, associated with a decrease in haemoglobin of 20 g/L or more; if it required a blood transfusion of 2 or more units; intracranial, intraocular, intraspinal or intraperitoneal; occurred into a prosthetic joint</p> <p>Minor bleeding - clinically overt but not meeting criteria for major</p>
Notes	<p>Funding: A grant-in-aid by Pharmacia & Upjohn to the University of Calgary</p> <p>Method of DVT and PE evaluation/confirmation: Participants with VTE symptoms received objective testing for confirmation; bilateral ascending venography was performed at discharge and at the end of the study period for all participants</p>
<i>Risk of bias</i>	

Fragmin Trial (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation performed using computer-derived treatment schedule, divided into consecutive blocks, stratified by treatment centre
Allocation concealment (selection bias)	Low risk	Randomisation by computer-derived methods
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Used placebo dalteparin injections and placebo warfarin capsules to maintain blind
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Venograms were interpreted by a blinded central reader as well as a local radiologist; disagreements resolved by a second blinded interpretation
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were accounted for
Selective reporting (reporting bias)	Low risk	All outcomes reported on
Other bias	Low risk	No indication of other bias

French Study

Methods	<p>Study design: Randomised, double-blind, placebo controlled trial</p> <p>Country: France</p> <p>Setting: Single centre; hospital and home; August 1991 to June 1994</p> <p>Intention-to-treat: Yes, ITT and per-protocol, although based on second bilateral venography</p> <p>For the purposes of our meta-analyses we used the reported ITT population</p>
Participants	<p>Number randomised: Total n = 179 (extended LMWH n = 90; placebo n = 89)</p> <p>Exclusions post randomisation: Total n = 6 (extended LMWH n = 5; placebo n = 1), had no second venogram and excluded from efficacy analysis</p> <p>Losses to follow up: No losses to follow up; all participants included in safety analysis</p> <p>Age mean years (SD): Extended LMWH 70 (9.1); placebo 68 (8.2)</p> <p>Sex M/F: Extended LMWH 47/43; placebo 55/34</p> <p>Inclusion criteria: Underwent primary total hip replacement or conversion/reversion of total hip replacement; received prophylactic treatment with enoxaparin for post-op VTE; > 45 years of age; body weight 45 - 95 kg; could walk unassisted using crutches; were free of DVT as assessed by bilateral ascending contrast venography performed within five days before discharge; had to be available for a follow-up visit at day 21 ± 2 days post discharge</p> <p>Exclusion criteria: History of documented DVT or PE within last six months; active</p>

French Study (Continued)

	cancer; underlying bleeding disorders or haemostasis abnormalities; prothrombin time < 60% or activated partial thromboplastin time > 8 seconds or longer than control subjects; active gastroduodenal ulcer; history of hypersensitivity to heparin or to contrast media; renal or hepatic insufficiency; uncontrolled hypertension; recent stroke; inability to give informed consent
Interventions	Treatment: 40 mg enoxaparin, subcutaneous, daily Control: 40 mg enoxaparin, subcutaneous, daily during hospitalisation (14 ± 1 day) followed by placebo (isotonic saline) injections Duration: 35 days after surgery
Outcomes	Primary: DVT and/or PE Secondary: Onset of proximal or distal DVT; safety: death, major and minor haemorrhages, adverse events Bleeding definitions: Major bleeding - overt and was associated with a decrease in haemoglobin concentration of 2 g/dL or more compared with the last postoperative value, or a need for transfusion of two or more units of packed red blood cells, or if it was retroperitoneal or intracranial. Minor bleeding - overt but did not meet the other criteria for major bleeding
Notes	Funding: Not reported Method of VTE evaluation/confirmation: Clinical evaluation of symptoms and clinical signs of DVT and bilateral venographic evaluation at day 35 post-surgery

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Randomization was balanced in blocks of four by means of a computer-generated randomization schedule."
Allocation concealment (selection bias)	Low risk	Used computer-generated randomisation schedule
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Open-label during hospitalisation period when all patients receiving enoxaparin, then double-blinded after randomisation to extended duration or placebo using saline injections for the placebo group; "The double-blind conditions (for patients, nurses, attending physicians, and investigators) were maintained until the database was locked."
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Venograms were independently evaluated by two blinded radiologists

French Study (Continued)

Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants accounted for
Selective reporting (reporting bias)	Low risk	All outcomes reported on
Other bias	Low risk	No indication of other bias

Heit 2000

Methods	<p>Study design: Randomised, double-blind, placebo-controlled trial</p> <p>Country: US</p> <p>Setting: Multicentre (33 centres); hospital and home; November 1994 to November 1997</p> <p>Intention-to-treat: Yes</p> <p>For the purposes of our analyses we used all participants randomised, as reported by the study authors</p>
Participants	<p>Number randomised: Total n = 1195 (Extended LMWH n = 607; Placebo n = 588)</p> <p>Exclusions post randomisation: Unclear</p> <p>Losses to follow up: Unclear</p> <p>Age mean years (SD): Extended LMWH 65 (11); placebo 66 (11)</p> <p>Sex M/F: Extended LMWH 265/342; placebo 275/313</p> <p>Inclusion criteria: Aged 18 years or older; received elective primary or revision unilateral total hip replacement, primary unilateral or bilateral total knee replacement</p> <p>Exclusion criteria: 'Pregnant, lactating or women of childbearing age; patients with clinical bleeding disorder; uncontrolled hypertension' severely impaired hepatic or renal function; active alcohol or drug abuse; patients who could not comply with home injections or complete a 10-week post-op follow-up; patients receiving warfarin or thrombolytic therapy; had a major surgery within previous seven days; had major orthopaedic surgery involving lower extremities in previous six weeks; history of substantial internal bleeding, active peptic ulcer, myocardial infarction or stroke; intracranial or intraocular surgery in previous eight weeks; patients planning to undergo staged bilateral total knee replacement with anticipated interval of less than 10 weeks; hypersensitivity to heparin, pork products, metabisulphite, methylparaben or propylparaben; weight great than 120 kg; prolonged activated partial thromboplastin time or prothrombin time at baseline; baseline platelet count less than $100 \times 10^9/L$; history of VTE; current use of dextran sulphate, desmopressin acetate, other LMWH, oral anticoagulants, thrombolytic agents or external pneumatic compression</p>
Interventions	<p>Treatment: Ardeparin sodium 100 anti-Xa IU/kg weight, subcutaneous injections, daily, starting within 24 hours after surgery</p> <p>Control: Four to 10 days ardeparin sodium 100 anti-Xa IU/kg weight (starting within 24 hours after surgery), daily, subcutaneous injection, followed by placebo injections from time of discharge</p> <p>Duration: Six weeks after surgery</p>

Outcomes	Primary: Incidence of symptomatic, objectively documented DVT or PE or death Secondary: The incidence of major and minor bleeding and thrombocytopenia Bleeding definitions: Major bleeding - overt bleeding associated with haemoglobin decrement of at least 20 g/L or transfusion of at least 2 units of blood products, any intracranial, retroperitoneal, intraocular or mediastinal bleeding that occurred after at least one dose of post-discharge study drug Minor bleeding - overt bleeding not meeting the criteria for major bleeding	
Notes	Funding: Wyeth-Ayerst Research, Philadelphia, US - performed statistical analysis, data interpretation and manuscript preparation done by writing committee, sponsor did not have prior right of approval for final manuscript publication Method of VTE evaluation/confirmation: Compression duplex ultrasonography or venography, ventilation perfusion lung scanning or pulmonary angiography	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Stratified by clinical centre, type of surgery and history of VTE; block randomisation derived from a randomisation table
Allocation concealment (selection bias)	Low risk	Allocation done in consecutively numbered, sealed envelopes
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind phase of study achieved by giving placebo injections in identical Tubex cartridges containing 0.5 mL ardeparin sodium or placebo (sodium chloride solution)
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes assessed by blinded, central adjudication committee
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants accounted for, although > 15% withdrew in both groups
Selective reporting (reporting bias)	Low risk	All outcomes reported on
Other bias	Low risk	No indication of other bias

Kolb 2003

Methods	Study design: Randomised, double blind, placebo controlled trial Country: Germany and Czech Republic Setting: Multicentre (13 centres), hospital and home Intention-to-treat: Yes and per-protocol For the purposes of our analyses we used all participants randomised, as reported by the study authors	
Participants	Number randomised: Total n = 310 (extended LMWH n = 161; placebo n = 149) Exclusions post randomisation: Total n = 37: protocol violation: 8, adverse events:10, withdrawal of consent: 19 Losses to follow up: None Age mean years (SD): Extended LMWH 78.1 (8.4); placebo 75.8 (8.4) Sex M/F: Extended LMWH 25/136; placebo 29/120 Inclusion criteria: Participants undergoing endoprosthetic joint replacement or osteosynthesis of the lower limb Exclusion criteria: Age under 18 years; hypersensitivity against heparin; clinical conditions with increased risk of bleeding; haemorrhagic diathesis; platelet count < 100.000/ul; concomitant treatment with anticoagulants or platelet inhibitors; renal or hepatic insufficiency; hypertension with systolic values > 200 mmHg and diastolic values > 105 mmHg despite treatment; malignancy; endocarditis lenta; drug abuse; pregnancy; participation in a clinical trial during the last four weeks; thromboembolic complications between start of treatment and randomisation; discontinuation of study medication due to adverse events; withdrawal of consent	
Interventions	Treatment: Certoparin 3000 u anti-Xa Control: Certoparin 3000 u anti-Xa for 14 days then placebo Duration: 42 days	
Outcomes	Primary: Composite of symptomatic or asymptomatic DVT (proximal and/or distal), symptomatic PE and deaths related to VTE Secondary: Coagulation parameters Bleeding definition - not provided	
Notes	Funding: Supported by Novartis Pharma, Germany, test kits for fibrin monomers and Ddimer sponsored by Roche Diagnostics Germany, protein C resistance kits sponsored by Dada Behring Germany Method of VTE evaluation/confirmation: DVT was screened for by compression and duplex ultrasonography every week and confirmed by ascending leg and pelvic venography (whenever possible). PE was verified by pulmonary angiography, spiral CT or perfusion lung scanning	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information provided on sequence generation

Kolb 2003 (Continued)

Allocation concealment (selection bias)	Unclear risk	Insufficient information provided on allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double-blind, participants given placebo
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information provided on assessor blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants accounted for, although treatment group was not indicated for loss-to-follow-ups
Selective reporting (reporting bias)	Low risk	All defined outcomes were reported on
Other bias	Low risk	No indication of other bias

Prandoni 2002

Methods	<p>Study design: Prospective randomised controlled trial</p> <p>Country: Italy</p> <p>Setting: Single centre; hospital and home; September 1998 to December 2000</p> <p>Intention-to-treat: Yes</p> <p>For the purposes of our meta-analyses we used the reported ITT population</p>
Participants	<p>Number randomised: Total n = 360 (extended duration n = 184; control n = 176)</p> <p>Exclusions post randomisation: Total n = 6: three protocol violations per group but all were available for clinical follow-up</p> <p>Losses to follow up: None</p> <p>Age median years (range): Extended duration 68 (48 - 82); control 69 (44 - 87)</p> <p>Sex M/F: Extended duration 83/101; control 79/97</p> <p>Inclusion criteria: Underwent elective total hip replacement; received warfarin prophylaxis during hospitalisation</p> <p>Exclusion criteria: Previous hip surgery on the same side; history of thromboembolic disorder; needing long-term anticoagulation; were unavailable for long-term follow-up; refused to give written informed consent; developed VTE complications, asymptomatic proximal DVT or major bleeding during hospitalisation period</p>
Interventions	<p>Treatment: 5 mg/d of warfarin sodium prophylaxis starting two days pre-op; dosage adjusted to increase international normalised ration between 2.0 and 3.0</p> <p>Control: 5 mg/d of warfarin sodium prophylaxis starting two days pre-op; dosage adjusted to increase international normalised ration between 2.0 and 3.0, discontinued at discharge</p> <p>Duration: 4 weeks after discharge (Median nine day hospitalisation plus four weeks extended treatment)</p>

Outcomes	Primary: Composite of symptomatic VTE and asymptomatic proximal DVT during first four weeks of follow up, efficacy during complete three months follow up, clinical parameters, also reports on major bleeding, death and other adverse events Secondary: Not specifically defined Bleeding definitions: Major bleeding - clinically overt and associated with either a decrease in haemoglobin of at least 2.0 g/dL or a need of transfusion of two or more units of blood, was intracranial or retroperitoneal, resulted in permanent discontinuation of treatment	
Notes	Funding: Not reported Method of VTE evaluation/confirmation: compression ultrasonography for DVT; PE confirmed by ventilation perfusion, spiral CT, abnormal finding on angiography or autopsy	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer-generated randomisation list
Allocation concealment (selection bias)	Low risk	Computer-generated list
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No discussion of blinding and no placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Ultrasound was performed by a blinded operator; cause of death adjudicated by a blinded physician and all outcomes evaluated by a blinded committee
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants accounted for and no loss to follow-up
Selective reporting (reporting bias)	Low risk	All outcomes reported on
Other bias	High risk	Terminated early “after inclusion of the first 360 patients because a statistically significant and clinically relevant superiority of extended over short-term thromboprophylaxis was observed”

RE-NOVATE II Trial

Methods	<p>Study design: Randomised, double-blind, double-dummy, non-inferiority, active-controlled trial</p> <p>Country: 19 countries in Europe, North America, India, Australia, New Zealand and South Africa</p> <p>Setting: Multicentre (108 locations); hospital and home; March 2008 to May 2009</p> <p>Intention-to-treat: Modified intention-to-treat: all participants who had surgery, received treatment and had evaluable venograms</p> <p>For the purposes of our meta-analyses we used the reported ITT population of participants that underwent surgery</p>
Participants	<p>Number randomised: Total n = 2055 (dabigatran n = 1036; enoxaparin n = 1019)</p> <p>Exclusions post randomisation: Total n = 477 (dabigatran n = 243; enoxaparin n = 234: not treated: dabigatran 25 and enoxaparin 16. Dabigatran 9 and enoxaparin 11 did not have surgery, dabigatran 209 and enoxaparin 207 no or not evaluable venogram</p> <p>Losses to follow up: All participants accounted for</p> <p>Age mean years (SD): Dabigatran 62 (12); enoxaparin 62 (11)</p> <p>Sex F%: Dabigatran 53.6%; enoxaparin 50.0%</p> <p>Inclusion criteria: 18 years or older; scheduled to undergo a primary, unilateral, elective total hip replacement; > 40 kg body weight; gave written informed consent</p> <p>Exclusion criteria: History of bleeding diathesis; excessive risk of bleeding as judged by investigators; major surgery or trauma within three months of enrolment; recent unstable cardiovascular disease; any history of haemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, arteriovenous malformation or aneurysm; ongoing treatment for VTE; clinical relevant bleeding within six months of enrolment; gastric or duodenal ulcer within one year of enrolment; liver disease expected to have any potential impact on survival; active liver disease or liver disease decreasing survival; known severe renal insufficiency; elevated creatinine that contraindicates venography; Treatment with anticoagulants, clopidogrel, ticlopidine, abciximab, aspirin or NSAID within seven days prior to hip replacement or anticipated need of such medication; anticipated required use of intermittent pneumatic compression and electric stimulation of lower leg; active malignant disease or current cytostatic treatment; pre-menopausal women who are pregnant or nursing, or are of child-bearing potential and are not practising or do not plan to continue practising acceptable methods of birth control; allergy to radio opaque contrast media, heparins or dabigatran; contraindications to enoxaparin; participation in a clinical trial during the last 30 days; leg amputee; known alcohol or drug abuse which would interfere with study completion; previous participation in this study; history of thrombocytopaenia</p>
Interventions	<p>Treatment 1: 220 mg dabigatran etexilate (2 x 110 mg tablets), orally, once daily, initial dose of 110 mg on the day of surgery plus placebo injection identical to enoxaparin treatment</p> <p>Treatment 2: 40 mg enoxaparin, subcutaneous, once daily, initial dose evening before surgery plus placebo tablets identical to dabigatran treatment</p> <p>Duration: 28 - 35 days</p>
Outcomes	<p>Primary: Composite of total VTE and all-cause mortality (VTE includes both proximal and distal DVT, symptomatic DVT, PE)</p> <p>Secondary: Major VTE and VTE-related death, proximal DVT, total DVT, symptomatic DVT, PE, all-cause mortality, bleeding events, lab parameters and adverse events</p> <p>Bleeding definitions: Major bleeding - fatal, clinically overt associated with loss of</p>

	haemoglobin greater than or equal to 20 g/L or leading to transfusion of greater than or equal to 2 units of packed cells or whole blood; symptomatic retroperitoneal, intracranial, intraocular or intraspinal; requiring treatment cessation; leading to reoperation. Clinically relevant bleeding - spontaneous skin haematoma greater than or equal to 25 cm ² ; wound haematoma greater than or equal to 100 cm ² ; spontaneous nose bleed lasting longer than 5 min; macroscopic haematuria spontaneous or lasting longer than 24 hours if associated with an intervention; spontaneous rectal bleeding (more than a spot on toilet paper); gingival bleeding lasting longer than 5 min; any other bleeding event considered clinically relevant by the investigator Minor bleeding - any other bleeding events that were not classified as major or clinically relevant	
Notes	Funding: Boehringer Ingelheim, Sweden Method of VTE evaluation/confirmation: DVT confirmed/detected by bilateral venography or compression ultrasound or autopsy; PE confirmed by pulmonary V-Q scintigraphy, chest X-ray, angiography, spiral CT or autopsy	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation by central computer-generated system, stratified by centre, prepared in blocks of six
Allocation concealment (selection bias)	Low risk	Utilised central computer-generated system
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Both treatment groups received one study drug and one placebo identical in appearance to the other active treatment
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Efficacy outcomes confirmed by blinded, central adjudication committee
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	All participants were accounted for, with similar numbers in each treatment group, but no description was given for excluded participants that did not take study medication
Selective reporting (reporting bias)	Low risk	No protocol but all expected outcomes reported
Other bias	Unclear risk	Study sponsors were involved in the design and conduct of the trial. The data were collected and analysed by the sponsors of the study

RE-NOVATE Trial

Methods	<p>Study design: Randomised, double-blind, active-controlled trial</p> <p>Country: Multi-country (16 countries) in Europe, Australia and South Africa</p> <p>Setting: Multicentre (115 centres); hospital and home; November 2006 to July 2006</p> <p>Intention-to-treat: No, per-protocol: excluding not treated, no surgery, and inadequate or no venogram</p> <p>For the purposes of our meta-analyses we used the reported ITT population of participants that underwent surgery</p>
Participants	<p>Number randomised: Total n = 3493 (220 mg dabigatran n = 1157; 150 mg dabigatran n = 1174; enoxaparin n = 1162)</p> <p>Exclusions post randomisation: Total n = 322 (220 mg dabigatran n = 108; 150 mg dabigatran n = 102; enoxaparin n = 112), reason for all: did not complete study</p> <p>Losses to follow up: Not specified</p> <p>Age mean years (SD): 220 mg dabigatran 65 (10); 150 mg dabigatran 63 (11); enoxaparin 64 (11)</p> <p>Sex %F: 220 mg dabigatran 56%; 150 mg dabigatran 57%; enoxaparin 56%</p> <p>Inclusion criteria: 18 years or older; scheduled to undergo a primary, unilateral, elective total hip replacement; > 40 kg body weight; gave written informed consent</p> <p>Exclusion criteria: Patients with an excessive risk of bleeding; active malignant disease or current cytostatic treatment; known severe renal insufficiency; liver disease expected to have any potential impact on survival, or elevated AST or ALT > 2 x upper limit of normal; recent unstable cardiovascular disease or history of myocardial infarction within the last three months; pre-menopausal women who are pregnant or nursing, or are of child-bearing potential and are not practising or do not plan to continue practising acceptable methods of birth control; allergy to radio opaque contrast media or iodine, heparins (including heparin-induced thrombocytopenia) or dabigatran; contraindications to enoxaparin; participation in a clinical trial during the last 30 days</p>
Interventions	<p>Treatment 1*: 150 mg dabigatran etexilate, orally, once daily, starting with half dose on day of surgery plus one placebo pill identical to other treatment and subcutaneous placebo injection</p> <p>Treatment 2*: 220 mg dabigatran etexilate, orally, once daily, starting with half dose on day of surgery plus one placebo pill identical to other treatment subcutaneous placebo injection</p> <p>Control: 40 mg enoxaparin, subcutaneous, once daily plus two placebo pills identical in appearance to active treatments</p> <p>Duration: 28 - 35 days (average 33 days)</p> <p>*For the analyses within this review, the 150 mg and 220 mg treatment groups were combined as both dosages are considered normal therapeutic dosages</p>
Outcomes	<p>Primary: Composite of total VTE and all-cause mortality; VTE includes both proximal and distal DVT, symptomatic DVT, PE</p> <p>Secondary: Major VTE and VTE-related death, proximal DVT, total DVT, symptomatic DVT, PE, all-cause mortality, bleeding events</p> <p>Bleeding definitions: Major bleeding - fatal, clinically overt associated with loss of haemoglobin greater than or equal to 20g/L or leading to transfusion of greater than or equal to 2 units of packed cells or whole blood; symptomatic retroperitoneal, intracranial, intraocular or intraspinal; requiring treatment cessation; leading to reoperation Clinically relevant bleeding - spontaneous skin haematoma greater than or equal to 25 cm</p>

	² ; wound haematoma greater than or equal to 100 cm ² ; spontaneous nose bleed lasting longer than 5 min; macroscopic haematuria spontaneous or lasting longer than 24 hours if associated with an intervention; spontaneous rectal bleeding (more than a spot on toilet paper); gingival bleeding lasting longer than 5 min; any other bleeding event considered clinically relevant by the investigator. Minor bleeding - any other bleeding events that were not classified as major or clinically relevant	
Notes	Funding: Steering committee and sponsor responsible for study design, data collection and analysis done by sponsor, independent data and safety committee monitored study, steering committee had overall responsibility for all aspects and final responsibility for decision to submit paper Method of VTE evaluation/confirmation: DVT detected and confirmed by bilateral venography; PE confirmed by pulmonary V-Q scintigraphy, chest X-ray, angiography, spiral CT or autopsy	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation by central computer-generated system, stratified by centre, prepared in blocks of six
Allocation concealment (selection bias)	Low risk	Utilised central computer-generated system
Blinding of participants and personnel (performance bias) All outcomes	Low risk	All treatment groups received one study drug and one placebo identical in appearance to the other active treatment as well as a subcutaneous injection
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Efficacy outcomes initially assessed locally, then confirmed by blinded, central adjudication committee
Incomplete outcome data (attrition bias) All outcomes	Low risk	All exclusions were reported with reasons and by study group
Selective reporting (reporting bias)	Low risk	All outcomes reported on
Other bias	Low risk	No indication of other bias

RECORD 1 Trial

Methods	<p>Study design: Randomised, double-blind trial</p> <p>Country: Multi-country (27 countries)</p> <p>Setting: Multi-centre; hospital and home; February 2006 to March 2007</p> <p>Intention-to-treat: Yes, modified ITT and per-protocol analysis</p> <p>For the purposes of our meta-analyses we used the reported modified ITT population of participants that underwent surgery</p>
Participants	<p>Number randomised: Total n = 4541 (rivaroxaban n = 2266; enoxaparin n = 2275)</p> <p>Exclusions post randomisation: Total n = 1177 (rivaroxaban n = 580; enoxaparin n = 597); 57 rivaroxaban and 51 enoxaparin randomised but not included in safety analysis - did not receive study drug but no further description; excluded from ITT if not treated and did not undergo surgery and had no suitable venograms (additional 523 rivaroxaban, 546 enoxaparin)</p> <p>Losses to follow up: No reports of loss-to-follow-up</p> <p>Age mean years (range): Rivaroxaban 63.1 (18 - 91); enoxaparin 63.3 (18 - 93)</p> <p>Sex F %: Rivaroxaban 55.2%; enoxaparin 55.8%</p> <p>Inclusion criteria: Men and women 18 years or older; scheduled to undergo elective total hip replacement</p> <p>Exclusion criteria: Scheduled to undergo staged, bilateral hip arthroplasty; pregnant or breastfeeding; active bleeding or a high risk of bleeding; contraindication for prophylaxis with enoxaparin; conditions preventing bilateral venography; substantial liver disease; severe renal impairment; concomitant use of protease inhibitors for the treatment of HIV; planned intermittent pneumatic compression; requirement for anticoagulant therapy that could not be stopped</p>
Interventions	<p>Treatment 1: 10 mg rivaroxaban, orally, once daily beginning after surgery</p> <p>Control: 40 mg enoxaparin, subcutaneously, once daily beginning the evening before surgery</p> <p>Duration: 35 days (range 31 - 39); mean duration 33.4 days in rivaroxaban and 33.7 in enoxaparin group - venography took place</p>
Outcomes	<p>Primary: Composite DVT (symptomatic or detected by venography), non-fatal PE or death from any cause at day 36</p> <p>Secondary: Major VTE (proximal DVT, non-fatal PE or death from VTE), major bleeding, DVT, symptomatic VTE, death, lab values and cardiovascular events</p> <p>Bleeding definitions: Major bleeding - fatal, occurred in a critical organ (e.g., retroperitoneal, intracranial, intraocular, and intraspinal bleeding), or required reoperation or extrasurgical-site bleeding that was clinically overt and was associated with a fall in the haemoglobin level of at least 2 g per decilitre or that required transfusion of 2 or more units of whole blood or packed cells</p>
Notes	<p>Funding: Bayer Healthcare and Johnson & Johnson: data collected and analysed by sponsors, steering committee designed and supervised, all authors contributing had access to all data and analysis and vouch for accuracy and completeness of data reported</p> <p>Method of VTE evaluation/confirmation: Mandatory bilateral venography the day after the last dose of the study drug</p>
<i>Risk of bias</i>	

RECORD 1 Trial (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation generated in permuted blocks and stratification according to centre by a central telephone system with a computer-generated randomised list
Allocation concealment (selection bias)	Low risk	Use of telephone system and computer-generated randomisation list
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Patients received study medication plus placebo tablets or injection
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes assessed by a central, blinded adjudication committee
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	57 rivaroxaban and 51 enoxaparin randomised but not included in safety analysis - did not receive study drug but no reasons given why
Selective reporting (reporting bias)	Low risk	No protocol provided but all outcomes reported on
Other bias	Unclear risk	Data was collected and analysed by the sponsors: Bayer HealthCare and Johnson & Johnson

RECORD 2 Trial

Methods	<p>Study design: Randomised, double-blind, controlled trial</p> <p>Country: Multinational (21 countries)</p> <p>Setting: Multicentre (123 centres); hospital and home; February 2006 to April 2007</p> <p>Intention-to-treat: Modified ITT: not-treated, did not receive surgery, no readable venogram</p> <p>For the purposes of our meta-analyses we used the reported modified ITT population of participants that underwent surgery</p>
Participants	<p>Number randomised: Total n = 2509 (rivaroxaban n = 1252; enoxaparin n = 1257)</p> <p>Exclusions post randomisation: Total n = 90 (rivaroxaban n = 40; enoxaparin n = 50). Rivaroxaban: 24, enoxaparin: 28 - not taken study medication (no reason why); rivaroxaban 16 and enoxaparin 22 did not receive surgery</p> <p>Losses to follow up: Not reported</p> <p>Age mean years (SD): Rivaroxaban 61.4 (13.2); enoxaparin 61.6 (13.7)</p> <p>Sex %F: Rivaroxaban 54.3% enoxaparin 53.0%</p> <p>Inclusion criteria: Aged 18 or older; scheduled to undergo elective total hip replacement</p>

RECORD 2 Trial (Continued)

	Exclusion criteria: Scheduled to undergo staged, bilateral hip arthroplasty; pregnant or breastfeeding; active bleeding or a high risk of bleeding; contraindication for prophylaxis with enoxaparin; conditions preventing bilateral venography; substantial liver disease; severe renal impairment; concomitant use of protease inhibitors for the treatment of HIV; use of fibrinolytic therapy; planned intermittent pneumatic compression; requirement for anticoagulant therapy that could not be stopped	
Interventions	Treatment: 10 mg rivaroxaban, orally, once daily beginning after surgery plus placebo injections for 10 - 14 days Control: 40 mg enoxaparin, subcutaneously, once daily beginning the evening before surgery and continued for 10 - 14 days and received placebo tablets for the entire study period Duration: 31 - 39 days	
Outcomes	Primary: Composite of any DVT, nonfatal PE and all-cause mortality; incidence of major bleeding events Secondary: Major VTE (composite of proximal DVT, non-fatal PE and VTE-related death); DVT (proximal and distal), symptomatic VTE, on-treatment bleeding, death Bleeding definitions: Major bleeding - fatal, occurred in a critical organ (e.g., retroperitoneal, intracranial, intraocular, and intraspinal bleeding), or required reoperation or extrasurgical-site bleeding that was clinically overt and was associated with a fall in the haemoglobin level of at least 2 g per decilitre or that required transfusion of 2 or more units of whole blood or packed cells	
Notes	Funding: Bayer HealthCare AG, Johnson & Johnson Pharmaceutical Research and Development LLC; sponsors involved in design and conduct of trial, data collection and analysis; all authors had full access to data and analyses and vouch for accuracy and completeness of data and were involved in decision to submit the manuscript Method of VTE evaluation/confirmation: DVT confirmed by bilateral venography; PE confirmed by perfusion/ventilation lung scintigraphy, angiography, chest X-ray or spiral CT or autopsy	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation generated in permuted blocks and stratification according to centre by a central telephone system with a computer-generated randomised list
Allocation concealment (selection bias)	Low risk	Use of telephone system and computer-generated randomisation list
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Patients received study medication plus placebo tablets or injection

RECORD 2 Trial (Continued)

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes assessed by a central, blinded adjudication committee
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	All participants were accounted for, with similar numbers in each treatment group, but no description was given for excluded participants that did not take study medication
Selective reporting (reporting bias)	Low risk	No protocol provided but all outcomes reported on
Other bias	Unclear risk	Funded by Bayer HealthCare and Johnson & Johnson - study sponsors were involved in the design and conduct of the trial. The data were collected and analysed by the sponsors of the study

SACRE Study

Methods	Study design: Randomised trial Country: France Setting: Multicentre (65 centres); hospital and home; September 1997 to October 1999 Intention-to-treat: Yes, and per-protocol For the purposes of our meta-analyses we used the reported ITT population
Participants	Number randomised: Total n = 1289 (LMWH n = 644; anticoagulant n = 645) Exclusions post randomisation: Total n = 10 (LMWH n = 1; anticoagulant n = 9); no treatment 7 (1 reviparin, 6 acenocoumarol); event at randomisation: 3 acenocoumarol Losses to follow up: Not reported Age mean years (SD): LMWH 66 (11); anticoagulant 65 (12) Sex %F: LMWH 51%; anticoagulant 50% Inclusion criteria: 18 years or older; scheduled to undergo elective unilateral primary total hip replacement Exclusion criteria: Femoral neck fracture; current active bleeding or disorders contraindicating anticoagulant therapy; a history of DVT or PE; heparin-induced thrombocytopenia, peptic ulcer, allergy to radiopaque contrast medium; use of aspirin or ticlopidine hydrochloride; renal insufficiency; liver failure; acute endocarditis; recent stroke; uncontrolled hypertension; pregnancy; alcoholism; inability to follow instructions
Interventions	Treatment: Fixed-dose subcutaneous LMWH reviparin sodium, 4200 anti-Xa IU, beginning 12 hours preoperatively Treatment 2: After initial LMWH treatment as described above, crossed over to adjusted-dose oral anticoagulant acenocoumarol, international normalised ratio, 2 - 3 Duration: 6 weeks after surgery

Outcomes	Primary: Combined clinical events of symptomatic thromboembolic event, major haemorrhage or death Secondary: Minor bleeding Bleeding definitions: Major bleeding - clinically overt and was associated with a decrease in haemoglobin level of more than 20 g/L or required a transfusion of 2 U or more of packed red blood cells after randomisation or was digestive, intracranial, retroperitoneal or intraocular or was located at the surgical site and required reoperation or, according to the investigator's opinion, led to discontinuation of the treatment. Minor bleeding - clinically overt but not major	
Notes	Funding: Supported by Knoll France, Investigators received USD 400 per patient included in the study and PI received final grant of USD 4000 Method of VTE evaluation/confirmation: Suspected DVT confirmed by venography or duplex scanning; suspected PE confirmed by ventilation-perfusion or angiography	
<i>Risk of bias</i>		
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"...randomized computer-derived treatment schedule" performed at a central location, stratified by each centre, balanced in blocks of four
Allocation concealment (selection bias)	Low risk	Utilised a centralised computer-derived randomisation schedule
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No mention of blinding of participants or personnel; most likely unblinded as one treatment given subcutaneously and the other orally
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes interpreted by a blinded adjudication committee
Incomplete outcome data (attrition bias) All outcomes	Low risk	Table 1. clearly demonstrates missing participants and reasons, although it should be noted the anticoagulant treatment group had a higher rate of protocol violations (statistical tests not performed)
Selective reporting (reporting bias)	Low risk	All outcomes reported on
Other bias	Low risk	No indication of other bias

Zhang 2014

Methods	<p>Study design: Randomised trial</p> <p>Country: China</p> <p>Setting: Single centre; hospital and outpatient clinic; June 2012 and May 2013</p> <p>Intention-to-treat: Yes</p> <p>For the purposes of our analyses we used all participants randomised, as reported by the study authors</p>
Participants	<p>Number randomised: Total n = 40 (extended n = 20; short n = 20)</p> <p>Exclusions post randomisation: Not stated</p> <p>Losses to follow up: None</p> <p>Age mean years (range): Extended 60.1 (37 - 76); short 61.3 (42 - 78)</p> <p>Sex (F/M): Extended 11/9; Short 12/8</p> <p>Inclusion criteria: All patients admitted to the Center for Bone and Joint Health between June 2012 and May 2013, who were diagnosed with osteonecrosis of the femoral head, scheduled for elective total hip replacement and provided informed consent</p> <p>Exclusion criteria: Had Doppler ultrasound performed 48 hrs prior to the surgery showing DVT; had undergone surgery recently, a history of active major bleeding or a tendency to bleed; had recent use of anticoagulants, antiplatelets or antifibrinogenics; were pregnant or nursing baby or did not take measures to prevent pregnancy; had severe kidney or liver dysfunction or other disease that could interfere with drug metabolism or blood coagulation</p>
Interventions	<p>Treatment: Oral rivaroxaban 10 mg once daily started within 6 - 10 hrs after the surgery for 35 days</p> <p>Control: Oral rivaroxaban 10 mg once daily started within 6 - 10 hrs after the surgery for 7 days followed by no treatment</p> <p>Duration: 35 days post surgery</p>
Outcomes	<p>Primary: Efficacy: haemostatic parameters including thrombin-antithrombin complexes, prothrombin fragment 1 and 2, D-dimer and fibrinogen</p> <p>Secondary: DVT</p> <p>Outcomes were recorded pre-operatively (within 48 hours before surgery) and at 1, 7, and 35 days after surgery</p>
Notes	<p>Funding: Not reported</p> <p>Method of VTE evaluation/confirmation: lower limb ultrasonography</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Using random numbers generated by computer prior to the surgery
Allocation concealment (selection bias)	Unclear risk	Insufficient information provided
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No mention of blinding of participants or personnel

Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No mention of blinding of outcome assessors
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants accounted for, similar numbers in groups, no missing outcome data
Selective reporting (reporting bias)	Low risk	All listed outcomes reported on
Other bias	Low risk	No indication of other bias

DVT: deep vein thrombosis

F: female

IU: international unit

LMWH: low-molecular-weight heparin

M: male

NSAID: non-steroidal anti-inflammatory drug

PE: pulmonary embolism

post-op: post-operatively, after operation

pre-op: prior to operation

VAS: visual analogue scale

V-Q: ventilation-perfusion

VTE: venous thromboembolism

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Comp 2001	Treatment duration only four weeks
EPCAT II	Treatment duration only 30 days
Kristensen 1990	Treatment not within scope of review: heparin plus indomethacin versus heparin plus placebo
Manganelli 1998	Treatment duration only 30 days
NPHDO Study Group	Treatment duration was extended but not to five weeks
PENTHIFRA PLUS Study	Treatment duration only four weeks
Swedish Study	Treatment duration for only one month

DATA AND ANALYSES

Comparison 1. Heparin versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Symptomatic VTE (DVT and PE)	5	2329	Odds Ratio (M-H, Fixed, 95% CI)	0.59 [0.35, 1.01]
1.1 Hip replacement	4	1296	Odds Ratio (M-H, Fixed, 95% CI)	0.69 [0.36, 1.30]
1.2 Knee replacement	1	723	Odds Ratio (M-H, Fixed, 95% CI)	0.78 [0.21, 2.92]
1.3 Hip or knee replacement	1	310	Odds Ratio (M-H, Fixed, 95% CI)	0.22 [0.05, 1.06]
2 Symptomatic DVT (proximal or distal)	4	2019	Odds Ratio (M-H, Fixed, 95% CI)	0.73 [0.39, 1.38]
2.1 Hip replacement	4	1296	Odds Ratio (M-H, Fixed, 95% CI)	0.80 [0.41, 1.55]
2.2 Knee replacement	1	723	Odds Ratio (M-H, Fixed, 95% CI)	0.32 [0.03, 3.12]
3 Symptomatic PE	3	1595	Odds Ratio (M-H, Fixed, 95% CI)	0.61 [0.16, 2.33]
3.1 Hip replacement	3	872	Odds Ratio (M-H, Fixed, 95% CI)	0.13 [0.01, 2.56]
3.2 Knee replacement	1	723	Odds Ratio (M-H, Fixed, 95% CI)	1.47 [0.24, 8.83]
4 Total VTE (symptomatic and asymptomatic)	6	2544	Odds Ratio (M-H, Fixed, 95% CI)	0.39 [0.28, 0.56]
4.1 Hip replacement	5	1511	Odds Ratio (M-H, Fixed, 95% CI)	0.37 [0.25, 0.56]
4.2 Knee replacement	1	723	Odds Ratio (M-H, Fixed, 95% CI)	0.78 [0.21, 2.92]
4.3 Hip or knee replacement	1	310	Odds Ratio (M-H, Fixed, 95% CI)	0.38 [0.16, 0.90]
5 Asymptomatic DVT	5	1304	Odds Ratio (M-H, Fixed, 95% CI)	0.38 [0.24, 0.60]
5.1 Hip replacement	4	994	Odds Ratio (M-H, Fixed, 95% CI)	0.35 [0.21, 0.58]
5.2 Hip or knee replacement	1	310	Odds Ratio (M-H, Fixed, 95% CI)	0.54 [0.19, 1.52]
6 All-cause mortality	5	2518	Odds Ratio (M-H, Fixed, 95% CI)	1.01 [0.31, 3.26]
6.1 Hip replacement	4	1485	Odds Ratio (M-H, Fixed, 95% CI)	0.56 [0.11, 2.75]
6.2 Knee replacement	1	723	Odds Ratio (M-H, Fixed, 95% CI)	0.98 [0.06, 15.65]
6.3 Hip or knee replacement	1	310	Odds Ratio (M-H, Fixed, 95% CI)	4.69 [0.22, 98.42]
7 Adverse events	2	460	Odds Ratio (M-H, Fixed, 95% CI)	1.06 [0.68, 1.64]
7.1 Hip replacement	2	460	Odds Ratio (M-H, Fixed, 95% CI)	1.06 [0.68, 1.64]
8 Bleeding - major	5	2500	Odds Ratio (M-H, Fixed, 95% CI)	0.59 [0.14, 2.46]
8.1 Hip replacement	4	1494	Odds Ratio (M-H, Fixed, 95% CI)	0.32 [0.03, 3.10]
8.2 Knee replacement	1	696	Odds Ratio (M-H, Fixed, 95% CI)	0.99 [0.14, 7.06]
8.3 Hip or knee replacement	1	310	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
9 Bleeding - minor	5	2500	Odds Ratio (M-H, Fixed, 95% CI)	2.01 [1.43, 2.81]
9.1 Hip replacement	4	1494	Odds Ratio (M-H, Fixed, 95% CI)	2.25 [1.53, 3.30]
9.2 Knee replacement	1	696	Odds Ratio (M-H, Fixed, 95% CI)	1.23 [0.58, 2.59]
9.3 Hip or knee replacement	1	310	Odds Ratio (M-H, Fixed, 95% CI)	2.79 [0.11, 69.13]
10 Reoperation	1	179	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10.1 Hip replacement	1	179	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]

Comparison 2. Vitamin K antagonists versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Symptomatic VTE (DVT and PE)	1	360	Odds Ratio (M-H, Fixed, 95% CI)	0.10 [0.01, 1.94]
1.1 Hip replacement	1	360	Odds Ratio (M-H, Fixed, 95% CI)	0.10 [0.01, 1.94]
2 Symptomatic DVT (proximal or distal)	1	360	Odds Ratio (M-H, Fixed, 95% CI)	0.13 [0.01, 2.62]
2.1 Hip replacement	1	360	Odds Ratio (M-H, Fixed, 95% CI)	0.13 [0.01, 2.62]
3 Symptomatic PE	1	360	Odds Ratio (M-H, Fixed, 95% CI)	0.32 [0.01, 7.84]
3.1 Hip replacement	1	360	Odds Ratio (M-H, Fixed, 95% CI)	0.32 [0.01, 7.84]
4 Total VTE (symptomatic and asymptomatic)	1	360	Odds Ratio (M-H, Fixed, 95% CI)	0.10 [0.01, 0.81]
4.1 Hip replacement	1	360	Odds Ratio (M-H, Fixed, 95% CI)	0.10 [0.01, 0.81]
5 All-cause mortality	1	360	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
5.1 Hip replacement	1	360	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6 Adverse events	1	360	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
6.1 Hip replacement	1	360	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7 Bleeding - major	1	360	Odds Ratio (M-H, Fixed, 95% CI)	2.89 [0.12, 71.31]
7.1 Hip replacement	1	360	Odds Ratio (M-H, Fixed, 95% CI)	2.89 [0.12, 71.31]

Comparison 3. DOAC versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Symptomatic VTE (DVT and PE)	1	2419	Odds Ratio (M-H, Fixed, 95% CI)	0.20 [0.06, 0.68]
1.1 Hip replacement	1	2419	Odds Ratio (M-H, Fixed, 95% CI)	0.20 [0.06, 0.68]
2 Symptomatic DVT (proximal or distal)	2	2459	Odds Ratio (M-H, Fixed, 95% CI)	0.18 [0.04, 0.81]
2.1 Hip replacement	2	2459	Odds Ratio (M-H, Fixed, 95% CI)	0.18 [0.04, 0.81]
3 Symptomatic PE	1	1733	Odds Ratio (M-H, Fixed, 95% CI)	0.25 [0.03, 2.25]
3.1 Hip replacement	1	1733	Odds Ratio (M-H, Fixed, 95% CI)	0.25 [0.03, 2.25]
4 Total VTE (symptomatic and asymptomatic)	1	1733	Odds Ratio (M-H, Fixed, 95% CI)	0.19 [0.11, 0.33]
4.1 Hip replacement	1	1733	Odds Ratio (M-H, Fixed, 95% CI)	0.19 [0.11, 0.33]
5 All-cause mortality	1	1733	Odds Ratio (M-H, Fixed, 95% CI)	0.33 [0.07, 1.66]
5.1 Hip replacement	1	1733	Odds Ratio (M-H, Fixed, 95% CI)	0.33 [0.07, 1.66]
6 Adverse events	1	2457	Odds Ratio (M-H, Fixed, 95% CI)	0.87 [0.74, 1.03]
6.1 Hip replacement	1	2457	Odds Ratio (M-H, Fixed, 95% CI)	0.87 [0.74, 1.03]
7 Bleeding - major	1	2457	Odds Ratio (M-H, Fixed, 95% CI)	1.00 [0.06, 16.02]
7.1 Hip replacement	1	2457	Odds Ratio (M-H, Fixed, 95% CI)	1.00 [0.06, 16.02]
8 Bleeding- clinically relevant non-major	1	2457	Odds Ratio (M-H, Fixed, 95% CI)	1.22 [0.76, 1.95]
8.1 Hip replacement	1	2457	Odds Ratio (M-H, Fixed, 95% CI)	1.22 [0.76, 1.95]
9 Bleeding - minor	1	2457	Odds Ratio (M-H, Fixed, 95% CI)	1.18 [0.74, 1.88]

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair (Review) 67

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

9.1 Hip replacement	1	2457	Odds Ratio (M-H, Fixed, 95% CI)	1.18 [0.74, 1.88]
10 Reoperation	1	2457	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
10.1 Hip replacement	1	2457	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
11 Wound infection	1	2457	Odds Ratio (M-H, Fixed, 95% CI)	1.34 [0.46, 3.86]
11.1 Hip replacement	1	2457	Odds Ratio (M-H, Fixed, 95% CI)	1.34 [0.46, 3.86]

Comparison 4. Anticoagulant (chosen at investigators' discretion) versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Symptomatic VTE (DVT and PE)	1	557	Odds Ratio (M-H, Fixed, 95% CI)	0.50 [0.09, 2.74]
1.1 Knee replacement	1	557	Odds Ratio (M-H, Fixed, 95% CI)	0.50 [0.09, 2.74]
2 Symptomatic DVT (proximal or distal)	1	557	Odds Ratio (M-H, Fixed, 95% CI)	0.33 [0.03, 3.21]
2.1 Knee replacement	1	557	Odds Ratio (M-H, Fixed, 95% CI)	0.33 [0.03, 3.21]
3 Symptomatic PE	1	557	Odds Ratio (M-H, Fixed, 95% CI)	1.00 [0.06, 16.13]
3.1 Knee replacement	1	557	Odds Ratio (M-H, Fixed, 95% CI)	1.00 [0.06, 16.13]
4 Total VTE (symptomatic and asymptomatic)	1	557	Odds Ratio (M-H, Fixed, 95% CI)	0.26 [0.14, 0.50]
4.1 Knee replacement	1	557	Odds Ratio (M-H, Fixed, 95% CI)	0.26 [0.14, 0.50]
5 Asymptomatic DVT	1	557	Odds Ratio (M-H, Fixed, 95% CI)	0.26 [0.13, 0.54]
5.1 Knee replacement	1	557	Odds Ratio (M-H, Fixed, 95% CI)	0.26 [0.13, 0.54]
6 Asymptomatic distal DVT	1	557	Odds Ratio (M-H, Fixed, 95% CI)	0.26 [0.13, 0.54]
6.1 Knee replacement	1	557	Odds Ratio (M-H, Fixed, 95% CI)	0.26 [0.13, 0.54]
7 All-cause mortality	1	842	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.1 Knee replacement	1	842	Odds Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
8 Bleeding - major	1	557	Odds Ratio (M-H, Fixed, 95% CI)	5.05 [0.24, 105.76]
8.1 Knee replacement	1	557	Odds Ratio (M-H, Fixed, 95% CI)	5.05 [0.24, 105.76]

Comparison 5. Vitamin K antagonists versus heparin

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Symptomatic VTE (DVT and PE)	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	1.64 [0.85, 3.16]
1.1 Hip replacement	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	1.64 [0.85, 3.16]
2 Symptomatic DVT (proximal or distal)	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	1.36 [0.69, 2.68]
2.1 Hip replacement	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	1.36 [0.69, 2.68]
3 Symptomatic PE	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	9.16 [0.49, 170.42]
3.1 Hip replacement	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	9.16 [0.49, 170.42]
4 Total VTE (symptomatic and asymptomatic)	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	1.64 [0.85, 3.16]
4.1 Hip replacement	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	1.64 [0.85, 3.16]

Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair (Review) 68

Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

5 All-cause mortality	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	5.07 [0.24, 105.83]
5.1 Hip replacement	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	5.07 [0.24, 105.83]
6 Bleeding - major	1	1272	Odds Ratio (M-H, Fixed, 95% CI)	3.87 [1.91, 7.85]
6.1 Hip replacement	1	1272	Odds Ratio (M-H, Fixed, 95% CI)	3.87 [1.91, 7.85]
7 Bleeding - minor	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	1.33 [0.64, 2.76]
7.1 Hip replacement	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	1.33 [0.64, 2.76]
8 Reoperation	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	4.60 [0.99, 21.38]
8.1 Hip replacement	1	1279	Odds Ratio (M-H, Fixed, 95% CI)	4.60 [0.99, 21.38]

Comparison 6. DOAC versus heparin

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Symptomatic VTE (DVT and PE)	5	15977	Odds Ratio (M-H, Random, 95% CI)	0.70 [0.28, 1.70]
1.1 Hip replacement	5	15977	Odds Ratio (M-H, Random, 95% CI)	0.70 [0.28, 1.70]
2 Symptomatic DVT (proximal or distal)	5	15977	Odds Ratio (M-H, Random, 95% CI)	0.60 [0.11, 3.27]
2.1 Hip replacement	5	15977	Odds Ratio (M-H, Random, 95% CI)	0.60 [0.11, 3.27]
3 Symptomatic PE	5	14731	Odds Ratio (M-H, Fixed, 95% CI)	0.91 [0.43, 1.94]
3.1 Hip replacement	5	14731	Odds Ratio (M-H, Fixed, 95% CI)	0.91 [0.43, 1.94]
4 Total VTE (symptomatic and asymptomatic)	4	12447	Odds Ratio (M-H, Random, 95% CI)	0.53 [0.29, 0.97]
4.1 Hip replacement	4	12447	Odds Ratio (M-H, Random, 95% CI)	0.53 [0.29, 0.97]
5 Asymptomatic DVT	2	6559	Odds Ratio (M-H, Random, 95% CI)	0.56 [0.19, 1.59]
5.1 Hip replacement	2	6559	Odds Ratio (M-H, Random, 95% CI)	0.56 [0.19, 1.59]
6 Asymptomatic proximal DVT	1	2704	Odds Ratio (M-H, Fixed, 95% CI)	0.73 [0.46, 1.15]
6.1 Hip replacement	1	2704	Odds Ratio (M-H, Fixed, 95% CI)	0.73 [0.46, 1.15]
7 Asymptomatic distal DVT	1	2639	Odds Ratio (M-H, Fixed, 95% CI)	1.22 [0.75, 1.99]
7.1 Hip replacement	1	2639	Odds Ratio (M-H, Fixed, 95% CI)	1.22 [0.75, 1.99]
8 All-cause mortality	5	14966	Odds Ratio (M-H, Fixed, 95% CI)	1.63 [0.64, 4.16]
8.1 Hip replacement	5	14966	Odds Ratio (M-H, Fixed, 95% CI)	1.63 [0.64, 4.16]
9 Adverse events	3	9908	Odds Ratio (M-H, Fixed, 95% CI)	0.96 [0.88, 1.05]
9.1 Hip replacement	3	9908	Odds Ratio (M-H, Fixed, 95% CI)	0.96 [0.88, 1.05]
10 Bleeding - major	5	16199	Odds Ratio (M-H, Fixed, 95% CI)	1.11 [0.79, 1.54]
10.1 Hip replacement	5	16199	Odds Ratio (M-H, Fixed, 95% CI)	1.11 [0.79, 1.54]
11 Bleeding - clinically relevant, non-major	4	15241	Odds Ratio (M-H, Fixed, 95% CI)	1.08 [0.90, 1.28]
11.1 Hip replacement	4	15241	Odds Ratio (M-H, Fixed, 95% CI)	1.08 [0.90, 1.28]
12 Bleeding - minor	4	11766	Odds Ratio (M-H, Fixed, 95% CI)	0.95 [0.82, 1.10]
12.1 Hip replacement	4	11766	Odds Ratio (M-H, Fixed, 95% CI)	0.95 [0.82, 1.10]
13 Reoperation	4	15241	Odds Ratio (M-H, Fixed, 95% CI)	1.06 [0.34, 3.24]
13.1 Hip replacement	4	15241	Odds Ratio (M-H, Fixed, 95% CI)	1.06 [0.34, 3.24]
14 Wound infection	2	6446	Odds Ratio (M-H, Fixed, 95% CI)	0.89 [0.46, 1.72]
14.1 Hip replacement	2	6446	Odds Ratio (M-H, Fixed, 95% CI)	0.89 [0.46, 1.72]

Analysis 1.1. Comparison 1 Heparin versus placebo, Outcome 1 Symptomatic VTE (DVT and PE).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 1 Heparin versus placebo

Outcome: 1 Symptomatic VTE (DVT and PE)

Analysis 1.2. Comparison 1 Heparin versus placebo, Outcome 2 Symptomatic DVT (proximal or distal).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 1 Heparin versus placebo

Outcome: 2 Symptomatic DVT (proximal or distal)

Analysis 1.3. Comparison 1 Heparin versus placebo, Outcome 3 Symptomatic PE.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 1 Heparin versus placebo

Outcome: 3 Symptomatic PE

Analysis 1.4. Comparison 1 Heparin versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 1 Heparin versus placebo

Outcome: 4 Total VTE (symptomatic and asymptomatic)

Analysis 1.5. Comparison 1 Heparin versus placebo, Outcome 5 Asymptomatic DVT.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 1 Heparin versus placebo

Outcome: 5 Asymptomatic DVT

Analysis 1.6. Comparison 1 Heparin versus placebo, Outcome 6 All-cause mortality.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 1 Heparin versus placebo

Outcome: 6 All-cause mortality

Analysis 1.7. Comparison 1 Heparin versus placebo, Outcome 7 Adverse events.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 1 Heparin versus placebo

Outcome: 7 Adverse events

Analysis 1.8. Comparison 1 Heparin versus placebo, Outcome 8 Bleeding - major.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 1 Heparin versus placebo

Outcome: 8 Bleeding - major

Analysis 1.9. Comparison 1 Heparin versus placebo, Outcome 9 Bleeding - minor.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 1 Heparin versus placebo

Outcome: 9 Bleeding - minor

Analysis 1.10. Comparison 1 Heparin versus placebo, Outcome 10 Reoperation.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 1 Heparin versus placebo

Outcome: 10 Reoperation

Analysis 2.1. Comparison 2 Vitamin K antagonists versus placebo, Outcome 1 Symptomatic VTE (DVT and PE).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 2 Vitamin K antagonists versus placebo

Outcome: 1 Symptomatic VTE (DVT and PE)

Analysis 2.2. Comparison 2 Vitamin K antagonists versus placebo, Outcome 2 Symptomatic DVT (proximal or distal).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 2 Vitamin K antagonists versus placebo

Outcome: 2 Symptomatic DVT (proximal or distal)

Analysis 2.3. Comparison 2 Vitamin K antagonists versus placebo, Outcome 3 Symptomatic PE.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 2 Vitamin K antagonists versus placebo

Outcome: 3 Symptomatic PE

Analysis 2.4. Comparison 2 Vitamin K antagonists versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 2 Vitamin K antagonists versus placebo

Outcome: 4 Total VTE (symptomatic and asymptomatic)

Analysis 2.5. Comparison 2 Vitamin K antagonists versus placebo, Outcome 5 All-cause mortality.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 2 Vitamin K antagonists versus placebo

Outcome: 5 All-cause mortality

Analysis 2.6. Comparison 2 Vitamin K antagonists versus placebo, Outcome 6 Adverse events.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 2 Vitamin K antagonists versus placebo

Outcome: 6 Adverse events

Analysis 2.7. Comparison 2 Vitamin K antagonists versus placebo, Outcome 7 Bleeding - major.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 2 Vitamin K antagonists versus placebo

Outcome: 7 Bleeding - major

Analysis 3.1. Comparison 3 DOAC versus placebo, Outcome 1 Symptomatic VTE (DVT and PE).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 3 DOAC versus placebo

Outcome: 1 Symptomatic VTE (DVT and PE)

Analysis 3.2. Comparison 3 DOAC versus placebo, Outcome 2 Symptomatic DVT (proximal or distal).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 3 DOAC versus placebo

Outcome: 2 Symptomatic DVT (proximal or distal)

Analysis 3.3. Comparison 3 DOAC versus placebo, Outcome 3 Symptomatic PE.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 3 DOAC versus placebo

Outcome: 3 Symptomatic PE

Analysis 3.4. Comparison 3 DOAC versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 3 DOAC versus placebo

Outcome: 4 Total VTE (symptomatic and asymptomatic)

Analysis 3.5. Comparison 3 DOAC versus placebo, Outcome 5 All-cause mortality.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 3 DOAC versus placebo

Outcome: 5 All-cause mortality

Analysis 3.6. Comparison 3 DOAC versus placebo, Outcome 6 Adverse events.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 3 DOAC versus placebo

Outcome: 6 Adverse events

Analysis 3.7. Comparison 3 DOAC versus placebo, Outcome 7 Bleeding - major.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 3 DOAC versus placebo

Outcome: 7 Bleeding - major

Analysis 3.8. Comparison 3 DOAC versus placebo, Outcome 8 Bleeding- clinically relevant non-major.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 3 DOAC versus placebo

Outcome: 8 Bleeding- clinically relevant non-major

Analysis 3.9. Comparison 3 DOAC versus placebo, Outcome 9 Bleeding - minor.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 3 DOAC versus placebo

Outcome: 9 Bleeding - minor

Analysis 3.10. Comparison 3 DOAC versus placebo, Outcome 10 Reoperation.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 3 DOAC versus placebo

Outcome: 10 Reoperation

Analysis 3.11. Comparison 3 DOAC versus placebo, Outcome 11 Wound infection.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 3 DOAC versus placebo

Outcome: 11 Wound infection

Analysis 4.1. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 1 Symptomatic VTE (DVT and PE).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 4 Anticoagulant (chosen at investigators' discretion) versus placebo

Outcome: 1 Symptomatic VTE (DVT and PE)

Analysis 4.2. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 2 Symptomatic DVT (proximal or distal).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 4 Anticoagulant (chosen at investigators' discretion) versus placebo

Outcome: 2 Symptomatic DVT (proximal or distal)

Analysis 4.3. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 3 Symptomatic PE.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 4 Anticoagulant (chosen at investigators' discretion) versus placebo

Outcome: 3 Symptomatic PE

Analysis 4.4. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 4 Total VTE (symptomatic and asymptomatic).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 4 Anticoagulant (chosen at investigators' discretion) versus placebo

Outcome: 4 Total VTE (symptomatic and asymptomatic)

Analysis 4.5. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 5 Asymptomatic DVT.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 4 Anticoagulant (chosen at investigators' discretion) versus placebo

Outcome: 5 Asymptomatic DVT

Analysis 4.6. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 6 Asymptomatic distal DVT.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 4 Anticoagulant (chosen at investigators' discretion) versus placebo

Outcome: 6 Asymptomatic distal DVT

Analysis 4.7. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 7 All-cause mortality.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 4 Anticoagulant (chosen at investigators' discretion) versus placebo

Outcome: 7 All-cause mortality

Analysis 4.8. Comparison 4 Anticoagulant (chosen at investigators' discretion) versus placebo, Outcome 8 Bleeding - major.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 4 Anticoagulant (chosen at investigators' discretion) versus placebo

Outcome: 8 Bleeding - major

Analysis 5.1. Comparison 5 Vitamin K antagonists versus heparin, Outcome 1 Symptomatic VTE (DVT and PE).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 5 Vitamin K antagonists versus heparin

Outcome: 1 Symptomatic VTE (DVT and PE)

Analysis 5.2. Comparison 5 Vitamin K antagonists versus heparin, Outcome 2 Symptomatic DVT (proximal or distal).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 5 Vitamin K antagonists versus heparin

Outcome: 2 Symptomatic DVT (proximal or distal)

Analysis 5.3. Comparison 5 Vitamin K antagonists versus heparin, Outcome 3 Symptomatic PE.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 5 Vitamin K antagonists versus heparin

Outcome: 3 Symptomatic PE

Analysis 5.4. Comparison 5 Vitamin K antagonists versus heparin, Outcome 4 Total VTE (symptomatic and asymptomatic).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 5 Vitamin K antagonists versus heparin

Outcome: 4 Total VTE (symptomatic and asymptomatic)

Analysis 5.5. Comparison 5 Vitamin K antagonists versus heparin, Outcome 5 All-cause mortality.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 5 Vitamin K antagonists versus heparin

Outcome: 5 All-cause mortality

Analysis 5.6. Comparison 5 Vitamin K antagonists versus heparin, Outcome 6 Bleeding - major.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 5 Vitamin K antagonists versus heparin

Outcome: 6 Bleeding - major

Analysis 5.7. Comparison 5 Vitamin K antagonists versus heparin, Outcome 7 Bleeding - minor.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 5 Vitamin K antagonists versus heparin

Outcome: 7 Bleeding - minor

Analysis 5.8. Comparison 5 Vitamin K antagonists versus heparin, Outcome 8 Reoperation.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 5 Vitamin K antagonists versus heparin

Outcome: 8 Reoperation

Analysis 6.1. Comparison 6 DOAC versus heparin, Outcome 1 Symptomatic VTE (DVT and PE).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 1 Symptomatic VTE (DVT and PE)

Analysis 6.2. Comparison 6 DOAC versus heparin, Outcome 2 Symptomatic DVT (proximal or distal).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 2 Symptomatic DVT (proximal or distal)

Analysis 6.3. Comparison 6 DOAC versus heparin, Outcome 3 Symptomatic PE.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 3 Symptomatic PE

Analysis 6.4. Comparison 6 DOAC versus heparin, Outcome 4 Total VTE (symptomatic and asymptomatic).

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 4 Total VTE (symptomatic and asymptomatic)

Analysis 6.5. Comparison 6 DOAC versus heparin, Outcome 5 Asymptomatic DVT.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 5 Asymptomatic DVT

Analysis 6.6. Comparison 6 DOAC versus heparin, Outcome 6 Asymptomatic proximal DVT.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 6 Asymptomatic proximal DVT

Analysis 6.7. Comparison 6 DOAC versus heparin, Outcome 7 Asymptomatic distal DVT.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 7 Asymptomatic distal DVT

Analysis 6.8. Comparison 6 DOAC versus heparin, Outcome 8 All-cause mortality.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 8 All-cause mortality

Analysis 6.9. Comparison 6 DOAC versus heparin, Outcome 9 Adverse events.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 9 Adverse events

Analysis 6.10. Comparison 6 DOAC versus heparin, Outcome 10 Bleeding - major.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 10 Bleeding - major

Analysis 6.11. Comparison 6 DOAC versus heparin, Outcome 11 Bleeding - clinically relevant, non-major.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 11 Bleeding - clinically relevant, non-major

Analysis 6.12. Comparison 6 DOAC versus heparin, Outcome 12 Bleeding - minor.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 12 Bleeding - minor

Analysis 6.13. Comparison 6 DOAC versus heparin, Outcome 13 Reoperation.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 13 Reoperation

Analysis 6.14. Comparison 6 DOAC versus heparin, Outcome 14 Wound infection.

Review: Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Comparison: 6 DOAC versus heparin

Outcome: 14 Wound infection

APPENDICES

Appendix I. CENTRAL search strategy

#1	MeSH descriptor: [Thrombosis] this term only	1309
#2	MeSH descriptor: [Thromboembolism] this term only	1067
#3	MeSH descriptor: [Venous Thromboembolism] this term only	461
#4	MeSH descriptor: [Venous Thrombosis] this term only	1060
#5	(thromboprophyla* or thrombus* or thrombotic* or thrombotic* or thromboemboli* or thrombos* or embol*):ti,ab,kw	17234
#6	MeSH descriptor: [Pulmonary Embolism] explode all trees	944
#7	PE or DVT or VTE:ti,ab,kw	4161

(Continued)

#8	(vein* or ven*) near thromb*:ti,ab,kw	6917
#9	#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8	20147
#10	MeSH descriptor: [Anticoagulants] explode all trees	4058
#11	anticoagul* or anti-coagu* or antithrombotic*	9328
#12	warfarin or (vitamin near/3 antagonist*) or VKA or Nicoumalone or phenindione or acenocoumarol* or Sintrome or dicoumarol* or nicoumalone or phenprocoumon or Marcoumar or Marcumar or Falithrom or AVK or bishydroxycoumarin* or coumarin* or coumadin* or phenprocoumon*	4024
#13	Ximelagatran or Exanta or Exarta or H 376/95 or dabigatran or rivaroxaban or Xarelto	874
#14	fondaparinux or Arixtra or BAY59-7939 or TTP889 or odiparcil or LY517717 or YM150 or DU-176b	395
#15	apixaban or betrixaban or edoxaban or idraparinux	402
#16	LMWH or UFH or heparin or nadroparin* or fraxiparin* or enoxaparin	9899
#17	Clexane or klexane or lovenox or dalteparin or Fragmin or ardeparin	762
#18	normiflo or tinzaparin or logiparin or Innohep or certoparin or sandoparin or reviparin or clivarin*	432
#19	danaproid or danaparoid or antixarin or ardeparin* or bemiparin*	136
#20	Zibor or cy 222 or embolex or monoembolex or parnaparin*	128
#21	rd 11885 or tedelparin or Kabi-2165 or Kabi 2165	78
#22	emt-966 or emt-967 or "pk-10 169" or pk-10169 or pk10169 or cy-216 or cy216	83
#23	seleparin* or tedeqliparin or seleparin* or tedeqliparin*	19
#24	wy90493 or "wy 90493" or "kb 101" or kb101	21

(Continued)

#25	lomoparan or orgaran or parnaparin or fluxum or lohepa or lowhepa or "op 2123" or parvoparin or AVE5026	113
#26	#10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25	17458
#27	MeSH descriptor: [Hip] explode all trees	309
#28	MeSH descriptor: [Knee] explode all trees	584
#29	hip:ti,ab,kw (Word variations have been searched)	11495
#30	knee:ti,ab,kw (Word variations have been searched)	13133
#31	orthop?edic	6896
#32	MeSH descriptor: [Orthopedic Procedures] explode all trees	10000
#33	#27 or #28 or #29 or #30 or #31 or #32	31372
#34	#9 and #26 and #33	1182

Appendix 2. Additional Summary of findings table: Heparin compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Heparin compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair							
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Setting: hospital and outpatient setting Intervention: heparin Comparison: placebo							
Outcomes	Anticipated (95% CI)	absolute	effects*	Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk placebo	with	Risk with heparin				
Total VTE (symptomatic and asymptomatic)	Study population			OR 0.39 (0.28 to 0.56)	2544 (6 RCTs)	⊕⊕⊕⊕ HIGH	-

(Continued)

Treatment duration 28 - 42 days						
	83 per 1000	34 per 1000 (25 to 48)				
Asymptomatic DVT Treatment duration 28 - 42 days	Study population		OR 0.38 (0.24 to 0.60)	1304 (5 RCTs)	⊕⊕⊕⊕ HIGH	-
	112 per 1000	46 per 1000 (29 to 71)				
Asymptomatic proximal DVT Treatment duration 28 - 42 days	see comment		not estimable	-	-	asymptomatic and proximal DVT reported separately but due to available data it was not possible to determine which events fell into which category
Asymptomatic distal DVT Treatment duration 28 - 42 days	see comment		not estimable	-	-	asymptomatic and distal DVT reported separately but due to available data it was not possible to determine which events fell into which category
All-cause mortality Treatment duration 28 - 42 days	Study population		OR 1.01 (0.31 to 3.26)	2518 (5 RCTs)	⊕⊕⊕○ MODERATE ¹	-
	4 per 1000	4 per 1000 (1 to 11)				
Adverse events Treatment duration 28 - 42 days	Study population		OR 1.06 (0.68 to 1.64)	460 (2 RCTs)	⊕⊕⊕○ MODERATE ²	-
	270 per 1000	281 per 1000 (201 to 377)				
Reoperation Treatment duration	see comment		-	179 (1 RCT)	-	one study reported no op-

(Continued)

tion 28 - 42 days					erations in either study arm. Three studies did not report on reoperation and two studies did not report sufficient data to analyse
Wound infection Treatment duration 28 - 42 days	see comment	-	-	-	four studies did not report on wound infection. Two studies did not provide specific details for wound infection
Wound healing Treatment duration 28 - 42 days	see comment	-	-	-	not reported

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **DVT:** deep vein thrombosis; **OR:** odds ratio; **PE:** pulmonary embolism; **RCT:** randomised controlled trial; **VTE:** venous thromboembolism

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Downgraded by one level, low number of events leading to imprecision of results

² Downgraded by one level due to imprecision

Appendix 3. Additional Summary of findings table: Vitamin K antagonists compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Vitamin K antagonists compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Setting: hospital and outpatient setting

Intervention: vitamin K antagonists

Comparison: placebo

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with placebo	Risk with vitamin K antagonists				
Total VTE (symptomatic and asymptomatic) Treatment duration 28 - 42 days	Study population 51 per 1000 5 per 1000 (1 to 42)		OR 0.10 (0.01 to 0.81)	360 (1 RCT)	⊕⊕⊕○ MODERATE ¹	-
Asymptomatic DVT Treatment duration 28 - 42 days	see comment		-	-	-	not reported in single included study in this comparison
Asymptomatic proximal DVT Treatment duration 28 - 42 days	see comment		-	-	-	not reported in single included study in this comparison
Asymptomatic distal DVT Treatment duration 28 - 42 days	see comment		-	-	-	not reported in single included study in this comparison
All-cause mortality Treatment duration 28 - 42 days	see comment		-	360 (1 RCT)	-	single included study reported no deaths in either study arm so not possible to assess risk
Adverse events Treatment duration 28 - 42 days	see comment		-	360 (1 RCT)	-	single included study reported no ad-

(Continued)

					verse events in either study arm so not possible to assess risk
Reoperation Treatment duration 28 - 42 days	see comment	-	-	-	not reported in single included study in this comparison
Wound infection Treatment duration 28 - 42 days	see comment	-	-	-	not reported in single included study in this comparison
Wound healing Treatment duration 28 - 42 days	see comment	-	-	-	not reported in single included study in this comparison

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **DVT:** deep vein thrombosis; **OR:** odds ratio; **PE:** pulmonary embolism; **RCT:** randomised controlled trial; **VTE:** venous thromboembolism

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Downgraded by one level, results from a single study only so heterogeneity could not be assessed

Appendix 4. Additional Summary of findings table: DOAC compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Setting: hospital and outpatient setting

Intervention: DOAC

Comparison: placebo

(Continued)

Outcomes	Anticipated absolute effects*		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk placebo	Risk with DOAC				
Total VTE (symptomatic and asymptomatic) Treatment duration 28 - 42 days	Study population		OR 0.19 (0.11 to 0.33)	1733 (1 RCT)	⊕⊕⊕○ MODERATE ¹	-
	86 per 1000	18 per 1000 (10 to 30)				
Asymptomatic DVT Treatment duration 28 - 42 days	see comment		-	-	-	not reported in single included study in this comparison
Asymptomatic proximal DVT Treatment duration 28 - 42 days	see comment		-	-	-	not reported in single included study in this comparison
Asymptomatic distal DVT Treatment duration 28 - 42 days	see comment		-	-	-	not reported in single included study in this comparison
All-cause mortality Treatment duration 28 - 42 days	Study population		OR 0.33 (0.07 to 1.66)	1733 (1 RCT)	⊕⊕○○ LOW ¹²	-
	7 per 1000	2 per 1000 (0 to 11)				
Adverse events Treatment duration 28 - 42 days	Study population		OR 0.87 (0.74 to 1.03)	2457 (1 RCT)	⊕⊕⊕○ MODERATE ¹	-
	657 per 1000	625 per 1000 (586 to 663)				
Reoperation Treatment duration 28 - 42 days	see comment		-	2457 (1 RCT)	-	single study reported no cases of reoperation in the study arms
Wound infection Treatment duration 28 - 42 days	Study population		OR 1.34 (0.46 to 3.86)	2457 (1 RCT)	⊕⊕○○ LOW ¹²	-

(Continued)

tion 28 - 42 days					
	5 per 1000	7 per 1000 (2 to 19)			
Wound healing Treatment dura- tion 28 - 42 days	see comment	-	-	-	not reported in single in- cluded study in this comparison

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **DOAC:** direct oral anticoagulant; **DVT:** deep vein thrombosis; **OR:** odds ratio; **PE:** pulmonary embolism; **RCT:** randomised controlled trial; **VTE:** venous thromboembolism

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Downgraded by one level, results from a single study so heterogeneity cannot be assessed

² Downgraded by one level, low number of events leading to wide CI and imprecision of results

Appendix 5. Additional Summary of findings table: Anticoagulants (chosen at investigators' discretion) compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Anticoagulants (chosen at investigators' discretion) compared to placebo for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Setting: hospital and outpatient setting

Intervention: anticoagulant (chosen at investigators' discretion)

Comparison: placebo

Outcomes	Anticipated (95% CI)	absolute	effects*	Relative effect (95% CI)	Number of par- ticipants (studies)	Quality of the evidence (GRADE)	Comments
----------	-------------------------	----------	----------	-----------------------------	--	---------------------------------------	----------

(Continued)

	Risk with placebo	Risk with anti-coagulant (chosen at investigators' discretion)				
Total VTE (symptomatic and asymptomatic) Treatment duration 28 - 42 days	Study population		OR 0.26 (0.14 to 0.50)	557 (1 RCT)	⊕⊕⊕○ MODERATE ¹	-
	158 per 1000	46 per 1000 (26 to 86)				
Asymptomatic DVT Treatment duration 28 - 42 days	Study population		OR 0.26 (0.13 to 0.54)	557 (1 RCT)	⊕⊕⊕○ MODERATE ¹	-
	125 per 1000	36 per 1000 (18 to 72)				
Asymptomatic proximal DVT Treatment duration 28 - 42 days	see comment		-	-	-	not reported in single included study in this comparison
Asymptomatic distal DVT Treatment duration 28 - 42 days	Study population		OR 0.26 (0.13 to 0.54)	557 (1 RCT)	⊕⊕⊕○ MODERATE ¹	-
	125 per 1000	36 per 1000 (18 to 72)				
All-cause mortality Treatment duration 28 - 42 days	see comment		-	842 (1 RCT)	-	the single included study reported no deaths in either study arm
Adverse events Treatment duration 28 - 42 days	see comment		-	-	-	not reported in single included study in this comparison
Reoperation Treatment duration 28 - 42 days	see comment		-	-	-	outcome reported as part of the definition of the outcome major bleeding but data not reported separately

(Continued)

Wound infection Treatment duration 28 - 42 days	see comment	-	-	-	not reported in single included study in this comparison
Wound healing Treatment duration 28 - 42 days	see comment	-	-	-	not reported in single included study in this comparison

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; **DVT:** deep vein thrombosis; **OR:** odds ratio; **PE:** pulmonary embolism; **RCT:** randomised controlled trial; **VTE:** venous thromboembolism

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Downgraded by one level, results from a single study so heterogeneity could not be assessed

Appendix 6. Additional Summary of findings table: Vitamin K antagonists compared to heparin for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Vitamin K antagonists compared to heparin for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair							
Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Setting: hospital and outpatient setting Intervention: vitamin K antagonists Comparison: heparin							
Outcomes	Anticipated absolute effects*		Relative effect (95% CI)	Number of participants (studies)	Quality of the evidence (GRADE)		Comments
	Risk with heparin	Risk with vitamin K antagonists					

(Continued)

To- tal VTE (symp- tomatic and asymptomatic) Treatment dura- tion 28 - 42 days	Study population		OR 1.64 (0.85 to 3.16)	1279 (1 RCT)	⊕⊕○○ LOW ¹²	-
	23 per 1000	38 per 1000 (20 to 70)				
Asymptomatic DVT Treatment dura- tion 28 - 42 days	see comment		-	-	-	not reported in single in- cluded study in this comparison
Asymptomatic proximal DVT Treatment dura- tion 28 - 42 days	see comment		-	-	-	not reported in single in- cluded study in this comparison
Asymptomatic distal DVT Treatment dura- tion 28 - 42 days	see comment		-	-	-	not reported in single in- cluded study in this comparison
All-cause mortality Treatment dura- tion 28 - 42 days	see comment		OR 5.07 (0.24 to 105.83)	1279 (1 RCT)	⊕⊕○○ LOW ¹³	no cases of death reported in the heparin study arm
Adverse events Treatment dura- tion 28 - 42 days	see comment		-	-	-	not reported in single in- cluded study in this comparison
Reoperation Treatment dura- tion 28 - 42 days	Study population		OR 4.60 (0.99 to 21.38)	1279 (1 RCT)	⊕⊕○○ LOW ¹³	-
	3 per 1000	14 per 1000 (3 to 63)				
Wound infection Treatment dura- tion 28 - 42 days	see comment		-	-	-	not reported in single in- cluded study in this comparison
Wound healing Treatment dura- tion 28 - 42 days	see comment		-	-	-	not reported in single in- cluded study in this comparison

(Continued)

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **DVT:** deep vein thrombosis; **OR:** odds ratio; **PE:** pulmonary embolism; **RCT:** randomised controlled trial; **VKA:** vitamin K antagonist; **VTE:** venous thromboembolism

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Downgraded by one level, single study so heterogeneity could not be assessed

² Downgraded by one level, wide CI

³ Downgraded by one level, low number of events leading to imprecision of results

Appendix 7. Additional Summary of findings table: DOAC compared to heparin for people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC compared to heparin for people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Patient or population: people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Setting: hospital and outpatient setting

Intervention: DOAC

Comparison: heparin

Outcomes	Anticipated (95% CI)	absolute	effects*	Relative effect (95% CI)	Number of par- ticipants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with hep- arin	Risk DOAC	with				
Total VTE (symptomatic and asymptomatic) Treatment duration 28 - 42 days	Study population			OR 0.53 (0.29 to 0.97)	12447 (4 RCTs)	⊕⊕⊕○ MODERATE ¹	-

(Continued)

	41 per 1000	22 per 1000 (12 to 40)				
Asymptomatic DVT	Study population		OR 0.56 (0.19 to 1.59)	6559 (2 RCTs)	⊕⊕○○ LOW ²	-
Treatment duration 28 - 42 days	42 per 1000	24 per 1000 (8 to 65)				
Asymptomatic proximal DVT	Study population		OR 0.73 (0.46 to 1.15)	2704 (1 RCT)	⊕⊕⊕○ MODERATE ³	-
Treatment duration 28 - 42 days	35 per 1000	26 per 1000 (16 to 40)				
Asymptomatic distal DVT	Study population		OR 1.22 (0.75 to 1.99)	2639 (1 RCT)	⊕⊕⊕○ MODERATE ³	-
Treatment duration 28 - 42 days	27 per 1000	33 per 1000 (20 to 52)				
All-cause mortality	Study population		OR 1.63 (0.64 to 4.16)	14966 (5 RCTs)	⊕⊕⊕○ MODERATE ⁴	-
Treatment duration 28 - 42 days	1 per 1000	1 per 1000 (1 to 4)				
Adverse events	Study population		OR 0.96 (0.88 to 1.05)	9908 (3 RCTs)	⊕⊕⊕⊕ HIGH	-
Treatment duration 28 - 42 days	691 per 1000	682 per 1000 (663 to 701)				
Reoperation	Study population		OR 1.06 (0.34 to 3.24)	15241 (4 RCTs)	⊕⊕⊕○ MODERATE ⁴	-
Treatment duration 28 - 42 days	1 per 1000	1 per 1000 (0 to 2)				
Wound infection	Study population		OR 0.89 (0.46 to 1.72)	6446 (2 RCTs)	⊕⊕⊕○ MODERATE ⁴	-
Treatment duration 28 - 42 days	6 per 1000	5 per 1000 (3 to 10)				
Wound healing	see comment		-	-	-	not re- ported in five in- cluded studies in this comparison

(Continued)

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: confidence interval; **DOAC:** direct oral anticoagulant; **DVT:** deep vein thrombosis; **OR:** odds ratio; **PE:** pulmonary embolism; **RCT:** randomised controlled trial; **VTE:** venous thromboembolism

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

¹ Downgraded by one level for inconsistency (heterogeneity, $I^2 = 87\%$)

² Downgraded by two levels for serious inconsistency (heterogeneity, $I^2 = 92\%$)

³ Downgraded by one level, single included study so unable to assess heterogeneity

⁴ Downgraded by one level, few events leading to wide CI and imprecision

FEEDBACK

Anticoagulant feedback, 14 February 2011

Summary

Feedback received on this protocol, and other reviews and protocols on anticoagulants, is available on the Cochrane Editorial Unit website at <http://www.editorial-unit.cochrane.org/anticoagulants-feedback>.

HISTORY

Protocol first published: Issue 2, 2003

Review first published: Issue 3, 2016

Date	Event	Description
14 February 2011	Amended	Link to anticoagulant feedback added
1 October 2008	Amended	Converted to new review format.
11 January 2002	New citation required and conclusions have changed	Substantive amendment

CONTRIBUTIONS OF AUTHORS

RF and MS selected the studies, extracted the data, performed the statistical analyses and wrote the review.

DECLARATIONS OF INTEREST

RF: none known.

MS: none known. MS is a member of Cochrane Vascular's editorial staff. To prevent any conflict of interest issues editorial decisions and activities related to this review were carried out by other editorial staff where appropriate.

SOURCES OF SUPPORT

Internal sources

- No sources of support supplied

External sources

- Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK.

The Cochrane Vascular editorial base is supported by the Chief Scientist Office.

- National Institute for Health Research (NIHR), UK.

This project was supported by the NIHR, via Cochrane Incentive Award funding to Cochrane Vascular. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

New authors have taken over this review.

The outcome 'Total VTE' was added as several studies did not report VTE (specifically DVT) as symptomatic or asymptomatic, making it difficult to place within the previously listed outcome definitions. This way more data could be combined for comparison, but needed to be done with caution as the outcomes would be more heterogenous.

'Clinically relevant non-major bleeding' was added to the bleeding outcomes as this was commonly reported in the newer, larger trials, and does not fit well within major or minor bleeding categories.

The outcomes 'Wound infection', 'Wound healing' and 'Reoperation following surgery' were added as they are deemed important outcomes for orthopaedic surgeons ([Wang 2014](#)).

Calculation of number needed to treat for an additional beneficial outcome (NNTB) and needed to treat for an additional harmful outcome (NNTH) were removed as the calculations in a meta-analysis setting can be misleading and should be treated with caution.

The method of evaluating study quality has changed since the protocol was published; we used the Cochrane 'Risk of bias' tool ([Higgins 2011](#)). We have also added 'Summary of findings' tables.

In the 'Sensitivity analysis' section, we have removed the indication to compare results using a fixed and random-effects model, as we are using the I^2 statistic to decide the appropriateness of the use of the different model types.